

Kevin C. Maki, PhD, CLS, MNLA, FTOS, FAHA
Tel: 630-469-6600

Administrative Office

Midwest Biomedical Research
211 East Lake St, Ste 3
Addison, Illinois 60101

Florida Office

MB Clinical Research
23125 Sanabria Loop
Bonita Springs, Florida 34135

E-MAIL:

kmaki@mbclinicalresearch.com

kcmaki@iu.edu

ACADEMIC & PROFESSIONAL EXPERIENCE:

2013-Present	President and Chief Scientist MB Clinical Research and Consulting, LLC; Divisions: • Midwest Biomedical Research; Addison, Illinois • MB Clinical Research, Bonita Springs, Florida
2019-Present	Adjunct Professor and Dean's Eminent Scholar Indiana University Department of Applied Health Science School of Public Health Bloomington, Indiana
2023-Present	Co-Editor in Chief Journal of Clinical Lipidology
2014-2021	Investigator/Managing Member Great Lakes Clinical Trials Chicago, Illinois
2013-2019	Adjunct Faculty, Epidemiology and Biostatistics DePaul University College of Science and Health Chicago, Illinois
2016-2018	Adjunct Faculty, Epidemiology and Biostatistics Illinois Institute of Technology Department of Food Science and Nutrition Chicago, Illinois
2004-2013	Chief Science Officer Biofortis Clinical Research (Formerly Provident Clinical Research) Addison, Illinois
2003-2004	Chief Science Officer Radiant Development (Formerly Protocare Development) Chicago, Illinois

Kevin C. Maki, Ph.D. – Curriculum Vitae
Page 2

2002-2003	Senior Vice President and Chief Science Officer Protocare Development, Inc. Chicago, Illinois
2000-2002	Vice President Protocare Development, Inc. Chicago, Illinois
1998-2000	Director, Nutrition and Metabolism Research Unit Chicago Center for Clinical Research/Protocare, Inc. Chicago, Illinois
1995-1998	Director, Biostatistics and Medical Writing Chicago Center for Clinical Research/Protocare, Inc. Chicago, Illinois
1991-1995	Research Health Scientist Rehabilitation Research and Development Center Edward Hines, Jr. Department of Veterans Affairs Medical Center Hines, Illinois
1989-1991	Exercise Physiologist Cardiac Rehabilitation Unit Elmhurst Memorial Hospital Elmhurst, Illinois
1988-1989	Instructor Departments of Biological Sciences and Preventive/Rehabilitative Cardiovascular Health Illinois Benedictine College Lisle, Illinois
1980-1988	Guest Service Manager Holiday Inn Countryside, Illinois

PROFESSIONAL ORGANIZATIONS:

Academy of Nutrition and Dietetics – 2021 Honorary Membership Award
American Diabetes Association
American Heart Association – Council on Arteriosclerosis, Thrombosis and Vascular Biology & Lifestyle and
Cardiometabolic Health – Clinical Lipidology, Lipoprotein, Metabolism & Thrombosis Committee
American Society for Nutrition
European Atherosclerosis Society
National Lipid Association – Past President
The Obesity Society

EDUCATION:

1998 University of Illinois at Chicago – School of Public Health
Chicago, Illinois
Degree: Ph.D. in Epidemiology/Public Health Sciences
Focus areas: Cardiovascular Disease/Diabetes
Collateral areas: Nutrition/Metabolism/Aging

- 1990 Illinois Benedictine College [now Benedictine University]
Lisle, Illinois
Degree: M.S. in Exercise Physiology, Preventive and
Rehabilitative Cardiovascular Health
- 1987 Northern Illinois University
DeKalb, Illinois
Degree: B.S. in Exercise Science Research

CERTIFICATION & FELLOWSHIPS:

Fellow, American Heart Association
Diplomate, Accreditation Council for Clinical Lipidology, Advanced Certification in Lipidology/Clinical Lipid
Specialist, Member of the Board of Governors, and Past President
Master, National Lipid Association (Past President)
Fellow, The Obesity Society
Member, American Society for Nutrition Statistical Review Board (2020-2023)

PUBLICATIONS (peer reviewed journals):

1. **Maki KC**, Duell PB. From the Editors: Updated guidelines for management of dyslipidemia. *J Clin Lipidol.* 2025;In press.
2. Guzman E, Edirisinghe I, Wilcox ML, Kirkpatrick CF, Adams CG, Burton-Freeman BM, **Maki KC**. Effects of diets containing beef versus poultry on pancreatic β -cell function and other cardiometabolic health indicators in men and women with prediabetes: A randomized, crossover trial. *Curr Develop Nutr.* 2025;In press.
3. Vedamurthy D, Sagheer U, Tyagi M, **Maki KC**, Kalra DK. Meta-analysis of the impact of statins on change in renal function in patients with moderate or severe chronic kidney disease. *J Clin Lipidol.* 2025;Epub ahead of print.
4. Dhurandhar EJ, **Maki KC**, Dhurandhar NV, Kyle TK, Yurkow S, Hawkins MAW, Agle J, Ho EH, Cheskin LJ, Sorensen TIA, Wang WR, Gorman B, Allison DB. Development and rigorous multistep validation of a psychometric tool to measure food noise. *Appetite.* 2025;Epub ahead of print.
5. Davidson MH, **Maki KC**. Pharmacotherapy development and trends in lipidology: An expert discussion. *J Clin Lipidol.* 2025;Epub ahead of print.
6. Nissen SE, Navar AM, Gaudet D, **Maki KC**. JCL Roundtable: Novel lipid management. *J Clin Lipidol.* 2025;Epub ahead of print.
7. Coleman CD, Kiel JR, Palacios OM, Bell M, Wilcox ML, **Maki KC**, Unick JL, Jonnalagadda SS. Early weight loss and other predictors of clinically significant weight loss on two commercial weight loss programs. *Clin Obes.* 2025;Epub ahead of print.
8. Duell PB, **Maki KC**. From the Editors: Effects of dietary cholesterol and eggs on circulating low-density lipoprotein cholesterol: Old news from a new study. *J Clin Lipidol.* 2025;19:719-722.
9. Bernasconi AA, **Maki KC**, Finkelstein EA. Cost-effectiveness of long-chain omega-3 supplementation for the secondary prevention of cardiovascular disease in the United States. *Value Health.* 2025;28:1481-1487.
10. Guarneiri LL, Kirkpatrick CF, **Maki KC**. Protein, fiber, and exercise: A narrative review of their roles in weight management and cardiometabolic health. *Lipids Health Dis.* 2025;24(1):237.

11. Yammine L, Leidy H, **Maki KC**, Weaver MF, Bodalski EA, Schmitz JM. A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol. *Contemp Clin Trials*. 2025;155:107989.
12. **Maki KC**, Duell PB. From the Editors: Evolving landscape for management of chylomicronemia. *J Clin Lipidol*. 2025;19:377-379.
13. Bridges MD, Vennam SS, Davis T, Wilcox ML, **Maki KC**, Shea J, Truesdale K, Lajoie D, Fabry V, Kohlmeier M, Shi Q, Hursting SD, Voruganti VS, Shaikh SR. Effects of a palmitoleic acid concentrated oil on C-reactive protein levels in adults: A randomized double-blind placebo controlled clinical trial. *Am J Clin Nutr*. 2025;Epub ahead of print.
14. French SJ, Kanter M, **Maki KC**, Rust BM, Allison DB. The harms of high protein intake: conjectured, claimed, and presumed, but shown? *Am J Clin Nutr*. 2025;122:9-16.
15. Dhurandhar EJ, **Maki KC**, Dhurandhar NV, Kyle TK, Yurkow S, Hawkins MAW, Agle J, Ho EH, Cheskin LJ, Sorensen TIA, Wang XR, Allison DB. Food noise: Definition, measurement, and future research directions. *Nutr Diabetes*. 2025;15(1):30.
16. Duell PB, **Maki KC**. From the Editors. Oral semaglutide and reduction in major adverse cardiovascular events. *J Clin Lipidol*. 2025;19:195-196.
17. **Maki KC**, Kirkpatrick CF, Wilkinson MJ, Petersen KS. JCL Roundtable: Dietary recommendations and intermittent fasting and time-restricted eating. *J Clin Lipidol*. 2025;19:748-758.
18. **Maki KC**, Kirkpatrick CF, Almandoz J. JCL Roundtable: Prediabetes. *J Clin Lipidol*. 2025;19:404-411.
19. **Maki KC**, Duell PB. From the Editors. Helping clinicians interpret the evidence supporting dietary recommendations. *J Clin Lipidol*. 2025;19:1-2.
20. Duell PB, **Maki KC**. From the Editors: Upcoming treatments for familial chylomicronemia syndrome: Agents that inhibit production of apolipoprotein CIII. *J Clin Lipidol*. 2024;18:e877-e1100.
21. **Maki KC**, Kirkpatrick CF, Cheeley MK, Jacobson TA. Statin-associated muscle symptoms: Identification and recommendations for management. *Curr Atheroscler Rep*. 2024;27(1):5.
22. Guarneiri LL, Wilcox ML, Kuan CM, **Maki KC**. Investigation of the influence of a bitter melon product on indicators of cardiometabolic health in adults with prediabetes. *J Am Nutr Assoc*. 2025;44:306-314.
23. Sanders LM, Palacios OM, Wilcox ML, **Maki KC**. Beef consumption and cardiovascular disease risk factors: A systematic review and meta-analysis of randomized controlled trials. *Curr Develop Nutr*. 2024;8:104500.
24. Guarneiri LL, Adams CG, Garcia-Jackson B, Koecher K, Wilcox ML, **Maki KC**. Effects of varying protein amounts and types on diet-induced thermogenesis: A systematic review and meta-analysis. *Adv Nutr*. 2024;15:100332.
25. Peterson RD, Guarneiri LL, Adams CG, Wilcox ML, Clark AJ, Rudemiller NP, **Maki KC**, Malinczak CA. A randomized, double-blind, controlled trial to assess the effects of lactoferrin at two doses vs. active control on immunological and safety parameters in healthy adults. *Int J Toxicol*. 2025;44:12-28.
26. **Maki KC**, Duell PB. NLA Expert Clinical Consensus on apolipoprotein B recommends expanded clinical use and improved patient access. *J Clin Lipidol*. 2024;18:e645-e646.

27. Kris-Etherton PM, Petersen KS, LaMarche B, Karmally W, Guyton JR, Champagne CM, Lichtenstein AH, Bray GA, Sacks FM, **Maki KC**. The role of nutrition-related clinical trials in informing dietary recommendations for health and treatment of diseases. *J Clin Lipidol*. 2025;19:10-27.
28. Petersen K, **Maki K**, Calder PC, Belury M, Messina M, Kirkpatrick C, Harris WS. Perspective on the health effects of unsaturated fatty acids and commonly consumed plant oils high in unsaturated fat. *Br J Nutr*. 2024;132:1039-1050.
29. Soffer DE, Marston NA, **Maki KC**, Jacobson TA, Bittner VA, Peña JM, Thanassoulis G, Martin SS, Kirkpatrick CF, Virani SS, Dixon DL, Ballantyne CM, Remaley AT. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. *J Clin Lipidol*. 2024:e664-e684.
30. Duell PB, **Maki KC**. From the Editors. Disparities in access to pharmacotherapies for weight loss and cardiovascular prevention. *J Clin Lipidol*. 2024;18:e485-e487.
31. **Maki KC**, Duell PB. From the Editors. Lipoprotein(a) and high-density lipoprotein – A tale of two cities? *J Clin Lipidol*. 2024;18:e295-e296.
32. Bays HE, Kirkpatrick C, **Maki KC**, Toth PP, Morgan RT, Tondt J, Christensen SM, Dixon D, Jacobson TA. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. *Obes Pillars*. 2024;10:100108.
33. Bays HE, Kirkpatrick C, **Maki KC**, Toth PP, Morgan RT, Tondt J, Christensen SM, Dixon D, Jacobson TA. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. *J Clin Lipidol*. 2024;18:e320-e350.
34. Dicklin MR, Anthony JC, Winters BL, **Maki KC**. ω -3 polyunsaturated fatty acid status testing in humans: A narrative review of commercially available options. *J Nutr*. 2024;154:1487-1504.
35. Duell PB, **Maki KC**. From the Editors: Familial hypercholesterolemia: Still underdiagnosed and undertreated. *J Clin Lipidol*. 2024;18:e130-e131.
36. **Maki KC**, Duell PB. From the Editors: New insights into lipid disorders in children and adolescents as well as cardiovascular benefits of pharmacotherapy for weight loss. *J Clin Lipidol*. 2024;18:e3-e4.
37. Davidson MH, Hsieh A, Dicklin MR, **Maki KC**. The imperative to enhance cost-effectiveness for cardiovascular therapeutic development. *JACC Basic Trans Sci*. 2024;9:1029-1040.
38. Guarneiri LL, Kirkpatrick CF, **Maki KC**. Viscous fiber from oats and barley: Keep them in your cholesterol-lowering portfolio. *Ann Transl Med*. 2024;12(1):18.
39. Coleman CD, Kiel JR, Guarneiri LL, Bell M, Wilcox ML, **Maki KC**, Unick JL, Jonnalagadda SS. Importance of early weight loss and other predictors of lower weight loss in a commercial program: A secondary data analysis. *Obes Sci Pract*. 2023;10(1):e724.
40. Duell PB, **Maki KC**. From the Editors: New concepts in obesity and cardiovascular disease. *J Clin Lipidol*. 2023;17:705-706.
41. **Maki KC**, Duell PB. From the Editors: More hot topics in clinical lipidology. *J Clin Lipidol*. 2023;17:562.
42. Duell PB, **Maki KC**. From the Editors: Inhibition of cholesteryl ester transfer protein (CETP): Still a promising therapeutic strategy? *J Clin Lipidol*. 2023;17:425-426.

43. Guarneiri LL, Wilcox ML, **Maki KC**. Comparison of the effects of a phospholipid-enhanced fish oil versus krill oil product on plasma levels of eicosapentaenoic and docosahexaenoic acids after acute administration: A randomized, double-blind, crossover study. *Nutrition*. 2023;114:112090.
44. Guarneiri LL, **Maki KC**. An update on nutrition guidance for cardiovascular health. *Curr Atheroscler Rep*. 2023;25:597-603.
45. Kirkpatrick CF, Sikand G, Petersen KS, Anderson CAM, Aspary KE, Bolick JP, Kris-Etherton PM, **Maki KC**. Nutrition interventions for adults with dyslipidemia: A clinical perspective from the National Lipid Association. *J Clin Lipidol*. 2023;17:428-451.
46. Ballantyne CM, Ditmarsch M, Kastelein JJ, Nelson AJ, Kling D, Hsieh A, Curcio DL, **Maki KC**, Davidson MH, Nicholls SJ. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. *J Clin Lipidol*. 2023;17:491-503.
47. Sanders LM, Dicklin MR, Zhu Y, **Maki KC**. The relationship of ready-to-eat cereal intake and body weight in adults: A systematic review of observational studies and controlled trials. *Adv Nutr*. 2023;14:671-684.
48. **Maki KC**, Kirkpatrick CF. Plant-based dietary patterns and atherogenic lipoproteins. *Eur Heart J*. 2023;44:2623-2625.
49. **Maki KC**, Kirkpatrick CF, Allison D, Gadde KM. Pharmacotherapy for obesity: Recent evolution and implications for cardiovascular risk reduction. *Exp Rev Endocrinol Metab*. 2023;18:307-319.
50. Sanders LM, Goltz S, **Maki KC**. Resiliency of the digestive system during aging and the impact of diet. *Nutr Today*. 2023;58:165-174.
51. Sanders LM, Mestre LM, Ejima K, Mehta T, Keith SW, **Maki KC**, Allison DB. Body mass index, obesity, and mortality – Part II: Weight loss and weight cycling. *Nutr Today*. 2023;58:158-164.
52. Rehm CD, Goltz SR, Katcher JA, Guarneiri LL, Dicklin MR, **Maki KC**. Trends and patterns of chickpea consumption among United States adults: Analyses of National Health and Nutrition Examination Survey Data. *J Nutr*. 2023;153:1567-1576.
53. Cassady BA, McDonald JD, Yalawar M, Baggs GE, **Maki KC**. Pilot study on the impact of a carbohydrate loading drink on postprandial glycemic responses and gastric emptying in adults with prediabetes and type 2 diabetes mellitus. *Nutr Clin Pract*. 2023;38:108-117.
54. **Maki KC**, Dicklin MR. Caution against rejecting all dietary supplements for LDL cholesterol reduction. *J Am Coll Cardiol*. 2023;81:13-15.
55. Sanders LM, Wilcox ML, **Maki KC**. Red meat consumption and risk factors for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Eur J Clin Nutr*. 2023;77:156-165.
56. Ludema C, Rosenberg M, Macy JT, Kianersi S, Luetke M, Chen C, Golzarri-Arroyo L, Ables E, **Maki K**, Allison DB. Does receiving a SARS-CoV-2 antibody test result change COVID-19 protective behaviors? Testing risk compensation in undergraduate students with a randomized controlled trial. *PLoS One*. 2022;17(12):e0279347.
57. Mestre LM, Lartey ST, Ejima K, Mehta T, Keith S, **Maki KC**, Allison DB. Body mass index, obesity, and mortality—Part I: Associations and limitations. *Nutr Today*. 2023;58:92-99.
58. Sanders LM, Dicklin MR, Shu Y, **Maki KC**. The impact of ready-to-eat cereal intake on body weight and body composition in children and adolescents: A systematic review of observational studies and controlled trials. *Adv Nutr*. 2023;14:161-172.

59. Kirkpatrick CF, Agarwala A, **Maki KC**. How low should one go in reducing carbohydrate? *J Clin Lipidol*. 2022;16:769-775.
60. **Maki KC**, Dicklin MR. Is there an optimal diet for primordial prevention of atherosclerosis? *Eur Heart J*. 2022;43:3189-3191.
61. Kirkpatrick CF, Willard KE, **Maki KC**. Keto is trending: implications for body weight and lipid management. *Curr Cardiol Rep*. 2022;24:1093-1100.
62. Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, Dixon DL, **Maki KC**. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. *J Clin Lipidol*. 2022;16:361-375.
63. **Maki KC**, Bays HE, Ballantyne CM, Underberg JA, Kastelein JJP, Johnson JB, Ferguson JJ. A head-to-head comparison of a free fatty acid formulation of omega-3 pentaenoic acids versus icosapent ethyl in adults with hypertriglyceridemia: the ENHANCE-IT study. *J Am Heart Assoc*. 2022;11(6):e024176.
64. **Maki KC**, Wilcox ML, Dicklin MR, Kakkar R, Davidson MH. Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis. *BMC Nephrol*. 2022;23:34.
65. Dicklin MR, Barron R, Goltz S, Warren J, Boileau T, Pigat S, **Maki KC**. Fibre and micronutrient intakes among fruit juice consumers and non-consumers in the UK and France: modelling the effects of consumption of an orange pomace juice product. *J Hum Nutr Diet*. 2022;35:1230-1244.
66. Sanders LM, Zhu Y, Wilcox ML, Koecher K, **Maki KC**. Whole grain intake, compared to refined grain, improves postprandial glycemia and insulinemia: a systematic review and meta-analysis of randomized controlled trials. *Crit Rev Food Sci Nutr*. 2021;Epub ahead of print.
67. **Maki KC**, Grant JK, Orringer CE. LDL-C estimation: the perils of living with imperfection. *J Am Coll Cardiol*. 2022;79:542-544.
68. Mozaffarian D, **Maki KC**, Bays HE, Alguilera F, Gould G, Hegele RA, Moriarty PM, Robinson JG, Shi P, Tur JF, Lapointe JF, Aziz S, Lemieux P; TRILOGY (Study of CaPre in Lowering Very High Triglycerides) investigators. Effectiveness of a novel omega-3 krill oil agent in patients with severe hypertriglyceridemia: a randomized clinical trial. *JAMA Network Open*. 2022;5(1):e2141898.
69. **Maki KC**, Dicklin MR, Kirkpatrick CF. Saturated fats and cardiovascular health: Current evidence and controversies. *J Clin Lipidol*. 2021;15:765-772.
70. **Maki KC**. Investigating contrasting results in REDUCE-IT and STRENGTH: Partial answers but questions remain. *Eur Heart J*. 2021;42:4818-20.
71. Baer DJ, Althouse A, Hermann M, Johnson J, **Maki KC**, Marklund M, Vogt L, Wesson D, Stallings VA. Targeting the dietary Na:K ratio – considerations for design of an intervention study to impact blood pressure. *Adv Nutr*. 2022;13:225-233.
72. Weaver CM, Lichtenstein AH, Kris-Etherton PM, **Maki KC**, Petersen KS. At last – best practices for conducting human nutrition randomized controlled trials: a brief review and commentary. *J Clin Nutr Diet*. 2021;7(5):1.
73. Sanders LM, **Maki KC**. The potential role of appetite in mediating the relationship of whole grains and body weight. *Nutr Today*. 2021;56:239-245.
74. Petersen KS, Kris-Etherton PM, McCabe GP, Raman G, Miller JW, **Maki KC**. Perspective: planning and conducting statistical analyses for human nutrition randomized controlled trials: ensuring data quality and integrity. *Adv Nutr*. 2021;12:1610-1624.

75. Kirkpatrick CF, **Maki KC**. Dietary influences on atherosclerotic cardiovascular disease risk. *Curr Atheroscler Rep*. 2021;23(10):62.
76. Orringer CE, Blaha MJ, Blankstein R, Budoff MJ, Goldberg RB, Gill EA, **Maki KC**, Mehta L, Jacobson TA. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. *J Clin Lipidol*. 2021;15:33-60.
77. Orringer CE, **Maki KC**. In reply-coronary artery calcium scores I and II. *Mayo Clin Proc*. 2021;96:262-263.
78. Sanders LM, Zhu Y, Wilcox ML, Koecher K, **Maki KC**. Effects of whole grain intake, compared with refined grain, on appetite and energy intake: a systematic review and meta-analysis. *Adv Nutr*. 2021;12:1177-1195.
79. Gourineni V, Stewart ML, Wilcox ML, **Maki KC**. Nutritional bar with potato-based resistant starch attenuated post-prandial glucose and insulin response in healthy adults. *Foods*. 2020;9(11):1679.
80. Sanders LM, Dicklin MR, Palacios OM, Maki CE, Wilcox ML, **Maki KC**. Effects of potato resistant starch intake on insulin sensitivity, related metabolic markers and appetite ratings in men and women at risk for type 2 diabetes: a pilot cross-over randomised controlled trial. *J Hum Nutr Diet*. 2021;34:94-105.
81. Chen O, Rogers GT, McKay DL, **Maki KC**, Blumberg JB. The effect of multi-vitamin/multi-mineral supplementation on nutritional status in older adults receiving drug therapies: a double-blind, placebo-controlled trial. *J Diet Suppl*. 2022;19:20-33.
82. Orringer C, Tokgozoglul L, **Maki K**, Ray K, Saseen J, Catapano A. Transatlantic lipid guideline divergence: same data but different interpretations. *J Am Heart Assoc*. 2020;9(21):e018189.
83. Anderson JR, **Maki KC**, Palacios OM, Edirisinghe I, Burton-Freeman B, Spitznagel MB. Varying roles of glucoregulatory function measures in postprandial cognition following milk consumption. *Eur J Nutr*. 2021;1499-1501.
84. **Maki KC**, Miller JW, McCabe GP, Raman G, Kris-Etherton PM. Perspective: laboratory considerations and clinical data management for human nutrition randomized controlled trials: guidance for ensuring quality and integrity. *Adv Nutr*. 2021;12:46-58.
85. Mustad V, Hegazi RA, Hustead DS, Budiman ES, Rueda R, **Maki K**, Powers M, Mechanick JI, Bergenstal RM, Hamdy O. The use of a diabetes-specific nutritional shake to replace a daily breakfast and afternoon snack improves glycemic responses assessed by continuous glucose monitoring in people with type 2 diabetes: a randomized clinical pilot study. *BMJ Open Diabetes Res Care*. 2020;8(1):e001258.
86. Palacios OM, Cortes HN, Jenks B, **Maki KC**. Naturally-occurring hormones in food and potential health effects. *Toxicology Research and Application*. 2020;4:1-12
87. **Maki KC**, Wilcox ML, Dicklin MR, Buggia M, Palacios OM, Maki CE, Kramer M. Substituting lean beef for carbohydrate in a healthy dietary pattern does not adversely affect the cardiometabolic risk factor profile in men and women at risk for type 2 diabetes. *J Nutr*. 2020;1824-1833.
88. **Maki KC**, Dicklin MR. Omega-3 fatty acid therapy for cardiovascular disease: justified or not? *Curr Opin Cardiol*. 2020;35:417-422.
89. Kirkpatrick CF, Liday C, **Maki KC**. The effects of carbohydrate-restricted dietary patterns and physical activity on body weight and glycemic control. *Curr Atheroscler Rep*. 2020;22(6):20.

90. **Maki KC**, Palacios OM, Kramer MW, Trivedi R, Dicklin MR, Wilcox ML, Maki CE. Effects of substituting eggs for high-carbohydrate breakfast foods on the cardiometabolic risk factor profile in adults at risk for type 2 diabetes mellitus. *Eur J Clin Nutr.* 2020;74:784-795.
91. Orringer CE, **Maki KC**. HOPE for rational statin allocation for primary prevention: a coronary calcium picture is worth 1000 words. *Mayo Clin Proc.* 2020;95:1740-1749.
92. Brown AW, Kaiser KA, Keitt A, Fontaine K, Gibson M, Gower BA, Shikany JM, Vorland CJ, Beitz DC, Bier DM, Brenna JT, Jacobs DR, Jr., Kris-Etherton P, **Maki K**, Miller M, St-Onge MP, Teran-Garcia M, Allison DB. Science dialogue mapping of knowledge and knowledge gaps related to the effects of dairy intake on human cardiovascular health and disease. *Crit Rev Food Sci Nutr.* 2021;6:179-195.
93. Hirahatake KM, Astrup A, Hill JO, Slavin JL, Allison DB, **Maki KC**. Potential health benefits of full-fat dairy: the evidence base. *Adv Nutr.* 2020;11:533-547.
94. Orringer CE, Jacobson TA, **Maki KC**. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. *J Clin Lipidol.* 2019;13:860-872.
95. Palacios OM, **Maki KC**, Xiao D, Wilcox ML, Dicklin MR, Kramer M, Trivedi R, Burton-Freeman B, Edirisinghe I. Effects of consuming almonds on insulin sensitivity and other cardiometabolic health markers in adults with prediabetes. *J Am Coll Nutr.* 2020;39:397-406.
96. Kirkpatrick CF, Bolick JP, Kris-Etherton PM, Sikand G, Aspary KE, Soffer DE, Willard KE, **Maki KC**. Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: a scientific Statement from the National Lipid Association Nutrition and Lifestyle Taskforce. *J Clin Lipidol.* 2019;13:689-711.
97. **Maki KC**. The fat of the matter: lipoprotein effects of dietary fatty acids vary by body weight status (invited editorial). *Am J Clin Nutr.* 2019;110:795-796.
98. **Maki KC**, Palacios OM, Koecher K, Sawicki CM, Livingston KA, Bell M, Nelson Cortes H, McKeown NM. The relationship between whole grain intake and body weight: results of meta-analyses of observational studies and randomized controlled trials. *Nutrients.* 2019;11(6).
99. Palacios OM, **Maki KC**. Vegetarian diet patterns and chronic disease risk: what we know and what we don't. *Nutr Today.* 2019;54:132-140.
100. Robinson JG, Jayanna MB, Brown AS, Aspary K, Orringer C, Gill EA, Goldberg A, Jones LK, **Maki K**, Dixon DL, Saseen JJ, Soffer D. National Lipid Association Statement. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. *J Clin Lipidol.* 2019;13:525-537.
101. Jacobson TA, Cheeley MK, Jones PH, LaForge R, **Maki KC**, López JAG, Xiang P, Bushnell DM, Martin ML, Cohen JD. The Statin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. *J Clin Lipidol.* 2019;13:415-424.
102. **Maki KC**, Dicklin MR. Strategies to improve bioavailability of omega-3 fatty acids from ethyl ester concentrates. *Curr Opin Clin Nutr Metab Care.* 2019;22:116-123.
103. Palacios OM, Kramer M, **Maki KC**. Diet and prevention of type 2 diabetes mellitus: beyond weight loss and exercise. *Exp Rev Endocrinol Metab.* 2019;14:1-12.

104. **Maki KC**, Palacios OM, Buggia MA, Trivedi R, Dicklin MR, Maki CE. Effects of a self-micro-emulsifying delivery system formulation versus a standard standard omega-3-acid ethyl ester product on the bioavailability of eicosapentaenoic acid and docosahexaenoic acid: a study in healthy men and women in a fasted state. *Clin Ther*. 2018;40:2065-2076.
105. Vincent MJ, Allen B, Palacios OM, Haber LT, **Maki KC**. Meta-regression analysis of the effects of dietary cholesterol intake on LDL and HDL cholesterol. *Am J Clin Nutr*. 2019;109:7-16.
106. **Maki KC**. Long-chain omega-3 fatty acid bioavailability: implications for understanding the effects of supplementation on heart disease risk (invited editorial). *J Nutr*. 2018;148:1701-1703.
107. **Maki KC**, Hasse W, Dicklin MR, Bell M, Buggia MA, Cassens ME, Eren F. Corn oil lowers plasma cholesterol compared with coconut oil in adults with above-desirable levels of cholesterol in a randomized, crossover trial. *J Nutr*. 2018;148:1556-1563.
108. **Maki KC**, Dicklin MR. Omega-3 fatty acid supplementation and cardiovascular disease risk: glass half full or time to nail the coffin shut? *Nutrients*. 2018;10(7).
109. **Maki KC**. The ODYSSEY Outcomes trial: clinical implications and exploration of the limits of what can be achieved through lipid lowering. *J Clin Lipidol*. 2018;12:1102-1105.
110. **Maki KC**, Eren F, Cassens ME, Dicklin MR. Omega-6 polyunsaturated fatty acids and cardiometabolic health: current evidence, controversies and research gaps. *Adv Nutr*. 2018;9:688-700.
111. **Maki KC**, Dicklin MR. Assessing cardiovascular disease risk and responses to preventive therapies in clinical practice. *Curr Atheroscl Rep*. 2018;20:23.
112. Palacios OM, Edirisinghe I, Wilcox ML, Burton-Freeman B, Xiao D, **Maki KC**. A lean pork-containing breakfast reduces hunger and glycemic response compared to a refined carbohydrate-containing breakfast in adults with prediabetes. *J Am Coll Nutr*. 2018;37:293-301.
113. Stewart ML, Wilcox ML, Bell M, Buggia MA, **Maki KC**. Type-4 resistant starch in substitution for available carbohydrate reduces postprandial glycemic response and hunger in acute, randomized, double-blind, controlled study. *Nutrients*. 2018;10(2).
114. Herrlinger KA, Nieman KM, Sanoshy KD, Fonseca BA, Lasrado JA, Schild AL, **Maki KC**, Wesnes KA, Ceddia MA. Spearmint extract improves working memory in men and women with age-associated memory impairment. *J Altern Complement Med*. 2018;24:37-47.
115. **Maki KC**, Nieman KM, Schild AL, Kaspar KL, Khoo C. The effect of cranberry juice consumption on the recurrence of urinary tract infection: relationship to baseline risk factors. *J Am Coll Nutr*. 2018;37:121-126.
116. **Maki KC**, Diwadkar-Navsariwala V, Kramer MW. Statin use and risk for type 2 diabetes: what clinicians should know. *Postgrad Med*. 2018;130:166-172.
117. Jacobson TA, Khan A, **Maki KC**, Brinton EA, Cohen JD. Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Education survey. *J Clin Lipidol*. 2018;12:78-88.
118. Gwin JA, **Maki KC**, Alwattar AY, Leidy HJ. Examination of protein quantity and protein distribution across the day on ad libitum carbohydrate and fat intake in overweight women. *Curr Develop Nutr*. 2017;1:e001933.
119. Gwin JA, **Maki KC**, Leidy HJ. Increased protein consumption during the day from an energy-restricted diet augments satiety but does not reduce daily fat or carbohydrate intake on a free-living test day in overweight women. *J Nutr*. 2017;147:2338-2346.

120. Marriage BJ, Williams JA, Choe YS, **Maki KC**, Vurma M, DeMichele SJ. Mono- and diglycerides improve lutein absorption in healthy adults: a randomized, double-blind, crossover, single-dose study. *Br J Nutr.* 2017;118:813-821.
121. Dai Perrard XY, Lian Z, Bobotas G, Dicklin MR, **Maki KC**, Wu H. Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia. *J Clin Lipidol.* 2017;11:1361-1371.
122. **Maki KC**, Palacios OM, Bell M, Toth PP. Use of supplemental long chain omega-3 fatty acids and risk for cardiac death: an updated meta-analysis and review of research gaps. *J Clin Lipidol.* 2017;11:1152-1160.
123. Cohen JD, Cziraky MJ, Jacobson TA, **Maki KC**, Karalis DG. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: results of a healthcare provider survey conducted by the National Lipid Association. *J Clin Lipidol.* 2017;11:891-900.
124. **Maki KC**, Dicklin MR. Do triglyceride-lowering drugs decrease risk of cardiovascular disease? *Curr Opin Lipidol.* 2017;28:374-379.
125. **Maki KC**, Palacios OM, Lindner E, Nieman KM, Bell M, Sorce J. Replacement of refined starches and added sugars with egg protein and unsaturated fats increases insulin sensitivity and lowers triglycerides in adults with elevated triglycerides. *J Nutr.* 2017;147:1267-1274.
126. **Maki KC**, Johns C, Harris WS, Puder M, Freedman SD, Thorsteinsson T, Daak A, Rabinowicz AL, Sancilio FD. Bioequivalence demonstration for omega-3 acid ethyl ester formulations: Rationale for modification of current guidance. *Clin Ther.* 2017;39:652-658.
127. Lopez-Toledano MA, Thorsteinsson T, Daak A, **Maki KC**, Johns C, Rabinowicz AL, Sancilio FD. A novel omega-3-acid ethyl ester formulation incorporating Advanced Lipid Technologies™ (ALT®) improves docosahexaenoic acid and eicosapentaenoic acid bioavailability compared with Lovaza®. *Clin Ther.* 2017;39:581-591.
128. Lopez-Toledano MA, Thorsteinsson T, Daak AA, **Maki KC**, Johns C, Rabinowicz AL, Sancilio FD. Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid Technologies™ (ALT®)-based formulation. *J Clin Lipidol.* 2017;11:394-405.
129. **Maki KC**, Bobotas G, Dicklin MR, Huebner M, Keane WF. Effects of MAT9001 containing eicosapentaenoic acid and docosahexaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables. *J Clin Lipidol.* 2017;11:102-109.
130. **Maki K**, Lawless A, Kelley K, Kaden V, Geiger C, Palacios O, Dicklin M. Corn oil intake favorably impacts lipoprotein cholesterol, apolipoprotein, and lipoprotein particle levels compared with extra-virgin olive oil. *Eur J Clin Nutr.* 2017;71:33-38.
131. Brinton EA, **Maki KC**, Jacobson TA, Sponseller CA, Cohen JD. Metabolic syndrome is associated with muscle symptoms among statin users. *J Clin Lipidol.* 2016;10:1022-1029.
132. Cook CM, Hallaraker H, Saebo PC, Innis SM, Kelley KM, Sanoshy KD, Berger A, **Maki KC**. Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols. *Prostaglandins Leukot Essent Fatty Acids.* 2016;111:17-24.
133. **Maki KC**, Kaspar KL, Khoo C, Derrig LH, Schild AL, Gupta K, on behalf of the UTI Study Group. Consumption of a cranberry juice beverage lowered the number of clinical urinary tract infection (UTI) episodes in women with a recent history of UTI. *Am J Clin Nutr.* 2016;103:1434-1442.

134. Karalis DG, Wild RA, **Maki KC**, Gaskins R, Jacobson TA, Sponseller CA, Cohen JD. Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. *J Clin Lipidol*. 2016;10:833-841.
135. Liska D, Kern HJ, **Maki KC**. Cranberries and urinary tract infections: how can the evidence lead to conflicting advice? *Adv Nutr*. 2016;7:498-506.
136. **Maki KC**, Guyton JR, Orringer CE, Hamilton-Craig I, Alexander DD, Davidson MH. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. *J Clin Lipidol*. 2016;10:905-914.
137. Rice HB, Bernasconi A, **Maki KC**, Harris WS, von Schacky C, Calder PC. Conducting omega-3 clinical trials with cardiovascular outcomes: proceedings of a workshop held at ISSFAL 2014. *Prostaglandins Leukot Essent Fatty Acids*. 2016;107:30-42.
138. **Maki KC**, Phillips-Eakley AK, Smith KN. The effects of breakfast consumption and composition on metabolic wellness with a focus on carbohydrate metabolism. *Adv Nutr*. 2016;7:613S-621S.
139. **Maki KC**, Dicklin MR, Baum SJ. Statins and diabetes. *Endocrinol Metab Clin North Am*. 2016;45:87-100.
140. Jacobson TA, **Maki KC**, Orringer C, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglius M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. *J Clin Lipidol*. 2015;9(6 Suppl):S1-S122.
141. Dunbar RL, Nicholls SJ, **Maki KC**, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. *Lipids Health Dis*. 2015;14:98.
142. Nieman KM, Sanoshy KD, Bresciani L, Schild AL, Kelley KM, Lawless AL, Ceddia MA, **Maki KC**, Del Rio D, Herrlinger KA. Tolerance, bioavailability, and potential cognitive health implications of a distinct aqueous spearmint extract. *FFHD*. 2015;5:165-187.
143. Cook CM, Rains TM, Kelley K, Lawless AL, Schild AL, Dicklin MR, **Maki KC**. Reduced sampling schedules for calculation of an insulin sensitivity index from the liquid meal tolerance test. *Diabetes Res Open J*. 2015;1:24-26.
144. Jacobson TA, Ito MK, **Maki KC**, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. *J Clin Lipidol*. 2015;9:129-169.
145. **Maki KC**, Geohas JG, Dicklin MR, Huebner M, Udani JK. Safety and lipid-altering efficacy of a new omega-3 fatty acid and antioxidant-containing medical food in men and women with elevated triacylglycerols. *PLEFA*. 2015;99:41-46.
146. Lafond DW, Greaves KA, **Maki KC**, Leidy HJ, Romsos DR. Effects of two dietary fibers as part of ready to eat cereal (RTEC) breakfasts on perceived appetite and gut hormones in overweight women. *Nutrients*. 2015;7:1245-1266.
147. **Maki KC**, Dicklin MR, Baum SJ. Statins and diabetes. *Cardiol Clin*. 2015;33:233-243.
148. Rains TM, Leidy H, Sanoshy KD, Lawless AL, **Maki KC**. A randomized, controlled, crossover trial to assess the acute appetitive and metabolic effects of sausage and egg-based convenience breakfast meals in overweight premenopausal women. *Nutr J*. 2015;14:17.

149. **Maki KC**, Phillips AK. Dietary substitutions for refined carbohydrate that show promise for reducing risk of type 2 diabetes in men and women. *J Nutr.* 2015;145:1S-5S.
150. **Maki KC**, Nieman KM, Schild AL, Kaden VN, Lawless AL, Kelley KM, Rains TM. Sugar-sweetened product consumption worsens glucose homeostasis compared with dairy product consumption in men and women at risk for type 2 diabetes mellitus. *J Nutr.* 2015;145:459-466.
151. **Maki KC**, Lawless AL, Kelley KM, Kaden VN, Geiger CJ, Dicklin MR. Corn oil improves the plasma lipoprotein lipid profile compared to extra-virgin olive oil consumption in men and women with elevated cholesterol: results from a randomized controlled feeding trial. *J Clin Lipidol.* 2015;9:49-57.
152. **Maki KC**, Poulos SP, Phillips AK, Lawless AL. Prescription omega-3 carboxylic acids for the treatment of severe hypertriglyceridemia. *Clinical Lipidology.* 2014;9:399-406.
153. Davidson MH, Phillips AK, Kling D, **Maki KC**. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. *Exp Rev Cardiovasc Ther.* 2014;4:1-10.
154. Jacobson TA, Ito MK, **Maki KC**, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill AE, Wild RA, Wilson DP, Brown WV. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – Executive Summary. *J Clin Lipidol.* 2014;8:473-488.
155. **Maki KC**, Yurko-Mauro K, Dicklin MR, Schild AL, Geohas JG. A new, microalgal DHA- and EPA-containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia. *PLEFA.* 2014;91:141-148.
156. **Maki KC**, Slavin JL, Rains TM, Kris-Etherton PM. Reply to Ankarfeldt. *Adv Nutr.* 2014;14:293-294. doi: 10.3945/an.114.005892.
157. Schmier JK, Miller PE, Levine JA, Perez V, **Maki KC**, Rains TM, Devareddy L, Sanders LM, Alexander DD. Cost savings of reduced constipation rates attributed to increased dietary fiber intakes: a decision-analytic model. *BMC Public Health.* 2014;14:374. doi:10.1186/1471-2458-14-374.
158. Davidson MH, Rosenson RS, **Maki KC**, Nicholls SJ, Ballantyne CS, Mazzone T, Williams LA, Kelly MT, Camp HS, Lele A, Stolzenbach JC. Effects of fenofibric acid on cIMT in patients with mixed dyslipidemia on atorvastatin therapy: A randomized, placebo-controlled study (FIRST). *Arterioscler Thromb Vasc Biol.* 2014;34:1298-1306.
159. **Maki KC**, Ridker PM, Brown WV, Grundy SM, Sattar N. An assessment by the Statin Diabetes Task Force: 2014 update. *J Clin Lipidol.* 2014;8:S17-S29.
160. Hirahatake KM, Slavin JL, **Maki KC**, Adams SH. Associations between dairy foods, diabetes, and metabolic health: potential mechanisms and future directions. *Metabolism.* 2014;63:618-627.
161. **Maki KC**, Slavin JL, Rains TM, Kris-Etherton PM. Limitations of observational evidence: Implications for evidence-based dietary recommendations. *Adv Nutr.* 2014;5:7-15.
162. McKenney JM, Jenks BH, Shneyvas E, Brooks JR, Shenoy SF, Cook CM, **Maki KC**. A softgel dietary supplement containing esterified plant sterols and stanols improves the blood lipid profile of adults with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled replication study. *J Acad Nutr Diet.* 2014;114:244-249.
163. Ito MK, **Maki KC**, Brinton EA, Cohen JD, Jacobson TA. Muscle symptoms in statin users, associations with CYP450 and membrane transporter inhibitor use: A sub-analysis of the USAGE study. *J Clin Lipid.* 2014;8:69-76.

164. Kastelein JJP, **Maki KC**, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) Trial. *J Clin Lipidol*. 2014; 8:94-106.
165. **Maki KC**, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk statin-treated patients with residual hypertriglyceridemia (the ESPRIT Trial). *Clin Ther*. 2013;35:1400-1411.
166. Hamilton-Craig I, Sullivan DR, **Maki KC**. The new cholesterol target. Recently introduced into Australian guidelines, the new cholesterol target better predicts cardiovascular events than LDL cholesterol and does not require fasting. *Cardiology Today*. 2013;3:25-27.
167. **Maki KC**, Rains TM, Schild AL, Dicklin MR, Park KM, Lawless AL, Kelley KM. Effects of low-fat dairy intake on blood pressure, endothelial function, and lipoprotein lipids in subjects with pre-hypertension or stage I hypertension. *Vasc Health Risk Manag*. 2013;9:369-379.
168. Lemke SL, **Maki KC**, Hughes G, Taylor ML, Krul ES, Goldstein DA, Su H, Rains TM, Mukherjea R. Consumption of stearidonic acid-rich oil in foods increases red blood cell eicosapentaenoic acid. *J Acad Nutr Diet*. 2013;113:1044-1056.
169. **Maki KC**, Rains TM, Kelley KM, Cook CM, Schild AL, Gietl E. Fibermalt is well tolerated in healthy men and women at intakes up to 60 g/d: A randomized, double-blind, crossover trial. *Int J Food Sci Nutr*. 2013;64:274-281.
170. **Maki KC**, Lawless AL, Reeves MS, Kelley KM, Dicklin MR, Jenks BH, Shneyvas E, Brooks JR. Lipid effects of a dietary supplement softgel capsule containing plant sterols/stanols in primary hypercholesterolemia. *Nutrition*. 2013;29:96-100.
171. Bays HE, Evans JL, **Maki KC**, Evans M, Maquet V, Cooper R, Anderson JW. Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized controlled trial. *Eur J Clin Nutr*. 2013;67:2-7.
172. **Maki KC**, Fulgoni VL 3rd, Keast DR, Rains TM, Park KM, Rubin MR. Vitamin D intake and status are associated with lower prevalence of metabolic syndrome in U.S. adults: National Health and Nutrition Examination Surveys 2003-2006. *Metab Syndr Relat Disord*. 2012;10:363-372.
173. Heaney RP, Kopecky S, **Maki KC**, Hathcock J, Mackay D, Wallace TC. A review of calcium supplements and cardiovascular disease risk. *Adv Nutr*. 2012;3:763-771.
174. Davidson M, Rosenson RS, **Maki KC**, Nicholls SJ, Ballantyne CM, Setze C, Carlson DM, Stolzenbach J. Study design, rationale, and baseline characteristics: Evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. *Cardiovasc Drug Ther*. 2012;26:349-358.
175. **Maki KC**, Dicklin MR, Bays HE. Clinical lipid management of patients with mild-to-moderate hypertriglyceridemia. *Clin Lipidol*. 2012;7:367-370.
176. **Maki KC**, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: Strategies based on the best available evidence. *J Clin Lipidol*. 2012;6:413-426.
177. Baum SJ, Kris-Etherton PM, Willett WC, Lichtenstein AH, Rudel LL, **Maki KC**, Whelan J, Ramsden CE, Block RC. Fatty acids in cardiovascular health and disease: A comprehensive update. *J Clin Lipidol*. 2012;6:216-234.
178. Brown WV, Bays HE, **Maki KC**, Wild R. Planning a clinical trial. *J Clin Lipidol*. 2012;6:484-495.

179. **Maki KC**, Rains TM. Stearidonic acid raises red blood cell membrane eicosapentaenoic acid. *J Nutr.* 2012;142:626S-629S.
180. Deckelbaum RJ, Calder PC, Harris WS, Akoh AA, **Maki KC**, Whelan J, Banz WJ, Kennedy E. Conclusions and recommendations from the symposium, Heart Health Omega-3s for Food: Stearidonic acid (SDA) as a Sustainable Choice. *J Nutr.* 2012;142:641S-643S.
181. **Maki KC**, Ndife LI, Kelley KM, Lawless AL, Brooks JR, Wright SB, Shields JM, Dicklin MR. Absorption of folic acid is similar from a softgel capsule compared to a standard tablet. *J Acad Nutr Diet.* 2012;112:1062-1067.
182. **Maki KC**, Gibson G, Dickmann R, Kendall CWC, Chen C-YO, Costabile A, Comelli EM, McKay DL, Almeida N, Jenkins D, Zello GA, Blumberg J. Digestive and physiological effects of a wheat bran extract, arabino-xylan-oligosaccharide, in breakfast cereal. *Nutrition.* 2012;28:1115-1121.
183. **Maki KC**, Pelkman CL, Finocchiaro T, Kelley KM, Lawless AL, Schild A, Rains TM. Resistant starch from high amylose maize increases insulin sensitivity in overweight and obese men. *J Nutr.* 2012;142:717-723.
184. **Maki KC**, Dicklin MR, Davidson MH, Mize PD, Kulkarni KR. Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women. *Vasc Health Risk Manag.* 2012;8:31-38.
185. **Maki KC**, Lawless AL, Reeves MS, Dicklin MR, Jenks BH, Shneyvas E, Brooks JR. Lipid-altering effects of a dietary supplement tablet containing free plant sterols and stanols in men and women with primary hypercholesterolemia: a randomized, placebo-controlled crossover trial. *Int J Food Sci Nutr.* 2012;63:476-482.
186. **Maki KC**, Van Elswyk ME, Alexander DD, Rains TM, Sohn EL, McNeill S. A meta-analysis of randomized controlled trials comparing lipid effects of beef with poultry and/or fish consumption. *J Clin Lipidol.* 2012;6:352-261.
187. Krul ES, Lemke SL, Mukherjea R, Taylor ML, Goldstein DA, Su H, Liu P, Lawless A, Harris WS, **Maki KC**. Effects of duration of treatment and dosage of eicosapentaenoic acid and stearidonic acid on red blood cell eicosapentaenoic acid content. *Prostaglandins Leukot Essent Fatty Acids.* 2012;86:51-59.
188. **Maki KC**, Bays HE, Dicklin MR, Johnson SL, Shabbout M. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII and lipoprotein-associated phospholipase A₂ mass in men and women with mixed dyslipidemia. *J Clin Lipidol.* 2011;5:483-492.
189. **Maki KC**, Lawless A, Kelley KM, Dicklin MR, Kaden VN, Schild AL, Rains TM, Marshall JW. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia. *J Cardiovasc Pharmacol.* 2011;57:489-494.
190. **Maki KC**, Lawless AL, Kelley KM, Dicklin MR, Schild AL, Rains TM. Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic β -cell response in subjects with primary hypertriglyceridemia. *Prostaglandins Leukot Essent Fatty Acids.* 2011;85:143-148.
191. Poulos SP, Rains TM, Rubin M, Kelley K, **Maki KC**. Acetate containing sports beverages appear to alter buffering capacity during endurance exercise in trained male athletes. *J Int Soc Sports Nutr.* 2011;8:P10.
192. Davidson MH, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT, Sniderman AD, Toth PP, Tsimikas S, Ziajka PE, **Maki KC**, Dicklin MR. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. *J Clin Lipidol.* 2011;5:338-367.

193. **Maki KC**, Rains TM. Hypcholesterolemic effects of plant sterols and stanols: Do the dose-response curves diverge? *Prostaglandins Leukot Essent Fatty Acids*. 2011;85:5-6.
194. Davidson MH, Kling D, **Maki KC**. Novel developments in omega-3 fatty acid-based strategies. *Curr Op Lipidol*. 2011;22:437-44.
195. **Maki KC**, Kelley KM, Lawless A, Hubacher R, Schild AL, Dicklin MR, Rains TM. Validation of insulin sensitivity and secretion indices derived from the liquid meal tolerance test. *Diabetes Technol Ther*. 2011;13:661-666.
196. **Maki KC**, Rubin MR, Wong LG, McManus JF, Jensen CD, Lawless A. Effects of vitamin D supplementation on 25-hydroxyvitamin D, high-density lipoprotein cholesterol and other cardiovascular risk markers in subjects with a high waist circumference. *Int J Food Sci Nutr*. 2011;62:318-327.
197. Banni S, Carta G, Murru E, Cordeddu L, Giordano E, Sirigu AR, Berge K, Vik H, **Maki KC**, Di Marzo V, Griinari M. Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. *Nutr Metab*. 2011;8:7.
198. **Maki KC**, Rains TM, Bell M, Reeves MS, Farmer MV, Yasunaga K. Fat mass, abdominal fat distribution and C-reactive protein concentrations in overweight and obese men and women. *Metab Syndr Relat Disord*. 2011;9:291-296.
199. **Maki KC**, Davidson MH, Dicklin MR, Bell M, Witchger M, Feinstein SB. Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. *J Clin Lipidol*. 2011;5:141-151.
200. Bays HE, **Maki KC**, Schmitz K. Colesevelam HCl powder for oral suspension versus cholestyramine powder for oral suspension: Comparison of acceptability and tolerability. *Endocr Pract*. 2011;17:218-225.
201. **Maki KC**, Rains TM. Low-dose eicosapentaenoic acid and/or docosahexaenoic acid and triglyceride lowering. *Nutr Rev*. 2010;68:567-568.
202. **Maki KC**, Butteiger DM, Rains TM, Lawless A, Reeves MS, Schasteen C, Krul ES. Effects of soy protein on lipoprotein lipids and fecal bile acid excretion in men and women with moderate hypercholesterolemia. *J Clin Lipidol*. 2010;4:531-542.
203. **Maki KC**, Rains TM, Dicklin MR, Bell M. Repeatability of indices of insulin sensitivity and secretion from standard liquid meal tests in subjects with type 2 diabetes mellitus or normal or impaired fasting glucose. *Diabetes Technol Ther*. 2010;12:419-425.
204. Bays HE, **Maki KC**, Schmitz K. The Bile Acid Sequestrant Acceptability validation study. *Intl J Clin Pract*. 2010;64:1393-1397.
205. Rains TM, Agarwal S, **Maki KC**. Anti-obesity effects of green tea catechins: A mechanistic review. *J Nutr Biochem*. 2011;22:1-7.
206. **Maki KC**, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM for the COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Baseline lipoprotein lipids and the low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to simvastatin therapy. *Am J Cardiol*. 2010;105:1409-1412.
207. Bays HE, **Maki KC**, McKenny J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. *Curr Med Res Opin*. 2010;26:907-915.

208. Alish CJ, Garvey WT, **Maki KC**, Sacks G, Hustead DS, Hegazi RA, Mustad VA. A diabetes-specific enteral formula improves glycemic variability in patients with type 2 diabetes. *Diabetes Technol Ther.* 2010;12:419-425.
209. **Maki KC**, Reeves MS, Farmer M, Griinari M, Berge K, Vik H, Hubacher R, Rains TM. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. *Nutr Res.* 2009;29:609-615.
210. Bays HE, McKenney J, **Maki KC**, Doyle RT, Carter RN, Stein E. Prescription omega-3-acid ethyl esters: effects on non-high-density lipoprotein cholesterol in combined hyperlipidemic patients when combined with escalating doses of atorvastatin. *Mayo Clin Proc.* 2010;85:122-128.
211. Davidson MH, **Maki KC**, Bays H, Carter R, Ballantyne CM. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein associated phospholipase A₂ mass in statin-treated subjects with hypertriglyceridemia. *J Clin Lipidol.* 2009;3:332-340.
212. **Maki KC**, Beiseigel JM, Jonnalagadda SS, Gugger CK, Reeves MS, Farmer MV, Kaden VN, Rains TM. Whole-grain ready-to-eat cereal, as part of a dietary program for weight loss, reduces low-density lipoprotein cholesterol in adults with overweight and obesity more than a dietary program including low-fiber control foods. *J Am Diet Assoc.* 2010;110:205-214.
213. Bays H, **Maki KC**, Doyle RT, Carter RN, Stein E. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. *Postgraduate Medicine.* 2009;121:145-150.
214. Davidson MH, **Maki KC**, Dicklin MR, Feinstein SB, Witchger MS, Bell M, McGuire DK, Provost JC, Liker H, Aviram M. Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. *Am J Cardiol.* 2009;104:936-942.
215. **Maki KC**, Rubin MR, Wong LG, McManus JF, Jensen CD, Marshall JW, Lawless A. Serum 25-hydroxyvitamin D is independently associated with high-density lipoprotein cholesterol and the metabolic syndrome in men and women. *J Clin Lipidol.* 2009;3:289-296.
216. **Maki KC**, Sanders LM, Reeves MS, Kaden VN, Rains TM, Cartwright Y. Beneficial effects of resistant starch on laxation in healthy adults. *Int J Food Sci Nutr.* 2009;60:296-305.
217. **Maki KC**, Carson ML, Anderson WHK, Geohas J, Reeves MS, Farmer MV, Turowski M, Miller M, Kaden VN, Dicklin MR, Rains TM. Lipid altering effects of different formulations of hydroxypropylmethylcellulose. *J Clin Lipidol.* 2009;3:159-166.
218. **Maki KC**, Dicklin MR, Lawless A, Reeves MS. Omega-3 fatty acids for the treatment of elevated triglycerides. *Clinical Lipidology.* 2009;4:425-437.
219. Roth EM, Bays HE, Forker AD, **Maki KC**, Carter R, Doyle RT, Stein EA. Prescription omega-3 fatty acids as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects. *J Cardiovasc Pharmacol.* 2009;54:196-203.
220. **Maki KC**, McKenney JM, Farmer MV, Reeves MS, Dicklin MR. Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose. *Nutr J.* 2009;28:8-22.
221. **Maki KC**, Lubin BC, Reeves MS, Dicklin MR, Harris WS. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia. *J Clin Lipidol.* 2009;3:33-38.

222. **Maki KC**, Mustad V, Dicklin MR, Geohas J. Postprandial metabolism with 1,3-diglyceride oil vs. equivalent intakes of long-chain and medium-chain triglyceride oils. *Nutrition*. 2009;25:627-633.
223. **Maki KC**, Reeves MS, Farmer M, Yasunaga K, Noburu M, Katsuragi Y, Komikado M, Tokimitsu I, Wilder DM, Jones F, Blumberg JB, Cartwright Y. Green tea catechin consumption enhances exercise-induced abdominal fat loss. *J Nutr*. 2009;139:264-270.
224. **Maki KC**, Kanter M, Rains TM, Hess SP, Geohas J. Acute effects of low insulinemic sweeteners on postprandial insulin and glucose concentrations in obese men. *Int J Food Sci Nutr*. 2009;60 Suppl 3:48-55.
225. Sanchez-Muniz FJ, **Maki KC**, Schaefer EJ, Ordovas JM. Serum lipid and antioxidant responses in hypercholesterolemic men and women receiving plant sterol esters vary by apolipoprotein E genotype. *J Nutr*. 2009;139:13-19.
226. **Maki KC**, Carson ML, Miller MP, Kerr Anderson WH, Turowski M, Reeves MS, Kaden V, Dicklin MR. Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia. *Eur J Clin Nutr*. 2009;63:1001-1007.
227. **Maki KC**, Reeves MS, Carson ML, Miller MP, Turowski M, Rains TM, Anderson K, Papanikolaou Y, Wilder DM. Dose-response characteristics of high-viscosity hydroxypropylmethylcellulose in subjects at risk for the development of type 2 diabetes mellitus. *Diabetes Technol Ther*. 2009;11:119-125.
228. Toth PP, **Maki KC**. A commentary on the implications of the ENHANCE (ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression) trial: should ezetimibe move to the “back of the line” as a therapy for dyslipidemia? *J Clin Lipidol*. 2008;2:313-317.
229. Voss AC, **Maki KC**, Garvey TW, Hustead DS, Alish C, Fix B, Mustad VA. Effects of two carbohydrate-modified tube-feeding formulas on metabolic responses in patients with type 2 diabetes. *Nutrition*. 2008;24:990-997.
230. **Maki KC**, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Effects of adding prescription omega-3 fatty acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. *Am J Cardiol*. 2008;102:429-433. Erratum *Am J Cardiol*. 2008;102:1425.
231. **Maki KC**, Curry LL, Carakostas MC, Tarka SM, Reeves MS, Farmer MV, McKenney JM, Toth PD, Schwartz SL, Lubin BC, Dicklin MR, Boileau AC, Bisognano JD. The hemodynamic effects of rebaudioside A in healthy adults with normal and low-normal blood pressure. *Food and Chemical Toxicology*. 2008;46:S40-S46.
232. **Maki KC**, Curry LL, Reeves MS, Toth PD, McKenney JM, Farmer MV, Schwartz SL, Lubin BC, Boileau AC, Dicklin MR, Carakostas MC, Tarka SM. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. *Food and Chemical Toxicology*. 2008;46:S47-S53.
233. **Maki KC**, Carson ML, Miller MP, Turowski M, Bell M, Wilder D, Rains TM, Reeves MS. High-viscosity hydroxypropylmethylcellulose lowers postprandial insulin levels. *J Nutr*. 2008;138:292-296.
234. Davidson MH, Stein EA, Bays H, **Maki KC**, Doyle R, Shalwitz RA, Ballantyne CM, Ginsberg HN. Efficacy and tolerability of adding prescription omega-3 fatty acids to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study – The COMBOS Trial. *Clin Ther*. 2007;29:1354-1367.
235. **Maki KC**, Carson ML, Miller MP, Turowski M, Wilder D, Reeves MS, Bell M. High-viscosity hydroxypropylmethylcellulose blunts postprandial glucose and insulin responses. *Diabetes Care*. 2007;30:1039-1043. Erratum *Diabetes Care*. 2008;31:1922-1923.

236. Izumi R, Hurt J, **Maki KC**, Bell M, Zavras AI, McCamish M. Clinical predictors of glycosylated hemoglobin responses to thiazolidinedione therapy. *Diabetes Technol Ther.* 2007;9:553-561.
237. **Maki KC**, Davidson MH, Witchger MS, Dicklin MR, Subbaiah PV. Effects of high-fiber oat and wheat cereals on postprandial glucose and lipid responses. *Int J Vitam Nutr Res.* 2007;77:347-356.
238. **Maki KC**, Rains TM, Kaden VN, Raneri KR, Davidson MH. Effects of a reduced glycemic load diet on body weight, body composition and cardiovascular risk markers in overweight and obese men and women. *Am J Clin Nutr.* 2007;85:724-734.
239. **Maki KC**, Galant R, Samuel P, Tesser J, Witchger MS, Ribaya-Mercado J, Blumberg J, Geohas J. Effects of consuming foods containing oat beta-glucan on blood pressure, carbohydrate metabolism and biomarkers of oxidative stress in men and women with elevated blood pressure. *Eur J Clin Nutr.* 2007;61:786-795.
240. Davidson MH, Bays HE, Stein E, **Maki KC**, Shalwitz RA, Doyle R. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. *Clin Cardiol.* 2006;29:268-273.
241. Ansell BJ, Fonarow GC, **Maki KC**, Dicklin MR, Bell M, Davidson MH. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. *Am Heart J.* 2006;152:976-981.
242. Deedwania PC, **Maki KC**, Dicklin MR, Stone NJ, Ballantyne CM, Davidson MH. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-technology. *J Cardiometab Syndr.* 2006;5:295-300.
243. **Maki KC**, Galant R, Davidson MH. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. *Am J Cardiol.* 2005;96(Suppl 9A):59-64.
244. Davidson MH, Dittakavi V, Bandari A, Davidson DJ, **Maki KC**, Subbaiah P. Colesevelam HCl decreases atherosclerosis and may activate reverse cholesterol transport in cholesterol-fed rabbits. *J Appl Res.* 2006;6:4-13.
245. Clark LT, **Maki KC**, Galant R, Maron DJ, Pearson TA, Davidson MH. Ethnic differences in achievement of cholesterol treatment goals: results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II. *J Gen Intern Med.* 2006;21:320-326.
246. **Maki KC**, Davidson MH, Dicklin MR. A comparison of Canadian and United States' guidelines for lipid management using data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II. *Can J Cardiol.* 2006;22:315-322.
247. LaPuma J, Szapary P, **Maki KC**. Predictors of physician overweight and obesity in the USA: an empiric analysis. *Nutrition & Food Science.* 2005;35:315-319.
248. Davidson MH, **Maki KC**, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM. Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey: Implications for treatment under the recent NCEP writing group recommendations. *Am J Cardiol.* 2005;96:556-563.
249. **Maki KC**, Van Elswyk ME, McCarthy D, Hess SP, Veith PE, Bell M, Subbaiah P, Davidson MH. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with low levels of high-density lipoprotein cholesterol. *J Am Coll Nutr.* 2005;24:189-199.

250. Adler G, Young D, Galant R, Quinn L, Witchger MS, **Maki KC**. A multi-center, open label study to evaluate patient satisfaction and menopausal quality-of-life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and systems. *Gynecol Obstet Invest*. 2005;59:212-219.
251. LaPuma J, Szapary P, **Maki KC**. Physicians recommendations for and personal use of low-fat and low-carbohydrate diets. *Int J Obes Relat Metab Disord*. 2005;29:251-253.
252. LaPuma J, Szapary P, **Maki KC**. Eating out, snacking frequency, and diet choices among overweight physicians. *Chicago Med*. 2004;107:32-34.
253. Williams JA, Lai CS, Corwin H, Ma Y, **Maki KC**, Garleb KA, Wolf BW. Inclusion of guar gum and alginate into a crispy bar improves postprandial glycemia in humans. *J Nutr*. 2004;134:886-889.
254. **Maki KC**. Dietary factors in the prevention of diabetes mellitus and coronary artery disease associated with the metabolic syndrome. *Am J Cardiol*. 2004;93(suppl):12C-17C.
255. La Puma J, Szapary P, **Maki KC**. Physicians' personal intake and prescription of weight loss products: Are we practicing what we preach? (Letter) *Arch Intern Med*. 2004;164:806-807.
256. **Maki KC**. Fibrates for treatment of the metabolic syndrome. *Curr Atheroscler Rep*. 2004;6:45-51.
257. **Maki KC**, Van Elswyk ME, McCarthy D, Seeley MA, Veith PE, Hess SP, Ingram KA, Halvorson JJ, Calaguas EM, Davidson MH. Lipid responses in mildly hypertriglyceridemic men and women to consumption of docosahexaenoic acid-enriched eggs. *Int J Vitam Nutr Res*. 2003;73:357-368.
258. Davidson MH, **Maki KC**, Umporowicz D, Wheeler A, Rittershaus C, Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. *Atherosclerosis*. 2003;169:113-120.
259. Davidson MH, Kurlandsky SB, Kleinpell RM, **Maki KC**. Lipid management and the elderly. *Prev Cardiol*. 2003;6:128-133.
260. Wolf BW, Garleb KA, Choe YS, Humphrey PM, **Maki KC**. Pullulan is a slowly digested carbohydrate in humans. *J Nutr*. 2003;133:1051-1055.
261. **Maki KC**, Davidson MH, Ingram K, Veith P, Bell M, Gugger E. Lipid responses to consumption of a beta-glucan containing ready-to-eat cereal in children and adolescents with mild-to-moderate primary hypercholesterolemia. *Nutr Res*. 2003;23:1527-1535.
262. **Maki KC**, Davidson MH, Dicklin MR, Cyrowski M, Umporowicz DM, Bell M, Elliott JG. Bioavailability of eicosapentaenoic and docosahexaenoic n-3 polyunsaturated fatty acids in salmon patties versus capsules. *J Food Sci*. 2003;68:761-766.
263. **Maki KC**, Dicklin MR, Cyrowski M, Umporowicz DM, Nagata Y, Moon G, Forusz S, Davidson MH. Improved calcium absorption from a newly formulated beverage compared with a calcium carbonate tablet. *Nutr Res*. 2002;22:1163-1176.
264. **Maki KC**, Shinnick F, Seeley MA, Veith PE, Quinn LC, Hallissey PJ, Temer A, Davidson MH. Food products containing free tall oil-based phytosterols and oat beta-glucan lower serum total and LDL cholesterol in hypercholesterolemic adults. *J Nutr*. 2003;133:808-813.
265. **Maki KC**, Davidson MH, Tsushima R, Matsuo N, Tokimitsu I, Umporowicz DM, Dicklin MR, Foster GS, Ingram KA, Anderson BD, Frost SD, Bell M. Consumption of diacylglycerol oil as part of a reduced-energy diet enhances loss of body weight and fat in comparison with consumption of a triacylglycerol control oil. *Am J Clin Nutr*. 2002;76:1230-1236.

266. Davidson MH, **Maki KC**, Karp SK, Ingram KA. Management of hypercholesterolemia in postmenopausal women. *Drugs Aging*. 2002;19:169-178.
267. Davidson MH, **Maki KC**, Umporowicz DM, Ingram KA, Dicklin MR, Schaefer E, Lane RW, McNamara JR, Ribaya-Mercado JD, Perrone G, Robins SJ, Franke WC. Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women. *J Am Coll Nutr*. 2001;20:307-319.
268. **Maki KC**, Kurlandsky SB. Syndrome X: A tangled web of risk factors for coronary heart disease and diabetes mellitus. *Topics Clin Nutr*. 2001;16:32-41.
269. Davidson MH, Dicklin MR, **Maki KC**, Kleinpell RM. Benefits of a new, nonsystemic lipid-lowering agent: the clinician's perspective. *Prev Cardiol*. 2001;4:38-39.
270. **Maki KC**, Davidson MH, Umporowicz DM, Schaefer EJ, Dicklin MR, Ingram KA, Chen S, McNamara JR, Gebhart BW, Ribaya-Mercado JD, Perrone G, Robins SJ, Franke WC. Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a NCEP Step I diet. *Am J Clin Nutr*. 2001;74:33-43.
271. Davidson M, Marwah A, Sawchuk RJ, **Maki KC**, Marwah P, Weeks C, Lardy H. Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. *Clin Invest Med*. 2000;23:300-310.
272. Davidson MH, Dicklin MR, **Maki KC**, Kleinpell RM. Colesevelam hydrochloride: A non-absorbed, polymeric cholesterol-lowering agent. *Expert Opin Investig Drugs*. 2000;9:2663-2671.
273. **Maki KC**, Davidson MH. Lean red meat and lean white meat in the NCEP Step I Diet. *Curr Treat Options Cardiovasc Med*. 2000;2:7-12.
274. **Maki KC**, Davidson MH, Cyrowski MS, Maki AC, Marx P. Low density lipoprotein subclass distribution pattern and adiposity-associated dyslipidemia in postmenopausal women. *J Am Coll Nutr*. 2000;19:23-30.
275. **Maki KC**, Davidson MH, Marx P, Cyrowski M, Maki AC. Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. *Am J Cardiol*. 2000;85:451-456.
276. **Maki KC**, Davidson MH, Torri S, Ingram KA, O'Mullane J, Daggy BP, Albrecht HH. High-molecular-weight hydroxypropylmethylcellulose taken with or between meals is hypocholesterolemic in adult men. *J Nutr*. 2000;130:1705-1710.
277. Hunninghake DB, **Maki KC**, Kwiterovich PO Jr., Davidson MH, Dicklin MR, Kafonek SD. Incorporation of lean red meat into a National Cholesterol Education Program Step I diet: A long-term, randomized clinical trial in free-living persons with hypercholesterolemia. *J Am Coll Nutr*. 2000;19:351-360.
278. Davidson MH, **Maki KC**, Marx P, Maki AC, Cyrowski MS, Nanavati N, Arce JC. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. *Arch Intern Med*. 2000;160:3315-3325.
279. Davidson MH, **Maki KC**. Effects of dietary inulin on serum lipids. *J Nutr*. 1999;129(Suppl):1474S-1477S.
280. Davidson MH, Hunninghake D, **Maki KC**, Kwiterovich PO Jr., Kafonek S. Comparison of the effects of lean red meat vs lean white meat on serum lipid levels among free-living persons with hypercholesterolemia: a long-term randomized clinical trial. *Arch Intern Med*. 1999;159:1331-1338.
281. **Maki KC**, Davidson MH, Malik KC, Albrecht HH, O'Mullane J, Daggy BP. Cholesterol-lowering with high-viscosity hydroxypropylmethylcellulose. *Am J Cardiol*. 1999;84:1198-1203.

282. Davidson MH, Dugan LD, Stocki J, Dicklin MR, **Maki KC**, Coletta F, Cotter R, McLeod M, Hoersten K. A low-viscosity soluble-fiber fruit juice supplement fails to lower cholesterol in hypercholesterolemic men and women. *J Nutr.* 1998;128:1927-1932.
283. Davidson MH, **Maki KC**, Synecki C, Torri SA, Drennan KB. Effects of dietary inulin on serum lipids in men and women with hypercholesterolemia. *Nutr Res.* 1998;18:503-517.
284. Davidson MH, **Maki KC**. Effects of conjugated equine estrogens on serum lipids in postmenopausal women. *Menopause Rev.* 1998;3:146-151.
285. Davidson MH, **Maki KC**, Kong JC, Dugan LD, Torri SA, Hall HA, Drennan KB, Anderson SM, Fulgoni VL, Saldanha LG, Olson BH. Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia. *Am J Clin Nutr.* 1998;67:367-376.
286. Davidson MH, **Maki KC**, Kalkowski J, Schaefer EJ, Torri SA, Drennan KB. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: A randomized, double-blind, placebo-controlled trial. *J Am Coll Nutr.* 1997;16:236-243.
287. Benbassat CA, **Maki KC**, Unterman TG. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: Relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. *J Clin Endocrinol Metab.* 1997;82:1484-1491.
288. Davidson MH, Macariola-Coad JR, McDonald AM, **Maki KC**, Hall HA. Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. *Am J Cardiol.* 1997;80:797-798.
289. Davidson MH, Testolin LM, **Maki KC**, von Duvillard S, Drennan KB. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. *Arch Intern Med.* 1997;157:1186-1192.
290. Hagarty EM, Skorodin MS, Langbein WE, Hultman CI, Jessen JA, **Maki KC**. Comparison of three oxygen delivery systems during exercise in hypoxemic patients with chronic obstructive pulmonary disease. *Am J Respir Critical Care Med.* 1997;155:893-898.
291. Luke A, **Maki KC**, Barkey N, Cooper R, McGee D. Simultaneous monitoring of heart rate and motion to assess energy expenditure. *Med Sci Sports Exer.* 1997;29:144-148.
292. **Maki KC**, Davidson MH, McDonald A, Malik KC. Fiber intake and risk of developing non-insulin-dependent diabetes mellitus [letter; comment]. *JAMA.* 1997;277:1761-1762.
293. **Maki KC**, Kritsch K, Foley S, Soneru I, Davidson MH. Age-dependence of the relationship between adiposity and serum low density lipoprotein cholesterol in men. *J Am Coll Nutr.* 1997;16:578-583.
294. **Maki KC**, Skorodin MS, Jessen JH, Laghi F. Effects of oral albuterol on serum lipids and carbohydrate metabolism in healthy men. *Metabolism.* 1996;45:712-717.
295. Anderson C, Foley S, **Maki K**. Comparison of two methods for evaluating dietary intake. *JADA.* 1996;96.
296. **Maki KC**, Langbein WE, Reid-Lokos C. Energy cost and locomotive economy of Handbike and Rowcycle propulsion by persons with spinal cord injury. *J Rehabil R&D.* 1995;32:170-178.
297. Langbein WE, **Maki KC**. Predicting oxygen uptake during counterclockwise arm crank ergometry in men with lower limb disabilities. *Arch Phys Med Rehabil.* 1995;76:642-646.
298. **Maki KC**, Briones ER, Langbein WE, Inman-Felton A, Nemchausky B, Welch M, Burton J. Associations between serum lipids and indicators of adiposity in men with spinal cord injury. *Paraplegia.* 1995;33:102-109.

299. **Maki KC**, Abaira C, Cooper RS. Arguments in favor of screening for diabetes in cardiac rehabilitation. *J Cardiopulm Rehabil.* 1995;15:97-102.
300. Skorodin MS, Tenholder MF, Yetter B, Owen KA, Waller RF, Khandelwahl S, **Maki KC**, Rohail T, D'Alfonso N. Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. *Arch Intern Med.* 1995;155:496-500.
301. Abaira C, **Maki KC**. Does insulin treatment increase cardiovascular risk in NIDDM? *Clin Diabetes.* 1995;13:29-31.
302. **Maki KC**, Abaira C. Insulin sensitivity, insulin secretion, and glucose effectiveness in anorexia nervosa: a minimal model analysis [letter]. *Metabolism.* 1994;43:529-530.
303. Langbein WE, **Maki KC**, Edwards LC, Hwang MH, Sibley P, Fehr L. Initial clinical evaluation of a wheelchair ergometer for diagnostic exercise testing: A technical note. *J Rehabil R&D.* 1994;31:317-325.

BOOKS, BOOK CHAPTERS AND OTHER PUBLICATIONS/REPORTS (confidential information represented by XXX):

1. Guarneiri LL, **Maki KC**. The impact of a bitter melon product on blood sugar levels. *The Academic.* Dec. 11, 2024. <https://theacademic.com/the-impact-of-a-bitter-melon-product-on-blood-sugar-levels/>.
2. Cardiovascular Outcomes Research. A Clinician's Guide to Cardiovascular Epidemiology and Clinical Outcomes Trials. **Maki KC**, Wilson DP (eds.). (2024). Contemporary Cardiology. Springer, Cham.
3. Guarneiri LL, Dicklin MR, **Maki KC**. (2024). Evolution of cardiovascular outcomes studies. In: **Maki KC**, Wilson DP (eds). Cardiovascular Outcomes Research. Contemporary Cardiology. Springer, Cham.
4. Kirkpatrick CF, Greaves JA, Foster E. (2024). Lifestyle interventions and atherosclerotic cardiovascular disease outcomes. In: **Maki KC**, Wilson DP (eds). Cardiovascular Outcomes Research. Contemporary Cardiology. Springer, Cham.
5. **Maki KC**, Kirkpatrick CF, Allison DB, Gadde KM. (2024). Pharmacotherapy for obesity: Recent evolution and implications for cardiovascular risk reduction. In: **Maki KC**, Wilson DP (eds). Cardiovascular Outcomes Research. Contemporary Cardiology. Springer, Cham.
6. Wilson DP, Hamilton L, **Maki KC**. (2024). Cardiovascular disease risk and risk reduction strategies in diabetes mellitus. In: **Maki KC**, Wilson DP (eds). Cardiovascular Outcomes Research—Contemporary Cardiology. Springer, Cham.
7. Kirkpatrick CF, Sikand G, Petersen KS, Anderson CAM, Aspry KE, Bolick JP, Kris-Etherton PM, **Maki KC**. Infographic: Nutrition Interventions for Adults with Dyslipidemia. A Clinical Perspective from the National Lipid Association. https://www.lipid.org/sites/default/files/files/NLA_2023_Nutrition_Interventions_for_Adults_with_Dyslipidemia.pdf.
8. Ballantyne CM, Gulati M, **Maki K**. There is an urgent need to re-establish LDL-C measurement and control as quality metrics in the US health care system. American College of Cardiology, Latest in Cardiology, Expert Analysis. June 21, 2023. <https://www.acc.org/Latest-in-Cardiology/Articles/2023/06/21/10/59/There-Is-an-Urgent-Need-to-Re-Establish-LDL-C-Measurement>.
9. **Maki KC**. Letter from the NLA President. A productive few months. *Lipid Spin.* Summer 2023:1.
10. **Maki KC**. Letter from the NLA President. Exciting year ahead! *Lipid Spin.* Spring 2023:1.

11. **Maki KC**. Letter from the NLA President. Hello, everyone! *Lipid Spin*. Fall 2022:1.
12. Kris-Etherton PM, Sanders L, Lawler O, Riley T, **Maki K**. 2023. Hyperlipidemia. In: Caballero B (Ed.), Encyclopedia of Human Nutrition, vol. 3. Elsevier, Academic Press, pp. 361-379.
13. Sanders LM, **Maki KC**. Importance of potassium in relation to sodium for cardiovascular health. White paper prepared for Campbell's. 2023. <https://www.regulations.gov/comment/FDA-2016-D-2335-1566>.
14. Jacobson TA, **Maki KC**. The Significance of NLA Scientific Statements and Clinical Perspectives. *Lipid Spin*. Commemorative Issue. Summer 2022:11-13.
15. Indiana University Restart Committee Recommendations for Fall 2021. Committee Members: Hess JL, Beeler CB, Dixon BE, Halverson PK, Webb DH, Carroll AE, Gardner A, Menachemi N, Saysana MS, McKeen GL, Allison DB, Dbeibo L, **Maki KC**, Simmons J, Wimbush JC. May 26, 2021. <https://www.iu.edu/covid/campus-info/fall-2021-restart-report-05-26-2021.pdf>.
16. Indiana University Restart Committee Recommendations For Summer 2021. Committee Members: Hess JL, Beeler CB, Dixon BE, Halverson PK, Webb DH, Carroll AE, Gardner A, Menachemi N, Saysana MS, McKeen GL, Allison DB, Dbeibo L, **Maki KC**, Simmons J, Wimbush JC. April 30, 2021. <https://www.iu.edu/covid/campus-info/summer-2021-restart-report-04-2021.pdf>.
17. Therapeutic Lipidology, 2nd edition. Eds. Davidson MH, Toth PP, **Maki KC**. Humana Press, Springer Nature. Switzerland AG. 2021.
18. Hirahatake KM, Dicklin MR, **Maki KC**. Chapter 5. Epidemiology of cardiovascular disease. In: Therapeutic Lipidology, 2nd edition. Eds. Davidson MH, Toth PP, **Maki KC**. Humana Press, Springer Nature. Switzerland AG. 2021.
19. **Maki KC**, Benes L, Dicklin MR. Chapter 16. Pathophysiology and management of dyslipidemias associated with insulin-resistant states. In: Therapeutic Lipidology, 2nd edition. Eds. Davidson MH, Toth PP, **Maki KC**. Humana Press, Springer Nature. Switzerland AG. 2021.
20. Indiana University Restart Committee Recommendations for Spring 2021. Committee Members: Hess JL, Beeler CB, Dixon BE, Halverson PK, Webb DH, Carroll AR, Gardner A, Menachemi N, Saysana MS, McKeen GL, Allison DB, Dbeibo L, Maki KC, Simmons J, Wimbush JC. December 24, 2020. <https://www.iu.edu/covid/docs/spring-2021-restart-report.pdf>.
21. Ejima K, **Maki KC**, Golzarria-Arroyo L, Allison DB. Utility of COVID-19 decision rules related to consecutive decline in positivity or hospitalizations: a data-driven simulation study. medRxiv preprint. Posted December 16, 2020.
22. Indiana University Restart Committee Recommendations Report. Committee Members: Hess JL, Dixon BE, Halverson PK, Webb DH, Carroll A, McKeen G, Egan JC, Kas J, Menachemi N, Saysana M, Allison DB, **Maki K**, Simmons J. May 15, 2020. <https://coronavirus.iu.edu/restart-report.pdf>.
23. **Maki KC**. SARS-CoV-2/Covid-19 pandemic update and commentary. <https://mbclinicalacademy.com/covid/>.
24. Dicklin MR, **Maki KC**. Comparing the effects of consuming egg-based breakfast meals, versus higher carbohydrate breakfast meals, on cardiometabolic risk factors. <https://mbclinicalacademy.com/egg-2/>.
25. **Maki KC**, Dicklin MR, Balakrishnan M, Neff DR. Postprandial dysmetabolism: understanding the impact of elevated postprandial glucose and triglycerides with the potential to prevent or intervene early. *Lipid Spin*. 2020;18:31-33.

26. Cortes HN, **Maki KC**. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes. <https://mbclinicalacademy.com/semaglutide/>.
27. Becraft A, **Maki KC**. The effects of nutritional supplements and dietary interventions on all-cause mortality and cardiovascular outcomes. <https://mbclinicalacademy.com/dietary/>.
28. Cortes HN, **Maki KC**. Therapeutic potential of selective peroxisome proliferator-activated receptor alpha modulators (SPPARM α) for management of patients with atherogenic dyslipidemia. <https://mbclinicalacademy.com/spparma/>.
29. Becraft A, **Maki KC**. Serum markers of oxidative stress to assess mortality risk in patients with type 2 diabetes. <https://mbclinicalacademy.com/serum/>.
30. Cortes HN, **Maki KC**. Suboptimal cholesterol response to initiation of statins future risk of cardiovascular disease. <https://mbclinicalacademy.com/cv/>.
31. Becraft A, **Maki KC**. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. <https://mbclinicalacademy.com/credence/>.
32. Becraft A, **Maki KC**. Oral semaglutide versus sitagliptin on glycated hemoglobin in adults with type 2 diabetes. <https://mbclinicalacademy.com/hemoglobin/>.
33. **Maki KC**, Cortes HN. Associations of dietary cholesterol and egg consumption with incident cardiovascular disease and total mortality. <https://mbclinicalacademy.com/consumption/>.
34. Cortes HN, **Maki KC**. Association of long-term consumption of sugar-sweetened and artificially sweetened beverages with total and cause-specific mortality. <https://mbclinicalacademy.com/sugar/>.
35. Becraft A, **Maki KC**. Effects of pioglitazone on risks for cardiovascular events and diabetes in patients with prediabetes and a history of stroke or transient ischemic attack. <https://mbclinicalacademy.com/effects/>.
36. Becraft A, **Maki KC**. Bempedoic acid in conjunction with statin therapy for dyslipidemia management. <https://mbclinicalacademy.com/bempedoic/>.
37. Becraft A, **Maki KC**. The effects of icosapent ethyl on total ischemic events: an analysis from REDUCE-IT. <https://mbclinicalacademy.com/reduceit/>.
38. Becraft A, **Maki KC**. C-reactive protein levels and cardiovascular events after acute coronary syndrome: results from a secondary analysis of the VISTA-16 trial. <https://mbclinicalacademy.com/vista16/>.
39. Cortes HN, **Maki KC**. Potential role of nut consumption for improving insulin sensitivity: results from a systematic review and meta-analysis of randomized controlled trials. <https://mbclinicalacademy.com/nuts/>.
40. Cortes HN, **Maki KC**. No additional benefits on cardiometabolic risk parameters of reduced red meat or increased fiber intake in an energy-restricted diet. <https://mbclinicalacademy.com/meat/>.
41. Becraft A, **Maki KC**. New trial suggests light therapy may be a promising intervention for treatment of depression with type 2 diabetes. <https://mbclinicalacademy.com/light/>.
42. Cortes HN, **Maki KC**. Suboptimal triglyceride levels among statin users in the National Health and Nutrition Examination Survey. <https://mbclinicalacademy.com/tg/>.
43. Cortes HN, **Maki KC**. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. <https://mbclinicalacademy.com/statin/>.

44. **Maki KC**, Dicklin MR. More evidence of low-density lipoprotein cholesterol and triglyceride-lowering genetic variants reduce risk of coronary heart disease. <https://mbclinicalacademy.com/chd/>
45. Cortes HN, **Maki KC**. Viscous fiber supplements in diabetes control: results form a systematic review and meta-analysis of randomized controlled trials. <https://mbclinicalacademy.com/fiber/>
46. Cortes HN, **Maki KC**. Potential cognitive benefits of intensive blood pressure lowering. <https://mbclinicalacademy.com/sprint/>
47. Dicklin MR, **Maki KC**. Comparing the effectiveness of second-line antidiabetic medications on cardiovascular events in patients with type 2 diabetes mellitus. <https://mbclinicalacademy.com/antidiabetic/>
48. **Maki KC**, Dicklin MR, Nieman KM. Chapter 1. Epidemiologic characterization of risk for cardiovascular disease. In: Comprehensive cardiovascular medicine in the primary care setting. Eds. Toth PP, Cannon CP. Springer Nature. Switzerland AG 2019.
49. Cortes HN, Dicklin MR, **Maki KC**. 2018 American College of Cardiology/American Heart Association cholesterol clinical practice guidelines. <https://mbclinicalacademy.com/guidelines/>
50. Cortes HN, **Maki KC**. Summaries of late-breaking science presentations at the 2018 American Heart Association meeting in Chicago, IL. <https://mbclinicalacademy.com/summary/>
51. **Maki KC**, Dicklin MR. More recent headlines from the late-breaking clinical trial presentations at the American Heart Association scientific sessions. Less pessimism called for when interpreting the results form VITAL regarding cardiovascular benefits with omega-3. <https://mbclinicalacademy.com/headlines-2/>. 2018.
52. **Maki KC**, Dicklin MR. Recent headlines from the late-breaking clinical trial presentations at the American Heart Association scientific sessions. REDUCE-IT – a landmark cardiovascular outcomes study of an omega-3 fatty acid. <https://mbclinicalacademy.com/headlines/>. 2018.
53. **Maki KC**, Dicklin MR. Fish oil is not snake oil – how the experts were fooled regarding omega-3 fatty acids and cardiovascular health. Nutri-Facts. https://www.nutri-facts.org/en_US/news.html. 2018.
54. **Maki KC**, Dicklin MR. Omega-3 fatty acids and cardiovascular health. <https://www.dsm.com/markets/human-nutrition/en/talking-nutrition/omega-3-fatty-acids-cardiovascular-health.html>. August 22, 2018.
55. **Maki KC**. Mechanisms responsible for the benefit on cardiovascular risk in the REDUCE-IT trial. <https://mbclinicalacademy.com/reduceit2/>. 2018.
56. **Maki KC**, Palacios OM. Meta-regression characterizes the relationships between changes in dietary cholesterol intake and plasma low-density and high-density lipoprotein cholesterol changes. <https://mbclinicalacademy.com/cholesterol/>. 2018.
57. **Maki KC**, Dicklin MR. Topline results from REDUCE-IT show a significant reduction in cardiovascular outcomes with omega-3 fatty acid. MB Clinical Academy. <https://mbclinicalacademy.com/reduce-2/>. 2018.
58. **Maki KC**, Dicklin MR. Results from A Study of Cardiovascular Events in Diabetes (ASCEND): taking a closer look at the potential benefit of omega-3 fatty acids for preventing cardiac death. MB Clinical Academy. <https://mbclinicalacademy.com/ascend/>. 2018

59. **Maki KC**, Dicklin MR. Omega-3 fatty acids and cardiovascular health. In DSM'S Talking Nutrition. Providing perspectives on recent research into vitamins and nutritionals. https://www.dsm.com/campaigns/talkingnutrition/en_US/talkingnutrition-dsm-com/2018/08/omega3_fatty_acids_and_cardiovascular_health.html. August 22, 2018.
60. Smith KN, Dicklin MR, **Maki KC**. A review of three recently published papers on dietary approaches to weight loss and fat mobilization. MB Clinical Academy. <https://mbclinicalacademy.com/review/>. 2018.
61. **Maki KC**, Dicklin MR. Participants with elevated Lp(a) had greater than average benefit from evolocumab in FOURIER. MB Clinical Academy. <https://mbclinicalacademy.com/participants/>. 2018.
62. Smith KN, Dicklin MR, **Maki KC**. Differential effects of n-3 and n-6 fatty acids on carotid plaque and its progression: analyses from the Multi-Ethnic Study of Atherosclerosis. MB Clinical Academy. <https://mbclinicalacademy.com/plaque/>. 2018.
63. **Maki KC**, Smith KN, Dicklin MR. ODYSSEY Outcomes Trial: Topline results and clinical implications. MB Clinical Academy. <https://mbclinicalacademy.com/odyssey/>. 2018.
64. Smith KN, Dicklin MR, **Maki KC**. 24-hour urinary collection data support strong associations between sodium and potassium excretion and blood pressure in the National Health and Nutrition Examination Survey. MB Clinical Academy. <https://mbclinicalacademy.com/bp/>. 2018.
65. Smith KN, Dicklin MR, **Maki KC**. Summary of results from a trial of a novel selective PPAR alpha modulator, pemafibrate, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia. MB Clinical Academy. <https://mbclinicalacademy.com/pemafibrate/>. 2018.
66. Smith KN, Dicklin MR, **Maki KC**. Substituting a type-4 resistant starch for available carbohydrate reduces postprandial glucose, insulin and hunger: an acute, randomized, double-blind, controlled study. MB Clinical Academy. <https://mbclinicalacademy.com/starch2/>. 2018.
67. Smith KN, **Maki KC**. An independent summary of low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk). MB Clinical Academy. <https://mbclinicalacademy.com/fourier-2/>. 2018.
68. Smith KN, Dicklin MR, **Maki KC**. Breakfast skippers beware: newly published data on breakfast patterns identifies association with atherosclerosis, independent of cardiovascular disease risk factors. Insights from the Progression of Early Subclinical Atherosclerosis (PESA) Study. MB Clinical Academy. <https://mbclinicalacademy.com/breakfast/>. 2017.
69. Palacios OM, **Maki KC**. Use of supplemental long chain omega-3 fatty acids and risk for cardiac death: an updated meta-analysis and review of research gaps. MB Clinical Academy. <https://mbclinicalacademy.com/fattyacids/>. 2017.
70. Palacios OM, **Maki KC**. Redefining a healthful diet: new results from the largest observational study ever conducted on nutrition and heart health challenge current advice. MB Clinical Academy. <https://mbclinicalacademy.com/redefining/>. 2017.
71. **Maki KC**. CVD-REAL results suggest that cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT-2) inhibitors are, indeed, real. MB Clinical Academy. <https://mbclinicalacademy.com/cvd-real/>. 2017.
72. **Maki KC**. Putting the FOURIER findings in perspective. MB Clinical Academy. <https://mbclinicalacademy.com/fourier/>. 2017.

73. **Maki KC.** Changes in diet quality and mortality. MB Clinical Academy. <https://mbclinicalacademy.com/diet/>. 2017.
74. **Maki KC.** Another CETP inhibitor fails to show cardiovascular benefit, despite reducing LDL cholesterol and raising HDL cholesterol: implications of the ACCELERATE trial. MB Clinical Academy. <https://mbclinicalacademy.com/accelerate/>. 2017
75. **Maki KC.** Debates rage on about the health effects of low-calorie sweeteners – newly published study shows no effect of sucralose on carbohydrate metabolism. MB Clinical Academy. <https://mbclinicalacademy.com/sweeteners/>. 2017.
76. Dicklin MR, **Maki KC.** MB Clinical Academy releases its first two educational programs. MB Clinical Academy. <https://mbclinicalacademy.com/education-programs/>. 2017.
77. **Maki KC.** Mendelian randomization – nature’s clinical trial – is providing new insights about the causes and potential treatments for cardiometabolic diseases. MB Clinical Academy. <https://mbclinicalacademy.com/mendelian/>. 2017.
78. **Maki KC.** Results from a systematic review and network meta-analysis suggest that lower systolic blood pressure targets are more effective for reducing risks for cardiovascular disease events and mortality. MB Clinical Academy. <https://mbclinicalacademy.com/reducing-risks/>. 2017.
79. **Maki KC.** Dr. Ralph DeFronzo Interview. MB Clinical Academy. <https://mbclinicalacademy.com/interview/>. 2017.
80. **Maki KC.** Replacing refined carbohydrates with egg protein and unsaturated fatty acids improves insulin sensitivity and the cardiometabolic profile. MB Clinical Academy. <https://mbclinicalacademy.com/egg/>. 2017.
81. **Maki KC.** Diet and prevention of type 2 diabetes mellitus: beyond weight loss and exercise (short course). MB Clinical Academy. <https://mbclinicalacademy.com/downloads/diabetes/>. 2017.
82. **Maki KC.** Interpreting efficacy results from cardiovascular outcomes trials (short course). MB Clinical Academy. <https://mbclinicalacademy.com/downloads/outcomes/>. 2017.
83. **Maki K,** Dicklin M, Baum SJ. Diet quality and cardiometabolic health: dietary patterns and risk for atherosclerotic cardiovascular disease and type 2 diabetes mellitus. American College of Cardiology – Latest in Cardiology – Expert Analysis. April 7, 2016. Available at: http://www.acc.org/latest-in-cardiology/articles/2016/04/07/10/05/diet-quality-and-cardiometabolic-health?w_nav=LC.
84. **Maki KC.** The Experts Speak, Type 2 diabetes and refined carbohydrate substitution as anti-diabetic therapy. Print Expert Interview and “Staying Healthy Today Show” Podcast. [www.Vitasearch.com](http://www.vitasearch.com). January, 2016.
85. **Maki KC,** Palacios OM. Phytosterol safety: use with other cholesterol lowering medications – Case 1. Pharmacy Times Continuing Education. December 18, 2015.
86. **Maki KC,** Palacios OM. Phytosterol adherence: helping patients meet TLC goals – Case 2. Pharmacy Times Continuing Education. December 18, 2015.
87. Sikand G, Kirkpatrick C, **Maki K,** Kris-Etherton PM. Go ‘Nuts’ for Your Heart-Health Tear Sheet. Patient Information from the Foundation of the National Lipid Association. 2015.
88. **Maki KC,** Dicklin MR, Eakley AK. Phytosterols for lowering cholesterol: pharmacy interventions to improve patient outcomes. Pharmacy Times. October 7, 2015.

89. Phillips AK, **Maki KC**. Beyond LDL cholesterol: alternative measures of atherogenic lipoprotein burden and cardiovascular disease risk. Nutrition Research Update (Egg Nutrition Center), 2015.
90. National Lipid Association. Self-Assessment Program: Volume 1. The Science of Clinical Lipidology: Lipid Metabolism, Pathogenesis of Atherosclerosis and Genetic Disorders. AKH Inc., 2013.
91. National Lipid Association. Self-Assessment Program: Volume 2. Cardiovascular Disease Risk Stratification: Identification of Risk Factors and Management of Patients at Risk. AKH Inc., 2013.
92. National Lipid Association. Self-Assessment Program: Volume 3. Contemporary Management of Dyslipidemia: Therapeutic Lifestyle Change. AKH Inc., 2013.
93. National Lipid Association. Self-Assessment Program: Volume 4. Contemporary Management of Dyslipidemia: Pharmacologic Therapy. AKH Inc., 2013.
94. National Lipid Association. Self-Assessment Program: Volume 5. Consultative Issues in Clinical Lipidology. AKH Inc., 2013.
95. Phillips AK, **Maki KC**. Plant sterols: an effective dietary adjunct for maintaining a healthy cholesterol level. Dietary Supplement Science News and Views (Pharmavite), 2014.
96. Rains TM, **Maki KC**. The effects of oats and oat β -glucan on blood lipoproteins and risk for cardiovascular disease. In: Chu Y-F (ed). *Oats Nutrition and Technology*. John Wiley & Sons, Ltd., 2014, pages 229-238.
97. Rains TM, **Maki KC**. The effects of oats and β -glucan on blood pressure and hypertension. In: Chu Y-F (ed). *Oats Nutrition and Technology*. John Wiley & Sons, Ltd., 2014, pages 239-254.
98. Cook CC, Rains TM, **Maki KC**. Effects of oats on obesity, weight management, and satiety. In: Chu Y-F (ed). *Oats Nutrition and Technology*. John Wiley & Sons, Ltd., 2014, pages 265-280.
99. Nieman K, Rains TM, Dicklin MR, **Maki KC**. Wheat fiber in postprandial metabolic outcomes and health. In: Watson RR, Preedy VR, Zibadi S (eds.). *Whole Wheat and Rice in Disease Prevention and Health*. Elsevier, 2013;5:59-66.
100. Rains RM, Nieman KM, Cook CM, Dicklin MR, **Maki KC**. Protein and satiety: A comprehensive review of the literature and potential benefit statements. Proprietary review prepared for XXX. 2013.
101. Nieman KM, Cook CM, Rains TM, **Maki KC**. Mental energy: Proceedings of a scientific advisory panel. Proprietary document prepared for XXX. 2013.
102. Harland JI, Krul ES, Mukherjee R, **Maki K**. Soy: Nutrition, Consumption, and Heart Health. In: Ahmad A (ed.). *Soy: Nutrition, Consumption, and Health*. Nova Science Publishers, Inc. 2013.
103. **Maki KC**. Measurement techniques for insulin sensitivity. In: Cho S and Almeida N (eds). *Dietary Fiber and Health*. 1st edition. CRC Press, 2012.
104. **Maki KC**, Silverman M. Casino blackjack for the recreational player—a guide to playing for fun and casino comps. Tipping the Odds Press, 2012.
105. **Maki KC**, Rains TM. Dietary fibers, insulin sensitivity and risk for type 2 diabetes. *SCAN's Pulse: A Publication for Sports, Cardiovascular, and Wellness Nutritionists from the Sports, Cardiovascular and Wellness Nutrition Practice Group within the American Dietetic Association*. 2011;30:6-9.

106. **Maki KC**, Rains TM. Fiber and insulin sensitivity. In: Zimering MB (ed). *Topics in the Prevention, Treatment, and Complications of Type 2 Diabetes*, InTech Open, 2011.
107. **Maki KC**, Rubin MR, Wong LG, McManus JF, Jensen CD, Marshall JW, Lawless A. Serum 25-hydroxyvitamin D is independently associated with high-density lipoprotein cholesterol and the metabolic syndrome in men and women. *International Atherosclerosis Society Commentaries*. Posted October, 2010.
108. **Maki KC**, Cofer-Chase L, Dicklin MR, Rains TM. High-viscosity hydroxypropylmethylcellulose: A promising agent to improve management of hypercholesterolemia. *International Atherosclerosis Society Commentaries*. Posted November, 2010.
109. Rains TM, **Maki KC**. The relationship between dietary protein and satiety in children and adults. Proprietary review prepared for XXX. 2010.
110. **Maki KC**, Rubin M. Cardiovascular epidemiology and characterization of atherosclerotic disease risk factors. In: Toth PP, Cannon CP, (eds). *Comprehensive Cardiovascular Care in the Primary Care Setting*, Humana Press, 2010.
111. **Maki KC**. *Tipping the Odds for the Entrepreneur: Big Ideas on Success for the Small Business Owner*. Glen Ellyn, IL: Provident Business Press, 2010.
112. **Maki KC**. Underutilization of dietary adjuncts in dyslipidemia management. *Lipid Spin-Practical Pearls*. 2009;7:15-34.
113. Rains TM, Anderson B, **Maki KC**. Green tea catechins and abdominal fat loss. *SCAN's Pulse: A Publication for Sports, Cardiovascular, and Wellness Nutritionists from the Sports, Cardiovascular and Wellness Nutrition Practice Group within the American Dietetic Association*. 2009;28:1-4.
114. Rains TM, Rubin M, **Maki KC**. Effects of breakfast consumption on selected elements of health and wellness in children and adolescents. Proprietary review prepared for XXX. 2009.
115. Cofer L, Rains TM, Rubin M, **Maki KC**. A scientific review of the health benefits of oats. Proprietary review prepared for XXX. 2009.
116. Rubin MR, Rains TM, **Maki KC**. Tools for the assessment of cognitive function in nutrition research. Proprietary review prepared for XXX. 2009.
117. Dicklin M, Rains TM, **Maki KC**. The relationships of cheese consumption with atherosclerotic heart disease and heart disease risk factors including metabolic syndrome and its components. Proprietary review prepared for XXX. 2009.
118. Cartwright Y, **Maki KC**, Rubin M, Rains TM. Health effects of fermentable dietary fibers. Proprietary review prepared for XXX. 2008.
119. **Maki KC**, Matsuo N, Dicklin MR. Clinical studies evaluating the benefits of diacylglycerol for managing excess adiposity. In: Katsuragi Y, Yasukawa T, Matsuo N, Flickinger BD, Tokimitsu I, and Matlock MG (eds). *Diacylglycerol Oil*, AOCS Press, 2nd ed. 2008.
120. **Maki, KC** and Dicklin MR. How well do various lipids and lipoprotein measures predict cardiovascular disease morbidity and mortality? In: Toth PP, Sica D (eds). *Clinical Challenges in Lipid Disorders*. Oxford: Clinical Publishing, 2008.
121. Toth PP, **Maki KC**. *Practical Lipid Management: Concepts and Controversies*. London: John Wiley & Sons, 2008.

122. *Therapeutic Lipidology*. Davidson MH, Toth PP, **Maki KC** (eds). Totowa, NJ: Humana Press, 2007.
123. **Maki KC**. Pathophysiology and management of dyslipidemias associated with obesity, type 2 diabetes and other insulin resistant states. In Davidson MH, Toth PP, **Maki KC** (eds). *Therapeutic Lipidology*. Totowa, NJ: Humana Press, 2007.
124. **Maki KC**. Maximizing the role of non-drug interventions in lipid management: A call to action. *Nutrition & the M.D.* 2006;32:1-4.
125. **Maki KC**. Clinical trial points to way of cutting heart attack risk. *Financial Times*. March 17, 2006.
126. **Maki KC**, Matsuo N, Dicklin MR. Clinical studies evaluating the benefits of diacylglycerol for managing excess adiposity. AOCS Press. *Diacylglycerol Oil*. 2003; 96-108.
127. **Maki KC**. Diacylglycerol oil vs. triacylglycerol oil in a weight reduction diet: A double-blind parallel study in the United States. In: Huang YS, Lin SJ, Huang PC (eds). *Essential Fatty Acids and Eicosanoids - Invited Papers from the Fifth International Congress*. 2003;328-332.
128. **Maki KC**. Investigating the health benefits of phytochemicals: The use of clinical trials. In: Johnson I, Williamson G (eds). *Phytochemical Functional Foods*. 2003;238-252.
129. **Maki KC**. How to buy a house, townhouse or condominium for at least 10% below market value. Chicago: *KBD Research Associates*, 2003.
130. **Maki KC**. Beating the Dow with rental houses. How small investors can create wealth and income with single-family rental properties. Chicago: *KBD Research Associates*, 2003.
131. Davidson MH, Ballantyne CM, Brewer HB, Brown VW, Jacobson T, **Maki KC**, McKenney JM, Mazzone T, McBride P. Preventive Cardiology Self-Assessment Program: Multiple Choice Questions Question Book. LaRocca DS (ed). Professional Evaluation, Inc.: Chicago, 2002.
132. **Maki KC**. Get started in real estate today. 14 success secrets for buying and managing rental houses. Chicago: *KBD Research Associates*, 2002.
133. Oldham KM, **Maki KC**. Issues in the design and conduct of clinical trials in obesity. Proprietary review prepared for General Mills, Inc. 2002.
134. **Maki KC**. Clinical trial design for evaluating phytochemical bioactivity. In: Bidlack WR, Omaye ST, Meskin MS, Jahner D (eds). *Phytochemicals as Bioactive Agents*. 2000;75-86.
135. Cyrowski MS, Dicklin MR, **Maki KC**. Psyllium and cardiovascular disease. *Nutrition in Complementary Care*. 1999;2:5.
136. Davidson MH, **Maki KC**. Cardiovascular risk factors: evaluation and treatment goals. In: Kris-Etherton PM, Burns J (eds). *Cardiovascular Nutrition: Strategies and Tools for Disease Management and Prevention*. Chicago, IL: American Dietetic Association, 1998;3-16.
137. McDonald A, **Maki KC**, Davidson MH. Management of dyslipidemia and hypertension. In: Kris-Etherton PM, Burns J (eds). *Cardiovascular Nutrition: Strategies and Tools for Disease Management and Prevention*. Chicago, IL: American Dietetic Association, 1998;17-27.
138. **Maki KC**. Diets rich in soy foods show promise as a means for lowering atherosclerotic disease risk. *Sports, Cardiovascular, and Wellness Nutritionists' Pulse*. 1996;15:1-3.
139. **Maki KC**. The minimum memory system. *Blackjack Forum*. 1996;16:36-40.

140. **Maki KC.** Risk factor management for patients with coronary heart disease: Time for a new approach. *ISCHR Newsletter*, Fall 1995;4-6.
141. Edwards LC, Langbein WE, Louie EK, Orebaugh C, **Maki KC.** Wheelchair exercise and digital echocardiography for the non-invasive assessment of cardiac function in active wheelchair users 55 years of age and older. *National Veterans Golden Age Games Research Monograph*, 1995;20-29.
142. **Maki KC**, Soneru I, Getlinger KR, Foley S, Langbein WE. Anthropometric and hormonal covariates of the Metabolic Cardiovascular Syndrome in men ≥ 55 years of age. *National Veterans Golden Age Games Research Monograph*, 1994;64-73.
143. Soneru I, Palla K, **Maki KC**, Roxas J, Moritz T, D'Anza J. Geriatric Assessment in Golden Age Games Participants: Prevalence of osteoporosis and hypogonadism. *National Veterans Golden Age Games Research Monograph*, 1994;90-96.
144. **Maki KC.** The metabolic cardiovascular syndrome: Importance for cardiac rehabilitation. *Illinois Soc for Cardiopul Rehabil Newsletter*. 1993;Fall issue:3-4.
145. **Maki KC.** Undiagnosed non-insulin-dependent (Type II) diabetes mellitus in patients referred for cardiac rehabilitation. *Illinois Soc for Cardiopul Rehabil Newsletter*. 1993;Fall issue: 4-5.

THESIS AND DISSERTATION:

1. Metabolic features of postmenopausal women with the low-density lipoprotein subclass pattern B phenotype. (1998) Doctor of Philosophy Dissertation. University of Illinois at Chicago, Chicago, Illinois.
2. Energy cost of Handbike and Rowcycle propulsion. (1990) Master of Science Thesis. Illinois Benedictine College, Lisle, Illinois.

ABSTRACTS:

1. Bhatt DL, Gaudet D, **Maki KC**, Banach M, Umpierrez G, Agollah GD, Hartsfield CL, Sterling L, Parli T, Bays H. Prevalence of metabolic-dysfunction associated steatotic liver disease (MASLD) and metabolic-dysfunction associated steatohepatitis (MASH) in subjects with severe hypertriglyceridemia (SHTG): Baseline data from the pegozafermin ENTRUST Phase 3 SHTG Trial. Presented at the Cardiometabolic Health Congress (CMHC), October 23-25, 2025, in Boston, MA.
2. Beidelman ET, Judge A, Allison DB, Dickinson S, Arroyo LG, Macagno ALM, Ricciardi MJ, Macy J, Perlman S, Ludema C, **Maki KC**, Rosenberg M. The relationship between psychological stress and SARS-CoV-2 nucleocapsid-antibody response following natural infection: Longitudinal findings from the Aegis Study. Presented at the 2025 Society for Epidemiologic Research Annual Meeting, June 10-13, 2025, in Boston MA.
3. Judge AS, Beidelman ET, Allison DB, Dickinson S, Arroyo LG, Macagno ALM, Macy J, **Maki KC**, Rosenberg M, Ludema C. Relative immune protection from combinations of prior infection and vaccination on incident SARS-CoV-2 infection/reinfection: a prospective cohort study comparing self-reported and antibody-based indicators of prior infection, February 2021 to January 2023. Presented at the 2025 Society for Epidemiologic Research Annual Meeting, June 10-13, 2025, in Boston MA.
4. Gundermann D, Ghatak S, Wilcox ML, **Maki KC**, Pauli EK. A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effects of a Reishi Mushroom and Ashwagandha Supplement on Perceived Stress in Healthy Humans. *Curr Develop Nutr*. 2025;9(Suppl 2):106183.

5. **Maki KC**, Wilcox ML, Kirkpatrick CF, Guarneiri LL, Beidelman ET, Allison DB. Associations of serum omega-6 polyunsaturated fatty acids with biomarkers of glucose homeostasis. *Curr Develop Nutr.* 2025;9(Suppl 2):106488.
6. **Maki KC**, Wilcox ML, Kirkpatrick CF, Beidelman ET, Guarneiri LL, Allison DB. Associations of serum omega-6 polyunsaturated fatty acids with biomarkers of inflammation. *Curr Develop Nutr.* 2025;9(Suppl 2):106449.
7. **Maki KC**, Edirisinghe I, Guzman E, Wilcox ML, Kirkpatrick CF, Adams CG, Burton-Freeman BM. Impact of diets containing beef versus poultry on pancreatic β -cell function in men and women with prediabetes: A randomized, crossover trial. *Curr Develop Nutr.* 2025;9(Suppl 2):106162.
8. Kalra DK, Ray KK, Bajaj A, Kushner PR, Wilcox ML, Dicklin MR, Kirkpatrick SF, **Maki KC**. A meta-analysis of the effects of low-density lipoprotein cholesterol lowering on major adverse cardiovascular event rates in primary prevention trials. *J Clin Lipidol.* 2025. Late-breaking Abstract.
9. Kirkpatrick CF, Wilcox ML, Guarneiri LL, Attia P, Allison DB, **Maki KC**. Associations of serum omega-3 polyunsaturated fatty acids with apolipoprotein B and atherogenic lipoprotein lipids. *J Clin Lipidol.* 2025;19:3(Suppl):E62.
10. **Maki KC**, Wilcox ML, Kirkpatrick CF, Guarneiri LL, Attia P, Allison DB. Associations of serum omega-6 polyunsaturated fatty acids with apolipoprotein B and atherogenic lipoprotein lipids. *J Clin Lipidol.* 2025;19:3(Suppl):E62-63.
11. **Maki KC**, Parli T, Sanyal AJ, Hartsfield C, Agollah G, Gottwald M, Margalit M, Mansbach H, Balic K, Tseng L, Bhatt DL. Triglyceride reduction with pegozafermin is highly correlated across metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia. *JACC.* 2025;85 (12, Suppl A): 2398.
12. Gletsu-Miller N, Wilcox M, Spence LA, Wright AJ, Guarneiri LL, Nadeem MM, Hutter MJ, Sprague KL, Brown A, Friedman A, **Maki KC**. Effects of replacing solid fats and added sugars with avocado in adults with elevated cardiometabolic risk: A randomized controlled trial. Presented at American Heart Association's Epidemiology and Prevention/Lifestyle and Cardiometabolic Health. March 6, 2025, in New Orleans, LA.
13. Coleman C, Kiel JR, Palacios OM, Bell M, Wilcox ML, **Maki KC**, Unick JL, Jonnalagadda SS. Early weight loss and other predictors of clinically significant weight loss on two commercial weight loss programs. *Curr Develop Nutr.* 2024;8 (Suppl 2):103536.
14. Kuan CM, Guarneiri LL, **Maki KC**, Wilcox M. Investigation of the hypoglycemic effect of a bitter melon extract in subjects with prediabetes: A randomized, placebo-controlled, and double-blind trial. *Curr Develop Nutr.* 2024;8 (Suppl 2):102881.
15. Malinczak CA, Peterson R, Clark AJ, Guarneiri LL, Wilcox ML, Adams CG, **Maki KC**. A randomized, double-blind, controlled trial to assess the effects of lactoferrin at two doses vs. active control on markers of immune safety in healthy adults. *Curr Develop Nutr.* 2024;8 (Suppl 2):103397.
16. Yerke A, Baer D, Novotny JA, **Maki K**, Petersen K, Shao J, Vinyard B, Campbell W, Fleming J, Kris-Etherton P, O'Connor LE. Protocol for the metabol(om)ic response to omnivorous dietary patterns using randomized controlled feeding trials (MET-OMNIV) research consortium and dataset. *Curr Develop Nutr.* 2024;8 (Suppl 2):103696.
17. Sanders LM, Dicklin MR, Zhu Y, **Maki KC**. The relationship of ready-to-eat cereal intake and body weight in adults and children: A systematic review. Presented at Nutrition 2023, July 22-25, 2023. *Curr Develop Nutr.* 2023;7 (Suppl 1):101615.

18. Guarneiri LL, Wilcox ML, **Maki KC**. A comparison of the effects of Ruby-O and krill oil on plasma levels of eicosapentaenoic and docosahexaenoic acids after acute administration. Presented at Nutrition 2023, July 22-25, 2023. *Curr Develop Nutr.* 2023;7 (Suppl 1):100539.
19. Nkrumah-Elie Y, **Maki KC**, Dicklin MR, Idoine R, Sanders LM, Wilcox M, Maki CE, Shao A. Effect of nicotinamide riboside supplementation on cognition and related outcomes in a group of healthy older adults. Presented at The NAD + Metabolism and Signaling Conference, June 26-30, 2022.
20. **Maki KC**, Bays HE, Ballantyne CM, Underberg JA, Kastelein JJP, Johnson JB, Ferguson JJ. An open-label, crossover study comparing EPA+DPA-free fatty acids and EPA-ethyl esters in adults with elevated triglycerides: ENHANCE-IT. Presented at 2021 National Lipid Association Scientific Sessions, September 24-26, 2021.
21. Sanders LM, Zhu Y, Wilcox ML, Koecher K, **Maki KC**. Effects of whole grain intake, compared to refined grain, on glycemia and insulinemia: a systematic review and meta-analysis of randomized controlled trials. Presented at Nutrition 2021 Live Online, June 7-10, 2021. *Curr Develop Nutr.* 2021;5(Suppl 2):521.
22. Sanders LM, Wilcox ML, **Maki KC**. Red mean intake and glycemic and insulinemic risk factors for type 2 diabetes: a systematic review and meta-analysis. Presented at Nutrition 2021 Live Online, June 7-10, 2021. *Curr Develop Nutr.* 2021;5(Suppl 2):522.
23. Cassady BA, McDonald JD, Yalawar M, **Maki KC**. The impact of a carbohydrate loading drink on postprandial glycemic responses and gastric emptying in adults with prediabetes and type 2 diabetes mellitus. Presented at ASPEN 2021 Nutrition Science & Practice Conference, Virtual Conference, March 20-23, 2021. *JPEN J Parenter Enteral Nutr.* 2021;45:S173.
24. Wilcox ML, Edirisinghe I, Dicklin MR, Xiao D, Burton-Freeman B, **Maki KC**. Comparison of two methods for assessing small, dense LDL cholesterol. Presented at 2020 National Lipid Association Scientific Sessions in Chicago, IL, December 13-16, 2020. *J Clin Lipidol.* 2020.
25. Sanders L, Zhu Y, Wilcox M, Palacios O, Koecher K, **Maki KC**. Effects of whole grain, compared to refined grain, intake on subjective measures of appetite: a systematic review and meta-analysis. Presented at Nutrition 2020 Live Online, June 1-4, 2020. *Curr Develop Nutr.* 2020;4(Suppl 2):657.
26. Devarshi P, Grant R, Wilcox M, Ali M, Sanders L, **Maki KC**. Absorption of folic acid from different delivery forms: a randomized, crossover study. Presented at Nutrition 2020 Live Online, June 1-4, 2020. *Curr Develop Nutr.* 2020;4(Suppl 2):970.
27. Cheeley MK, Jacobson TA, Jones PH, LaForge R, **Maki KC**, Lopez AG, Xiang P, Bushnell DM, Martin ML, Cohen JD. The Statin Adverse Treatment Experience (STATE) Survey: Experience of patients reporting the side-effects of statin therapy. Presented at National Lipid Association Scientific Sessions in Miami, FL, May 16-19, 2019.
28. **Maki KC**, Dicklin MR, Cassens ME, Bell M, Bunczek M, Eren F. Predictors of cholesterol lowering with corn oil consumption: results from a pooled analysis of randomized, free-living feeding trials. Presented at Nutrition 2019 in Baltimore, MD, June 8-11, 2019.
29. **Maki KC**, Palacios OM, Buggia M, Dicklin M, Bell M, Maki C. The effect of replacing carbohydrate-based breakfast foods with eggs on cardiometabolic risk factors in adults at risk for type 2 diabetes. Presented at Nutrition 2019 in Baltimore, MD, June 8-11, 2019.
30. Palacios OM, **Maki KC**, Buggia M, Dicklin M, Bell M, Maki C. Dietary effects of replacing carbohydrate-based breakfast foods with eggs in adults at risk for type 2 diabetes. Presented at Nutrition 2019 in Baltimore, MD, June 8-11, 2019.

31. **Maki KC**, Palacios OM, Wilcox ML, Dicklin M, Bell M, Maki CE. Effects of lean beef intake, as part of a healthful dietary pattern, on cardiometabolic risk markers in subjects at risk for diabetes mellitus: a controlled feeding trial. Presented at Nutrition 2019 in Baltimore, MD, June 8-11, 2019.
32. **Maki KC**, Palacios OM, Koecher K, Sawicki CM, Livingston KA, Bell M, McKeown NM. The relationship between whole grain intake and body weight: results of meta-analyses of observational studies and randomized controlled trials. Presented at Nutrition 2019 in Baltimore, MD, June 8-11, 2019.
33. Anderson J, **Maki KC**, Edirisinghe I, Spitznagel MB. The moderating role of response to a blood glucose challenge in postprandial cognition following consumption of milk, fruit juice, and water. Presented at Nutrition 2019 in Baltimore, MD, June 8-11, 2019.
34. **Maki KC**, Palacios OM, Buggia MA, Trivedi R, Dicklin MR, Maki CE. A randomized, crossover study to assess the relative bioavailability of eicosapentaenoic acid and docosahexaenoic acid from a novel dietary formulation compared to that of a standard ethyl ester product in healthy men and women. Presented at the 2018 Food & Nutrition Conference & Expo (FNCE) in Washington DC, October 22, 2018.
35. **Maki KC**, Hasse W, Dicklin MR, Bell M, Buggia MA, Cassens M, Eren F. Corn oil consumption improves the plasma lipid profile vs. coconut oil in men and women with above-desirable levels of cholesterol. Presented at Nutrition 2018 in Boston, MA, June 10-12, 2018.
36. **Maki KC**, Jenks BH, Dicklin MR, Ndife LI, Bell M, Maki CE, Hasse W. Effects of plant sterols and stanols plus pantethine on lipoprotein lipids in men and women with above-desirable low-density lipoprotein cholesterol. Presented at Nutrition 2018 in Boston, MA, June 10-12, 2018.
37. Palacios OM, Vincent MJ, Allen B, Taber LT, **Maki KC**. The effect of dietary cholesterol on high-density lipoprotein cholesterol levels in men and women – a meta-analysis of randomized controlled trials. Presented at Nutrition 2018 in Boston, MA, June 10-12, 2018.
38. Vincent MJ, Allen B, **Maki KC**, Palacios OM, Taber LT. Non-linear models best characterize the relationship between dietary cholesterol intake and circulating low-density lipoprotein cholesterol levels. Presented at Nutrition 2018 in Boston, MA, June 10-12, 2018.
39. **Maki KC**, Nieman KM, Eren F, Cassens M. Modeling of the relationships between the consumption of commonly consumed dietary fats/oils and mortality. *J Acad Nutr Diet.* 2017;117:A136.
40. Martin M, Jacobson T, Cheeley MK, Harrison D, Jones P, LaForge R, Lopez JA, **Maki K**, McCarrier K, Miller T, Patel J, Thompson P, Cohen J. Qualitative study to identify patient perceived symptoms of statin intolerance. *Value in Health.* 2017;20:A1-A283.
41. **Maki KC**, Bell M, Dicklin MR, Davidson MH. Discordance of low-density lipoprotein cholesterol with alternate lipid measures in statin-treated men and women with mixed dyslipidemia. *J Clin Lipidol.* 2017;11:774.
42. Lopez-Toledano MA, Thorsteinsson T, Daak A, **Maki KC**, Johns C, Rabinowicz AL, Sancilio F. A novel omega-3-acid ethyl ester formulation incorporating Advanced Lipid Technologies™ (ALT®) improves docosahexaenoic acid and eicosapentaenoic acid bioavailability compared with Lovaza®. *J Clin Lipidol.* 2017;11:829-830.
43. Daak AA, Lopez-Toledano MA, Thorsteinsson T, **Maki KC**, Johns C, Rabinowicz AL, Sancilio F. Minimal food effect for eicosapentaenoic acid and eicosapentaenoic acid bioavailability from omega-3 acid ethyl esters with an Advanced Lipid Technologies™ (ALT®)-based formulation. *J Clin Lipidol.* 2017;11:829.

44. Palacios OM, Nieman KM, Cook CM, **Maki KC**. Evaluation of a reduced sampling schedule for assessment of pancreatic beta-cell function with the intravenous glucose tolerance test during a dietary intervention. *FASEB J*. 2017;31:1b284.
45. Edirisinghe I, Palacios OM, Burton-Freeman B, Spitznagel MB, Nieman KM, Bell M, **Maki KC**. A randomized, controlled crossover trial to assess the acute cognitive, appetite, glucose and insulin responses to milk and juice beverages in men and premenopausal women. *FASEB J*. 2017;31:1b283.
46. Winters BL, Anthony JC, Remensperger A, Boorsma A, van den Broek, T, **Maki KC**. Validation of a macronutrient mixed challenge beverage for personalized nutrition applications using a reduced sampling period. *FASEB J*. 2017;31:1b289.
47. **Maki KC**, Palacios OM, Nieman KM, Lindner E, Huebner M, Sorce J. Replacement of refined carbohydrates with a combination of egg protein and unsaturated fatty acids improves insulin sensitivity in adults with elevated triglycerides. *FASEB J*. 2017;31:966.6.
48. Palacios OM, **Maki KC**, Nieman KM, Lindner E, Huebner M, Sorce J. Replacement of refined carbohydrates with a combination of egg protein and unsaturated fatty acids improves the lipoprotein lipid profile in adults with elevated triglycerides. *FASEB J*. 2017;31:966.7.
49. Nieman KM, **Maki KC**, Palacios OM, Lindner E, Huebner M, Sorce J. Replacement of refined carbohydrates with a combination of egg protein and unsaturated fatty acids: effects on lipoprotein particle concentrations and LDL peak size in adults with elevated triglycerides. *FASEB J*. 2017;31:966.8.
50. Nieman KM, Dicklin MR, Schild AL, Kaspar KL, Khoo C, Derrig LH, Gupta K, **Maki KC**. Cranberry beverage consumption reduces antibiotic use for clinical urinary tract infection in women with a recent history of urinary tract infection. *FASEB J*. 2017;31:964.26.
51. **Maki KC**, Keane WF, Bobotas G, Wu H, Ballantyne CM. Effects of eicosapentaenoic acid plus docosapentaenoic acid and eicosapentaenoic acid alone on fasting and postprandial lipids. *National Lipid Association Scientific Sessions*. May, 2016.
52. Wu H, Perrard XD, Bobotas G, **Maki KC**, Ballantyne CM. Effects of eicosapentaenoic acid plus docosapentaenoic acid and eicosapentaenoic acid alone on fasting and postprandial monocyte phenotypes. *Arteriosclerosis, Thrombosis, and Vascular Biology/Peripheral Vascular Disease*. May, 2016.
53. Cook CM, Halaraker H, Saebo PC, Innis SM, Kelley KM, Sanoshy KD, Berger A, **Maki KC**. Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols. *FASEB J*. 2016;30:684.3.
54. **Maki KC**, Nieman KM, Cook CM, Huebner M, Baum SJ. Evaluation of an insulin sensitivity index from the short intravenous glucose tolerance test for detecting response to a dietary intervention. *FASEB J*. 2016;30:1b288.
55. **Maki KC**, Chad CM, Huebner M, Palacios OM. Evaluation of an insulin sensitivity index from the short intravenous glucose tolerance test. *FASEB J*. 2016;30:1b287.
56. **Maki KC**, Keane WF, Bouhajib M, Pop R, Bobotas G. Pharmacokinetics of MAT9001, an omega-3 fatty acid medication, compared with eicosapentaenoic acid ethyl esters in hypertriglyceridemic subjects. *FASEB J*. 2016;30:1198.7.
57. **Maki KC**, Lawless AL, Kelley KM, Kaden VN, Geiger CJ, Palacios OM, Dicklin MR. Effects of corn oil, compared to extra virgin olive oil, intake on lipoprotein and subfraction cholesterol levels in men and women: results from a randomized, controlled feeding study. *FASEB J*. 2016;30:130.5.

58. **Maki KC**, Lawless AI, Kelley KM, Kaden VN, Geiger CJ, Palacios OM, Dicklin MR. Effects of corn oil, compared to extra virgin olive oil, intake on low-density lipoprotein particle and apolipoprotein B and AI levels in men and women: results from a randomized, controlled feeding study. *FASEB J.* 2016;1163:16.
59. **Maki KC**, Keane WF, Bobotas G. Effects of MAT9001, an omega-3 fatty acid drug, compared with eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol and related variables in hypertriglyceridemic subjects. *National Lipid Association Scientific Sessions.* June, 2015.
60. Abdullah K, **Maki KC**, Ito MK, Sponseller CA, Bell M, Brinton EA, Jacobson TA. Statin associated muscle symptoms: characteristics of patients and recommendations by providers. *National Lipid Association Scientific Sessions.* June, 2015.
61. **Maki KC**, Guyton JR, Orringer CE, Hamilton-Craig I, Dominik AD, Davidson MH. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. *National Lipid Association Scientific Sessions.* June, 2015.
62. Fonseca B, Herrlinger KA, Nieman KM, Ceddia MA, Fullmer L, Niehoff ML, Sanoshy KD, Kelley KM, Cook CM, **Maki KC**. Effects of a distinct phenolic complex on working memory performance in healthy men and women with age-associated memory impairment. *American Academy of Neurology.* April, 2015.
63. **Maki KC**, Geohas JG, Dicklin MR, Huebner M, Udani JK. Effects of an eicosapentaenoic acid and antioxidant-containing medical food in hypertriglyceridemia management. *Experimental Biology.* March, 2015.
64. Cook CM, Herrlinger K, Nieman KM, Sanoshy KD, Fonseca BA, Schild AL, Kelley KM, Lawless AL, **Maki KC**, Ceddia MA. Effects of a proprietary spearmint extract on cognitive function and tolerance parameters in men and women with age-associated memory impairment. *Experimental Biology.* March, 2015.
65. Liska D, Kerns C, **Maki KC**. Cranberries and urinary tract infection (UTI): assessment of the evidence. *Experimental Biology.* March, 2015.
66. Ceddia MA, Herrlinger KA, Farr SA, Niehoff ML, Lewis BJ, Feng S, Nieman KM, Sanoshy KD, Schild AL, Kelley KM, Morley JE, **Maki KC**. Spearmint extract containing rosmarinic acid improves cognitive function in a SAMP8 mouse model of accelerated aging and in men and women with self-reported memory impairment. *Academic Society for Functional Foods and Bioactive Compounds.* May, 2014.
67. **Maki KC**, Kling D, Dicklin MR, Davidson MH. On-treatment triglyceride concentration is a determinant of the change in LDL particle size during therapy with omega-3 free fatty acids. *National Lipid Association Annual Scientific Sessions.* May, 2014.
68. **Maki KC**, Dicklin MR, Schild AL, Kling D, Davidson MH. Plasma fatty acids as predictors of triglyceride and non-HDL cholesterol responses to omega-3 free fatty acid therapy in hypertriglyceridemia. *National Lipid Association Annual Scientific Sessions.* May, 2014.
69. Williams JA, Choe YS, DeMichele SJ, Katz GE, Vurma M, **Maki KC**, Marriage BJ. Effects of different oil systems on lutein absorption in healthy adults. *Experimental Biology.* April, 2014.
70. Schmier JK, Miller PE, Levine JA, Perez V, **Maki KC**, Rains TM, Devareddy L, Sanders LM, Alexander DD. Healthcare savings from reduced constipation rates attributed to increased dietary fiber intakes: a decision-analytic model. *Experimental Biology.* April, 2014.
71. Leidy HJ, Ortinau LC, Rains TM, **Maki KC**. Acute effects of higher protein, sausage, and egg-based convenience breakfast meals on postprandial glucose homeostasis in healthy, premenopausal women. *Experimental Biology.* April, 2014.

72. Nieman KM, Dicklin MR, Bell M, Rains TM, **Maki KC**. Relationship between baseline triglyceride concentration and triglyceride reduction with 4 g/d long-chain omega-3 acid ethyl esters. *Experimental Biology*. April, 2014.
73. **Maki KC**, Nieman KM, Schild AL, Kaden VN, Lawless AL, Kelley KM, Rains TM. Effects of dairy vs. sugar-sweetened products on insulin sensitivity, pancreatic β -cell function and plasma lipids in men and women at risk for type 2 diabetes mellitus. *Experimental Biology*. April, 2014.
74. Nieman KM, Herrlinger K, Sanoshy KD, Schild AL, Kelley KM, **Maki KC**, Ceddia MA. Tolerance and cognitive function effects of a proprietary spearmint extract in men and women with self-reported memory impairment – A pilot study. *Experimental Biology*. April, 2014.
75. **Maki KC**, Lawless AL, Kelley KM, Kaden VN, Dicklin MR. Benefits of corn oil compared to extra-virgin olive oil consumption on the plasma lipid profile in men and women with elevated cholesterol: results from a controlled feeding trial. *American Society for Nutrition - Advances and Controversies in Clinical Nutrition*. December, 2013.
76. Rains TM, Leidy HJ, Sanoshy KD, Lawless AL, **Maki KC**. Acute satiety effects of egg/sausage-based convenience breakfast meals in premenopausal women. *The Obesity Society*. November, 2013.
77. Kastelein JJP, **Maki KC**, Susekov A, Ezhov M, Nordestgaard BG, Kling DF, Davidson MH. Management of severe hypertriglyceridemia with a novel omega-3 free-fatty acid formulation: Subgroups in the EVOLVE trial. *National Lipid Association Annual Scientific Sessions*. May, 2013; Abstract 159.
78. **Maki KC**, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Johnson J, Kling DF, Davidson MH. Epanova lowers apolipoprotein CIII and increases LDL-particle size in statin-treated patients with mild hypertriglyceridemia. *National Lipid Association Annual Scientific Sessions*. May, 2013; Abstract 155.
79. **Maki KC**, Dicklin MR, Rains TM, Schild AL, Lawless AL. Effects of prescription omega-3-acid ethyl esters on fasting and postprandial lipoprotein subclass cholesterol concentrations. *National Lipid Association Annual Scientific Sessions*. May, 2013; Abstract 154.
80. Rains TM, **Maki KC**, Fulgoni VL, Auestad N. Protein intake at breakfast is associated with reduced energy intake at lunch: An analysis of NHANES 2003-2006. *Experimental Biology*. April, 2013; Abstract 3443.
81. **Maki KC**, Rains TM, Schild AL, Dicklin MR, Lawless AL, Kelley KM, Park KM. Effects of low-fat dairy intake on blood pressure and endothelial function in subjects with pre-hypertension or stage I hypertension. *Experimental Biology*. April, 2013; Abstract 834.
82. **Maki KC**, Rains TM, Schild AL, Dicklin MR, Lawless AL, Kelley KM, Park KM. Low-fat dairy intake improves endothelial function in subjects with pre-hypertension or stage I hypertension and impaired endothelial dysfunction. *Experimental Biology*. April, 2013; Abstract 4498.
83. LaFond D, Rains TM, **Maki KC**, Schild A, Kaden VN, Kelley K, Lawless, Romsos D. Acute appetite responses to two different dietary fibers as part of ready-to-eat breakfast cereals in overweight women. *Experimental Biology*. April, 2013; Abstract 4139.
84. **Maki KC**, Orloff D, Nicholls S, Dunbar R, Roth E, Curcio DL, Johnson J, Kling DF, Davidson MH. A highly bioavailable omega-3 free-fatty acid reduces non-high density lipoprotein cholesterol in high-risk patients treated with a statin and residual hypertriglyceridemia (ESPRIT Trial). *American College of Cardiology 62nd Annual Scientific Sessions*. March, 2013.

85. Davidson MH, Rosenson R, **Maki KC**, Nicholls S, Ballantyne C, Mazzone T, Williams L, Kelly M, Camp H, Lele A, Stolzenbach J. Results from the fenofibric acid on carotid intima-media thickness in subjects with type IIb dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. *American College of Cardiology 62nd Annual Scientific Sessions*. March, 2013.
86. Kastelein JJP, **Maki KC**, Susekov A, Ezhov M, Nordestgaard BG, Kling D, Davidson MH. Dose response of a novel free-fatty acid formulation of omega-3 for the management of dyslipidemia in patients with severe hypertriglyceridemia - EpanoVa fOR Lowering Very High Triglycerides (The EVOLVE trial). *American Heart Association Scientific Sessions*. November, 2012.
87. Rader DJ, Dunbar RL, **Maki KC**, Jacobson TA, Kling D, Davidson MH. Apolipoprotein C-III is significantly reduced by prescription omega-3 free fatty acids (Epanova) in patients with severe hypertriglyceridemia and changes correlate with increases in LDL-C: A sub-analysis of the EVOLVE trial. *American Heart Association Scientific Sessions*. November, 2012.
88. LaFond D, Rains TM, **Maki KC**, Schild A, Kelley K, Lawless A. Acute appetitive effects of ready-to-eat breakfast cereals containing different dietary fiber ingredients in overweight women. *The Obesity Society*. September, 2012; Abstract 440-P.
89. **Maki KC**, Gower BA, Rains TM, Schild A. Reduced sample schedules for calculation of an insulin sensitivity index from the liquid meal tolerance test. *Experimental Biology*. April, 2012; Abstract 6265.
90. **Maki KC**, Gower BA, Rains TM, Schild A, Granger WM. A comparison of meal-derived indices for predicting glucose tolerance. *Experimental Biology*. April, 2012; Abstract 6469.
91. McKenney JM, Jenks BH, Shneyvas E, Brooks J, Rains TM, Cook CM, **Maki KC**. Favorable Lipid-Altering Effects of a Softgel Plant Sterol/Stanol Dietary Supplement in Men and Women with Primary Hypercholesterolemia. *National Lipid Association Annual Scientific Sessions*. May, 2012.
92. **Maki KC**, Dicklin MR, Davidson MH, Mize PD, Kulkarni KR. Indicators of the atherogenic lipoprotein phenotype measured with the vertical auto profile test predict changes in carotid intima-media thickness in men and women. *American Heart Association - Nutrition, Physical Activity and Metabolism and Cardiovascular Disease Epidemiology and Prevention 2011 Scientific Sessions*. March, 2012; Abstract 567.
93. Evans JL, Bays H, **Maki KC**, Evans M, Maquet V, Cooper R, Anderson JW. Chitin-glucan fiber effects on oxidized low-density lipoprotein: A randomized controlled trial. *American Heart Association - Nutrition, Physical Activity and Metabolism and Cardiovascular Disease Epidemiology and Prevention 2011 Scientific Sessions*. March, 2012; Abstract 41.
94. Krul E, Mukherjee R, Hughes G, Lemke SL, Taylor ML, Goldstein DA, **Maki KC**. A randomized, controlled trial to assess the effects of foods containing stearidonic acid soybean oil on eicosapentaenoic acid. *American Heart Association Scientific Sessions 2011*. November, 2011; No. 14032.
95. **Maki KC**, Schild AL, Dicklin MR, Rains TM, Kelley KM, Lawless AL. Evaluation of alternative measures of pancreatic beta-cell function from the liquid meal tolerance test. *Annual Scientific Meeting of The Obesity Society*. October, 2011; Poster 526-P.
96. **Maki KC**, Rains TM, Schild AL, Dicklin MR, Kelley KM, Lawless AL. Reduced sampling schedules for calculation of an insulin sensitivity index from the liquid meal tolerance test. *Annual Scientific Meeting of The Obesity Society*. October, 2011; Poster 533-P.
97. Bard JM, **Maki KC**. Do current food regulations discourage functional foods innovation? US and European perspectives. *Better Foods for Better Health*. September 2011.

98. **Maki KC.** Monounsaturated fatty acid intake and atherosclerotic cardiovascular disease risk: The NLA Fatty Acid Summit. *National Lipid Association Annual Scientific Sessions*. May, 2011.
99. **Maki KC,** Lawless AL, Kelley KM, Dicklin MR, Schild AL, Rains, TM. Effects of 4 g/d prescription omega-3-acid ethyl esters on fasting and postprandial lipids and indices of glucose homeostasis. *National Lipid Association Annual Scientific Sessions*. May, 2011; Abstract 375.
100. **Maki KC,** Van Elswyk ME, Alexander DD, Rains TM, Sohn EL, McNeill S. A meta-analysis of randomized controlled trials comparing lipid effects of beef with poultry and/or fish consumption. *National Lipid Association Annual Scientific Sessions*, May, 2011; Abstract 393.
101. **Maki KC,** Fulgoni VL, Keast DR, Park K, Rubin MR. Vitamin D intake and status are associated with lower prevalence of metabolic syndrome in U.S. adults: An analysis of NHANES 2003-2006. *Experimental Biology*. April, 2011; Abstract 2459.
102. Mukherjea R, Krul ES, Liu P, Lemke SL, Taylor ML, Goldstein DA, Su H, Harris WS, **Maki KC.** Effects of duration of dose and treatment of dietary eicosapentaenoic acid (EPA) and stearidonic acid (SDA) on EPA levels in red blood cell (RBC) membranes. *Experimental Biology*. April, 2011; Abstract 4900.
103. **Maki KC,** Rubin KH, Matusheski NV, Rubin MR, Reeves MS, Lawless A, Kaden VN, Black RM. Reliability characteristics of continuous glucose monitoring in overweight and obese men and women with type 2 diabetes mellitus. *Experimental Biology*. April, 2011; Abstract 1532.
104. **Maki KC,** Gibson G, Dickmann R, Kendall CWC, Chen C-YO, Almeida N, Blumberg J. A double-blind, randomized, controlled crossover trial to assess the prebiotic effects of arabinoxylan-oligosaccharides (AXOS) in healthy men and women. *Experimental Biology*. April, 2011; Abstract 4899.
105. **Maki KC,** Pelkman CL, Kelley KM, Lawless AL, Schild A, Rains TM. Effects of type 2 resistant starch consumption on insulin sensitivity in men and women. *Experimental Biology*. April, 2011; Abstract 2914.
106. **Maki KC,** Kelley KM, Lawless AL, Hubacher RL, Rains TM. Validation of insulin sensitivity and secretion indices derived from the liquid meal tolerance test. *Experimental Biology*. April, 2011; Abstract 1172.
107. **Maki KC,** Ndife LI, Kelley KM, Lawless AL, Brooks JR, Wright SB, Shields JM, Dicklin MR. Absorption of folic acid is similar from a softgel capsule and a standard tablet. *Experimental Biology*. April, 2011; Abstract 9016.
108. **Maki KC,** Dicklin MR, Johnson SL, Shabbout M, Bays HE. Prescription omega-3 fatty acids improve low-density lipoprotein subclass distribution without increasing low-density lipoprotein particle concentration in statin-treated patients with mixed dyslipidemia. *American College of Cardiology Scientific Sessions*. April, 2011; Poster Number 276.
109. **Maki KC,** Lawless A, Kelley KM, Dicklin MR, Kaden VN, Schild AL, Rains TM, Marshall JW. Effects of prescription omega-3 fatty acids on aspects of the fasting lipid profile in subjects with primary hypercholesterolemia. *Joint Conference - Nutrition, Physical Activity and Metabolism and Cardiovascular Disease Epidemiology and Prevention 2011 Scientific Sessions*. March, 2011; Abstract 463.
110. **Maki KC,** Lawless A, Reeves MS, Kelley KM, Dicklin MR, Jenks BH, Schneyvas E, Brooks JR. Lipid-altering effects of a dietary supplement softgel capsule containing plant sterols and stanols in men and women with primary hypercholesterolemia. *Joint Conference - Nutrition, Physical Activity and Metabolism and Cardiovascular Disease Epidemiology and Prevention 2011 Scientific Sessions*. March, 2011; Abstract 397.
111. **Maki KC.** Stearidonic acid-enriched soybean oil: a source of cardioprotective omega-3 fatty acids. Presentation at The American College of Nutrition 51st Annual Meeting, June 2010. *J Am Coll Nutr*. 2010;5:527. Published online 2013.

112. **Maki KC**, Harris WS, Lubin BC, Reeves MS, Dicklin MR. Stability of lipid responses to prescription omega-3 acid ethyl esters plus simvastatin over two years. *National Lipid Association Annual Scientific Session*. May, 2010; Abstract 118.
113. **Maki KC**, Rubin MR, Wong LG, McManus JF, Jensen CD, Lawless A. Effects of vitamin D supplementation on 25-hydroxyvitamin D and markers of cardiovascular disease risk in subjects with high waist circumferences. *National Lipid Association Annual Scientific Session*. May, 2010; Abstract 121.
114. **Maki KC**, Davidson MH, Dicklin MR, Bell M. Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. *National Lipid Association Annual Scientific Session*. May, 2010; Abstract 122.
115. **Maki KC**, Butteiger DN, Rains TM, Lawless A, Reeves MS, Schasteen C, Krul ES. Effects of an insoluble fraction of soy protein vs. milk protein on plasma lipids and fecal bile acids in men and women with hypercholesterolemia. *National Lipid Association Annual Scientific Session*. May, 2010; Abstract 126.
116. **Maki KC**, Lawless A, Reeves MS, Dicklin MR, Jenks BH, Shneyvas E, Brooks J. A plant sterol/stanol supplement in tablet form lowers LDL and Non-HDL cholesterol in men and women with primary hypercholesterolemia. *National Lipid Association Annual Scientific Session*. May, 2010; Abstract 127.
117. **Maki KC**, Rubin KH, Matusheski NV, Rubin MR, Reeves MS, Kaden VN, Black RM. Reductions in 24-hour glucose, blood pressure, and body weight in men and women with type 2 diabetes mellitus: A pilot study assessing the impact of a novel, simplified approach to diet guidance. *Experimental Biology 2010*. April, 2010; Abstract 4924.
118. Rubin KH, Matusheski NV, **Maki KC**, Rubin MR, Reeves MS, Kaden VN, Black RM. Dietary changes in men and women with type 2 diabetes mellitus: A pilot study assessing the impact of a novel, simplified approach to diet guidance. *Experimental Biology 2010*. April, 2010; Abstract 4697.
119. Jonnalagadda SS, **Maki KC**, Reeves MS, Rains TM, Witchger M. Effects of consuming a yogurt containing plant sterols, as part of a Therapeutic Lifestyle Changes (TLC) Diet, on blood lipids in men and women with primary hypercholesterolemia. *Experimental Biology 2010*. April, 2010; Abstract 38.
120. **Maki KC**, Rains TM, Bell M, Reeves MS, Farmer MV. Fat mass, but not abdominal fat distribution, predicts C-reactive protein concentrations in overweight and obese men and women. *Joint Conference-50th Cardiovascular Disease Epidemiology and Prevention -and - Nutrition, Physical Activity and Metabolism Conference*. March 2010; Poster 656.
121. **Maki KC**, Rains TM, McKenney JM, Reeves MS, Farmer MV. Repeatability of insulin sensitivity and secretion indices from liquid meal tolerance tests in subjects with normal fasting glucose, impaired fasting glucose, or type 2 diabetes mellitus. *Obesity Society's Annual Scientific Sessions*. October 2009; Poster 229-P.
122. **Maki KC**, Bays, HE, McKenney J, Doyle RT, Carter RN, Stein E. Effect of prescription omega-3 fatty acids coadministered with escalating doses of atorvastatin on non-HDL-C in patients with hypertriglyceridemia. *American College of Clinical Pharmacy Conference*. October, 2009; Poster 28E.
123. Alish CJ, Garvey W, **Maki KC**, Sacks GS, Hustead DS, Mustad VA. Continuous feeding with a diabetes-specific formula improves glycemic variability and reduces insulin requirements in tube fed patients with type 2 diabetes managed with insulin. *European Society for Clinical Nutrition and Metabolism: 31st ESPEN Congress. Clin Nutr Suppl*. 2009;4:119. Abstract P223.

124. Bays HE, **Maki KC**, McKenney J, Doyle RT, Stein E. Long-term efficacy of prescription omega-3 fatty acids coadministered with simvastatin in hypertriglyceridemic patients. *XV International Symposium on Atherosclerosis*. June, 2009.
125. Bays HE, **Maki KC**, Carter RN, Doyle RT, Stein E. Effect of prescription omega-3 fatty acids on body weight in patients with very high triglyceride levels. *American Diabetes Association: 69th Scientific Sessions*. *Diabetes* 2009; 58 (Suppl 1);A629-630.
126. **Maki KC**, Rubin MR, Wong LG, McManus JF, Jensen CD, Marshall JW, Lawless A. Serum 25-hydroxyvitamin D is an independent predictor of high density lipoprotein cholesterol and metabolic syndrome in men and women. *National Lipid Association Annual Scientific Session*. May, 2009.
127. **Maki KC**, Bays, HE, McKenney J, Doyle RT, Carter RN, Stein E. Effects of prescription omega-3 fatty acids co-administered with escalating doses of atorvastatin on lipoprotein particle sizes and concentration in hypertriglyceridemic patients. *Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference*. May, 2009. Poster 504.
128. **Maki KC**, Sanders, L, Reeves MS, Kaden VN, Cartwright Y. Resistant starch improves laxation in healthy adults. *Experimental Biology 2009*. April, 2009. Abstract 334.
129. **Maki KC**, Beiseigel JM, Jonnalagadda SS, Reeves MS, Farmer MV. Ready-to-eat oat cereal, as part of a reduced energy diet, reduces low-density lipoprotein cholesterol and waist circumference in overweight and obese adults. *Experimental Biology 2009*. April, 2009. Abstract 3983.
130. **Maki KC**, Curry LL, McKenney JM, Farmer MV, Reeves, MS, Dicklin MR, Gerich JE, Zinman B. Glycemic and blood pressure responses to acute doses of rebaudioside A, a steviol glycoside, in subjects with normal glucose tolerance or type 2 diabetes mellitus. *Experimental Biology 2009*. April, 2009. Abstract 1779.
131. **Maki KC**, McKenney JM, Farmer MV, Reeves, MS, Dicklin MR. Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired and normal fasting glucose. *Experimental Biology 2009*. April, 2009. Abstract 348.
132. **Maki KC**, Davidson MH, Doyle RT, Ballantyne CM. Effect of prescription omega-3 fatty acids on non-HDL cholesterol (stratified by baseline LDL cholesterol level) in statin-treated patients with hypertriglyceridemia. *American Heart Association: 49th Cardiovascular Disease Epidemiology and Prevention Conference*. March, 2009. Poster 230.
133. Davidson MH, **Maki KC**, Feinstein S, Bell M. Triglyceride/high-density lipoprotein cholesterol ratio is the strongest predictor of carotid intima-media thickness progression. *American Heart Association: 49th Cardiovascular Disease Epidemiology and Prevention Conference*. March, 2009. Poster 250.
134. Alish CJ, Hustead DS, **Maki KC**, Reeves MS, Herther DC, Mustad V. Continuous glucose monitoring demonstrates less glycemic variability with a diabetes-specific nutritional formula compared to a standard formula in patients with type 2 diabetes. *The Diabetes Technology Society*. November, 2008.
135. **Maki KC**, Carson ML, Miller MP, Anderson WHK, Turowski M, Reeves MS, Dicklin MR. Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia. *American Dietetic Association*. October, 2008.
136. **Maki KC**, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Effects of prescription omega-3 acid ethyl esters plus simvastatin on lipids and lipoprotein particles in mixed dyslipidemia. *J Clin Lipidol*. May/June, *National Lipid Association*, 2008.

137. **Maki KC**, Reeves MS, Farmer M, Yasunaga K, Matsuo N, Katsuragi Y, Komikado M, Tokimitsu I, Wilder DM, Jones F, Cartwright Y. Effects of daily consumption of a tea catechin containing beverage on exercise-induced changes in body composition and fat distribution in overweight and obese adults. *The Obesity Society*, 2008, Abstract # 369-P.
138. **Maki KC**, Reeves MS, Carson ML, Miller MP, Turowski M, Rains TM, Anderson K, Papanikolaou Y, Wilder DM. Dose-response characteristics of high-viscosity hydroxypropylmethylcellulose on postprandial glucose and insulin concentrations in subjects at risk for the development of type 2 diabetes mellitus. *The Obesity Society*, 2008, Abstract #368-P.
139. **Maki KC**, McKenney JM, Lubin BC, Reeves MS. Lipid effects of prescription omega-3-acid ethyl esters plus simvastatin in subjects with hypertriglyceridemia. *FASEB J*, 2008, Abstract #147.8.
140. Sanders LM, Kendall CW, **Maki KC**, Stewart ML, Slavin JL, Potter SM. A novel maize-based dietary fiber is well tolerated in humans. *FASEB J*, 2008, Abstract #LB761.
141. Davidson M, **Maki KC**, Doyle RT, Shalwitz R, Bays HE, Stein E. Correlates of the apolipoprotein C-III response to the addition of prescription Omega-3 in adults with hypertriglyceridemia despite stable statin therapy. *Circulation* 2007;116:II_17.
142. **Maki KC**, Rains TM. Designing a Clinical Trial. *Proceedings of the IFT Annual Meeting and Food Expo*, 2007, Abstract 201-03.
143. **Maki KC**. High-viscosity hydroxypropylmethylcellulose (HPMC) – A promising agent for metabolic risk factor management. *Proceedings of the Am Chem Soc*, 2007, Abstract AGFD3.
144. Davidson MH, Bays H, Stein E, **Maki KC**, Doyle R, Shalwitz RA. COMBOS – The combination of prescription omega-3s with simvastatin: A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of prescription omega-3 (OMACOR®) added to stable statin therapy in hypertriglyceridemic patients. *Proceedings of the ACCP*, 2007, Abstract #11952.
145. **Maki KC**, Carson ML, Miller MP, Turowski M, Jones F, Wilder DM, Rains TM, Reeves MS. Effects of high-viscosity hydroxypropylmethylcellulose and methylcellulose on postprandial glucose and insulin responses in overweight and obese men and women. *Obesity* 2007;15. Abstract # 304-P.
146. Davidson M, **Maki KC**, Zavoral JH, Yu S, Popovici C, Price, G. Lapaquistat acetate, a novel squalene synthase inhibitor, co-administered with atorvastatin reduces plasma lipids and C-reactive protein levels in subjects with primary hypercholesterolemia. *Circulation* 2007;116(suppl):S193.
147. **Maki KC**, Davidson MH, Bays HE, Stein EA, Shalwitz RA, Doyle R. Effects of omega-3-acid ethyl esters on LDL particle size in subjects with hypertriglyceridemia despite statin therapy. *FASEB J*, 2007, Abstract # 231.2.
148. Larsen EK, **Maki KC**, Lofgren P, Kronmal R. Vitamin E use and congestive heart failure in the cardiovascular health study. *FASEB J*, 2007, Abstract # 837.19.
149. **Maki KC**, Carson ML, Miller MP, Turowski M, Bell M, Wilder DM, Reeves MS. Glucose tolerance modifies the effects of high-viscosity hydroxypropylmethylcellulose on postprandial glucose and insulin excursions. *FASEB J*, 2007, Abstract # 368.6.
150. Izumi R, Hurt J, **Maki KC**, Bell M, Zavras A, McCamish M. Clinical predictors of glycosylated hemoglobin responses to thiazolidinedione therapy. *Proceedings of the American Heart Association Epidemiology and Prevention Sessions* 2007, Abstract 285.

151. Shalwitz RA, **Maki KC**, Doyle R. Lipoprotein subfraction responses differentially predict changes in lipoprotein associated phospholipase A2 during prescription omega-3 therapy. *American Heart Association Arteriosclerosis, Thrombosis and Vascular Biology Abstract* #P328, 2007.
152. Bays H, **Maki KC**, Doyle R, Stein, EA, Davidson MH, Shalwitz R. Effects of prescription omega-3-acid ethyl esters on glycemic response in subjects with persistent hypertriglyceridemia despite statin therapy. *Endocrine Society*. 2007.
153. Davidson MH, Bays H, Stein E, **Maki KC**, Doyle R, Shalwitz RA. COMBOS – The combination of prescription omega-3s with simvastatin: A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of prescription omega-3 (OMACOR®) added to stable statin therapy in hypertriglyceridemic patients. *Proceedings of the Midwest Lipid Association 3rd Annual Scientific Forum*, 2006.
154. **Maki KC**, Carson ML, Miller MP, Turowski M, Wilder DM, Bell M, Ratcliff N, Reeves MS. High-viscosity hydroxypropyl-methylcellulose blunts postprandial glucose and insulin responses. *J Am Coll Nutr*. 2006;25:464.
155. **Maki KC**. Meta-analysis as a tool in nutrition and medicine. *J Am Coll Nutr*. 2005;24(suppl):S84.
156. **Maki K**, Rains T, Kaden V, Quinn J, Davidson M. A longer-term modified carbohydrate diet vs. a low-fat, portion-controlled diet on weight loss/weight maintenance in overweight or obese men and women. *Obesity Res*. 2005;13:A79.
157. Davidson MH, Bays H, Stein E, **Maki KC**, Kling D, Doyle R, Shalwitz R. Enhanced response to fenofibrate in hypertriglyceridemic women with the metabolic syndrome. *Proceedings at the National Lipid Association*, 2005.
158. Davidson MH, Bays H, Stein E, **Maki KC**, Shalwitz R, Doyle R, Kling D. Treatment of dyslipidemia in patients with the metabolic syndrome: A target triglyceride level is necessary to produce shifts in LDL particle size. *Proceedings at the National Lipid Association*, 2005.
159. **Maki KC**, Galant R, Samuel P, Tesser J, Witchger MS, Geohas J. Effects of consuming oat β -glucan on blood pressure and carbohydrate metabolism in men and women with elevated blood pressure. *FASEB J*, 2005;19:A1348.
160. **Maki KC**, Pearson TA, Galant R, Davidson MH. Dietary compliance and cholesterol goal achievement in patients and treated dyslipidemia. *FASEB J*, 19:5:A1024, 2005.
161. **Maki KC**, Rains TM, Kaden VN, Quinn J, Davidson MH. A randomized, controlled clinical trial to evaluate the efficacy of a modified carbohydrate diet for reducing body weight and fat in overweight and obese men and women. *FASEB J*, 19:4:A771-2, 2005.
162. Clark LT, **Maki KC**, Fonarow GC, Maron DJ, Pearson TA, Davidson MH. Low rates of goal achievement among African Americans undergoing treatment for dyslipidemia: Results of the NEPTUNE II national survey. *AHA Cardiovascular Disease Epidemiology and Prevention Conference*, April 28-May 1, 2005.
163. **Maki KC**, Stone NJ, Ballantyne CM, Dicklin MR, Ansell BJ, Davidson MH. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. *AHA Second International Conference on Women, Heart Disease, and Stroke*, February 16-19, 2005.
164. Mustad V, Ruey P, **Maki KC**. Effects of diacylglycerol or dietary medium- or long-chain triacylglycerol on postprandial blood triglycerides in insulin resistant individuals with hypertriglyceridemia. Presented at the North American Association for the Study of Obesity Annual Meeting, 2004. *Obesity Research* 2004;12:A56:213-P

165. Davidson MH, **Maki KC**, Pearson TA, Pasternak RC. Undertreatment among high-risk dyslipidemic patients: Results of a national survey of goal achievement for national cholesterol education program adult treatment panel III guidelines. Presented at the XV International Symposium on Drugs Affecting Lipid Metabolism. October 24-27, 2004;147.
166. Davidson MH, **Maki KC**, Dicklin M, Umporowicz DM. Achievement of both the LDL cholesterol and total/HDL cholesterol ratio Canadian guideline goals by US physicians: Results from Neptune II. Presented at the Canadian Cardiovascular Congress Society 57th Annual Meeting, October 23-27, 2004. *Canadian J Cardiology* 2004; 20:140D:378.
167. Davidson MH, Pasternak RC, Caplan R, Joukova I, Umporowicz D, Oldham K, and **Maki KC**. Cholesterol management in patients with coronary heart disease and risk equivalents: Results of a national survey. American Heart Association 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; 2004.
168. **Maki KC**, McKenney JM, Dicklin MR, Bell M, Joukova I, Caplan R, Davidson MH. Achievement of National Cholesterol Education Program non-HDL cholesterol goals in clinical practice: Results of a national survey. American Heart Association 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; 2004.
169. **Maki, KC**, Davidson MH, Deedwania PC, Pearson TA. Prevalence of obesity, diabetes, and the metabolic syndrome in patients treated for dyslipidemia: Results of a national survey. American Diabetes Association 64th Scientific Sessions; June 4-8, 2004. *Diabetes* 2004;53(suppl 2):A520, 2186-PO.
170. Davidson MH, **Maki KC**, Umporowicz D, Oldham KM, Quinn L, Neptune I (NCEP Evaluation Project Utilizing Novel E-Technology): Adherence to the NCEP Adult Treatment Panel III Guidelines in Clinical Practice. Presented at American Heart Association Second Asia Pacific Scientific Forum, June 2003.
171. **Maki K**, Davidson M, Hess S, Bell M, McCarthy D, Van Elswyk M. Lipid responses to algal-derived docosahexaenoic acid in men and women with low levels of high density lipoprotein cholesterol. Presented at American College of Nutrition, 2003.
172. Stonebrook K, Davies A, Topham D, **Maki KC**, Randolph K. Lack of association between fruit and vegetable intake and markers of antioxidant status in healthy adults. Presented at American College of Nutrition, 2003.
173. Juturu V, Komorowski JR, Greenberg D, **Maki KC**. Chromium with biotin decreases coronary risk lipids and lipoproteins in people with type 2 diabetes ingesting moderate carbohydrate nutritional beverages. Presented at *FASEB*, 2003.
174. **Maki KC**. Beneficial lipid- altering and bone preserving properties of low dose synthetic conjugated estrogens, A (Cenestin®) in healthy postmenopausal women. Presented at the North American Menopause Society (NAMS), 2002.
175. **Maki KC**. Diacylglycerol oil vs. triacylglycerol oil in a weight reduction diet. A double blind parallel study in the United States. Presented at the Fifth International Congress on Essential Fatty Acids And Eicosanoids. 2002.
176. **Maki KC**, Shinnick F, Seeley MA, Veith PE, Davidson MH. Lipid effects of food products containing free tall oil-based phytosterols and oat beta-glucan. Presented at *FASEB*. 2002.
177. **Maki KC**, Bell M, Oldham KM, Davidson MH. Is hyperfibrinogenemia a component of the metabolic syndrome? Presented at the American Diabetes Association. 2001.

178. Davidson MH, Wheeler A, Rittershaus C, Emmett C, Umporowicz D, **Maki KC**. A phase I trial of an immunotherapeutic approach for managing low plasma HDL-C. Presented at the XIV International Symposium on Drugs Affecting Lipid Metabolism. 2001.
179. Komorowski J, Greenberg D, **Maki KC**, Rosenblatt S. Chromium picolinate with biotin attenuates elevation in blood glucose levels in people with type II diabetes ingesting medium carbohydrate nutritional beverages. Presented at the American College of Nutrition conference, 2001.
180. **Maki KC**, Veith PE, Bell M, Dicklin MR, Davidson MH. Low-density lipoprotein subclass pattern B and adiposity-associated dyslipidemia. Presented at the American College of Nutrition conference, 2001.
181. **Maki KC**, Davidson MH, Palmisano J, Susmano A, Dobs A, Kerber I, Hunninghake D, Knopp R, Goldberg A, McKenney J, Kakavas P, Waters D, Bittar N. Separate and combined effects of hormone replacement and simvastatin 10 mg on lipoprotein (a) and lipoprotein subfractions in postmenopausal women with hypercholesterolemia. Presented at the American College of Cardiology conference, 2001.
182. Davidson MH, Manlinow MR, Subbaiah PV, Stein JH, **Maki KC**, Greene JJ, Marinucci LN. Reduction in cardiac risk factors by an indication-specific dietary supplement. *FASEB Journal*. 2001;15:A729
183. **Maki KC**, Davidson MH, Cyrowski M, Maki AC, Marx P. Adiposity-associated dyslipidemia in postmenopausal women. Presented at FASEB, 2000.
184. **Maki KC**, Davidson MH, Cyrowski M, Maki AC, Marx P. Low density lipoprotein (LDL) subclass pattern B amplifies adiposity-associated dyslipidemia in postmenopausal women. Presented at FASEB, 2000.
185. **Maki KC**, Davidson MH, Marx P, Arce JC, Nanavati N. Effects of low-dose, continuous combined hormone replacement on hemostatic parameters in postmenopausal women. Poster presentation at the First Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, 2000.
186. **Maki KC**, Davidson MH, Marx P, Cyrowski M, Arce JC. Effects of continuous combined hormone replacement therapy on indicators of carbohydrate metabolism. *Diabetes* 2000;49 (supplement 1):A231. Presented at the American Diabetes Association 60th Scientific Sessions, 2000.
187. **Maki KC**, Davidson MH, Tsushima R, Matsuo N, Tokimitsu I, Umporowicz D, Ingram KA, Dicklin MR, Bell M, Anderson BD, Frost SD, Tagala A. Diacylglycerol oil vs. soybean oil in a weight reduction diet. Presented at North American Association for the Study of Obesity, 2000.
188. Davidson MH, **Maki KC**, Hunninghake DB, Knopp RH, Goldberg AC, Waters D, Dobs AS, Cyrowski M. Effects of low dose simvastatin and hormone replacement therapy on serum lipids in postmenopausal women with hypercholesterolemia. American College of Cardiology 49th Annual Scientific Session, 2000.
189. Davidson MH, **Maki KC**, Marx P, Arce JC, Nanavati N. Effects of low-dose, continuous combined hormone replacement on serum lipids in postmenopausal women. Poster presentation at the First Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, 2000.
190. **Maki KC**, Davidson MH, Susmano A, Maki AC. Low-density lipoprotein subclass pattern B and adiposity-associated dyslipidemia in postmenopausal women. Presented at the American College of Nutrition annual meeting, 2000.
191. **Maki KC**, Davidson MH, Cyrowski M, Maki AC. Association between elevated plasma fibrinogen and the small, dense low density lipoprotein phenotype among postmenopausal women. *Circulation*. 1999;99:1124.
192. **Maki KC**, Davidson MH, Umporowicz D, Dicklin MR, Ingram KA, Gebhart B, Schaefer E, Chen S, Franke WC. Effects of plant sterol-enriched reduced-fat spreads on serum carotenoid and fat-soluble vitamin levels. *J Am Coll Nutr*. 1999;18:536.

193. **Maki KC**, Davidson MH, Marx P, Cyrowski M, Maki AC. Low density lipoprotein subclass distribution pattern does not modify serum lipid and apolipoprotein responses to hormone replacement therapy. 1999 Oct; Proceedings, 9th International Menopause Society World Congress on Menopause.
194. **Maki KC**, Davidson MH, Umporowicz D, Schaefer E, Dicklin MR, Ingram KA, Chen S, Gebhart B, Franke WC. Lipid responses to plant sterol-enriched reduced-fat spreads incorporated into a Step I diet. *Circulation*. 1999;100:I-115.
195. **Maki KC**, Davidson MH, O'Mullane J, Albrecht H, Daggy B. Hypocholesterolemic effects of hydroxypropylmethylcellulose (HPMC) consumed with versus between meals. *FASEB Journal*. 1998;12:A654.
196. Davidson MH, Weeks CE, Lardy H, **Maki KC**, Umporowicz D. Safety and endocrine effects of 3-acetyl-7-OXO DHEA (7-KETO DHEA). *FASEB Journal*. 1998;12:A764.
197. Davidson MH, Hunninghake D, Kwiterovich PO, **Maki KC**, Dicklin MR, Kafonek SD. Effective incorporation of lean red meat into an NCEP Step 1 Diet. *Circulation*. 1998;98:584.
198. **Maki KC**, Walton C, Pigeon RL. Evaluation of two techniques for estimating insulin sensitivity from the short intravenous glucose tolerance test. *Proceedings, Endocrine Society Meeting*, 1997.
199. Davidson MH, **Maki KC**, Kong JC, Kugan LD, Torri SA, Hall HA, Drennan KB, Anderson S, Fulgoni V, Saldanha L, Olson B, McDonald A. Long-term lipid response to psyllium-enriched foods. *Prev Cardiol*, 1997.
200. Davidson MH, Miglieri C, Glendinning K, Weber J, **Maki KC**. Design of a trial to compare the effects of lean red vs. white meat on serum lipids among hypercholesterolemic subjects consuming a low-fat diet. *FASEB Journal*, 1996;10:A484.
201. Davidson MH, Testolin LM, **Maki KC**, von Duvillard S, Drennan KB. Effects of conjugated estrogens alone or in combination with pravastatin for management of hypercholesterolemia in postmenopausal women. *J Am Coll Cardiol*. 1996;27(suppl A):412A.
202. Inman-Felton A, Briones ER, **Maki KC**. Dietary intervention for nutritionally compromised spinal cord injury patients with pressure ulcers. *J Am Diet Assoc*. 1995;95(suppl):A-21.
203. Davidson MH, Kalkowski J, **Maki KC**, Drennan KB, Torri S. A double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy of docosahexaenoic acid for the management of Type IIb hyperlipidemia. *J Am Diet Assoc*. 1995;95(suppl):A-21.
204. Rosen MD, Foley S, **Maki KC**, Cannon M. Evaluation of limb measurements for predicting stature in men ≥ 60 years of age. *J Am Diet Assoc*. 1995;95 (suppl): A-27.
205. **Maki KC**, Langbein WE, Nemchausky B, Sam M, Briones E. Lack of association between spinal cord injury and dyslipidemia in men. *J Spinal Cord Med*. 1995.
206. **Maki KC**, Skorodin MS, Jessen J, Laghi F. Effects of two weeks oral beta₂ agonist administration on serum lipids and carbohydrate metabolism. *Diabetes*. 1995;44(suppl):255A.
207. Benbassat C, **Maki KC**, Oehler D, Unterman T. Insulin-like growth factors and binding proteins in aging men: Relationships to insulin levels and anthropometric measures. *Proceedings, Endocrine Society Meeting*, 1995.
208. Skorodin MS, Hagarty EM, Langbein WE, Hultman CI, Jessen JA, **Maki KC**. Oxygen conserving devices during exercise in COPD. *Chest*. 1994;149:A1023.

209. Skorodin MS, Tenholder MF, Yetter B, Khandelwahi S, **Maki KC**, Rohail T, D'Alfonso N. Magnesium sulfate in the treatment of acute exacerbations of chronic obstructive pulmonary disease. *Chest*. 1994;149:A310.
210. **Maki KC**, Sam M, Nemchausky BA, Orebaugh C, Langbein WE. Insulin sensitivity and serum lipoproteins in lean men with spinal cord injury. *J Spinal Cord Med*. 1994;17:203.
211. Briones ER, **Maki KC**, Langbein WE, Inman-Felton A, Nemchausky B, Burton J, Welch M. Dietary intake and lipid profile assessment in persons with chronic spinal cord injury. *J Am Coll Nutr*. 1993;12:591.
212. Inman-Felton A, **Maki KC**, Briones ER. Factors associated with improved pressure ulcer status during nutritional intervention in veterans with spinal cord injury. *J Am Paraplegia Soc*. 1993;16:4.
213. Lawson L, Orebaugh C, Sibley P, Lokos C, Langbein WE, **Maki KC**, Reid R. Exercise training in hypertension: Effects on BP during work. *Proceedings of the Midwest Nursing Research Society Annual Conference*. 1993;133.
214. **Maki KC**, Briones ER, Langbein WE, Inman-Felton A, Nemchausky B, Burton J, Welch M. Lipid profiles of persons with spinal cord injury. *Med Sci Sports Exerc*. 1993;25(Suppl 1): S123.
215. **Maki KC**, Briones ER, Langbein WE, Inman-Felton A, Nemchausky BA, Burton J, Welch M. A comparison between bioelectrical impedance and near infrared interactance for assessing body composition in persons with spinal cord injury. *J Am Coll Nutr*. 1993;12:616.
216. Langbein WE, Edwards LC, Hwang M, **Maki KC**, Sibley P. Wheelchair ergometry for the detection of coronary artery disease in persons with lower limb disabilities. *Med Sci Sports Exerc*. 1992;24:S33.
217. Langbein WE, **Maki KC**, Hwang M, Reid C. Estimating exercise oxygen uptake in the lower limb disabled. *J Cardiopulmonary Rehabil*. 1992;12:336.
218. **Maki KC**, Langbein WE, Reid CM, Hedrick BN. Energy cost of Handbike and Rowcycle propulsion. *Med Sci Sports Exerc*. 1992;24:S33.

STATISTICAL AND/OR CLINICAL TRIAL REPORTS (confidential information represented by XXX):

1. Guarneiri LL, Wilcox ML, Adams CG, **Maki KC**. An observational study to assess variability of anti-lactoferrin antibodies in healthy adults. Helaina, 2025.
2. Guarneiri LL, Wilcox ML, Adams CG, **Maki KC**. A randomized, double-blind controlled trial to assess the effects of lactoferrin at two doses vs. active control on immunological and safety parameters in healthy adults. Helaina. 2025.
3. Palacios OM, Bell M, Wilcox ML, **Maki KC**. Exploratory analysis: Predictors of clinically relevant weight loss at 16 weeks among participants in XXX. Medifast, Inc. 2023.
4. Sanders LM, Guarneiri LL, Blumberg JB, **Maki KC**. XXX and body weight outcomes: A systematic review of observational studies and controlled trials. Bragg Live Food Products. 2022.
5. Guarneiri LL, Bell M, Wilcox ML, **Maki KC**. Predictors of failure to achieve clinically important weight loss among participants in XXX. Medifast, Inc. 2022.
6. Sanders LM, **Maki KC**. XXX and energy digestibility. General Mills, Inc. 2022.
7. Pharmacodynamic effects of XXX to ENHANCE efficacy in adults with hypertriglyceridemia: The ENHANCE-IT Trial. Matinas Biopharma, Inc., 2021.

8. Dicklin MR, Wilcox ML, Maki CE, Ali M, **Maki KC**. A survey to assess the feasibility of conducting a pharmacokinetic and pharmacodynamic evaluation of XXX in subjects with elevated triglycerides. Midwest Biomedical Research, 2021.
9. Wilcox M, Maki CE, **Maki KC**. A randomized, crossover study to assess the effects of XXX on appetite ratings in children and adolescents 8-14 years of age. Kellogg Company, 2020.
10. **Maki KC**, Dicklin MR, Sanders LM, Palacios OM, Wilcox M, Maki CE. Safety and metabolic effects of XXX in a randomized, double-blind, crossover, placebo-controlled trial of men and women ≥ 55 years of age. ChromaDex, Inc., 2020.
11. **Maki KC**, Dicklin MR, Sanders LM, Palacios OM, Wilcox M, Maki CE. Effects of XXX on cognitive function, mood and sleep in men and women ≥ 55 years of age with normal cognitive function. ChromaDex, Inc., 2020.
12. Dicklin MR, Wilcox M, Maki CE, **Maki KC**. A Study to Characterize Responses for XXX and Related Metabolites to XXX. ChromaDex, Inc., 2019.
13. Cortes HN, Wilcox M, Maki CE, Dicklin MR, **Maki KC**. A Randomized Crossover Study to Assess the Effects of XXX on Postprandial Glucose and Insulin Responses. Ingredion Incorporated, 2019.
14. Becraft AR, Maki CE, **Maki KC**. A Randomized, Crossover Study to Assess the Effects of XXX on Appetite Ratings in Men and Women. Kellogg Company, 2019.
15. Palacios OM, **Maki KC**. A Randomized, Crossover Trial to Assess the Effects of Replacing Commonly Consumed Breakfast Foods with XXX on Insulin Sensitivity and Other Markers of Cardiometabolic Health in Men and Women at Increased Risk for Type 2 Diabetes Mellitus. Egg Nutrition Center, 2019.
16. **Maki KC**, Bell M, Dicklin MR. Pooled Analyses from Corn Oil Studies. ACH Food Companies, Inc., 2018.
17. Palacios OM, Dicklin M, Bell M, **Maki KC**. A Randomized, Controlled-Feeding Crossover Trial to Assess the Effects of XXX within a Healthy Dietary Pattern on Insulin Sensitivity in Men and Women with Risk Factors for Diabetes Mellitus. National Cattlemen's Beef Association, 2018.
18. **Maki KC**, Palacios OM, Buggia MA, Dicklin M, Maki CE. A Randomized, Crossover Study to Assess the Relative Bioavailability of XXX Compared with XXX in Healthy Men and Women. Pharmavite, LLC, 2018.
19. Palacios OM, **Maki KC**. A Randomized, Double-blind, Controlled, Crossover Study to Assess Postprandial Lipid and Glycemic Responses to Consumption of XXX. Habit LLC, 2018.
20. Palacios OM, **Maki KC**. An Open-label, Pilot Trial to Assess the Effects of XXX on Fasting Lipoprotein Lipids and a Marker of Inflammation in Men and Women with Above-desirable Levels of Low-density Lipoprotein Cholesterol. FMC Corporation, 2017.
21. Dicklin MR, Bell M, Maki C, **Maki KC**. A Randomized, Double-Blind, Controlled, Crossover Trial to Assess the Effects XXX on Post-consumption Responses. Ingredion, 2017.
22. **Maki KC**, Dicklin MR, Bell M, Maki CE, Hasse W. Effects of XXX on Lipoprotein Lipids in Men and Women with Above-Desirable Low-Density Lipoprotein Cholesterol Levels. Pharmavite, 2017.
23. **Maki KC**, Palacios O, Edirisinghe I, Burton-Freeman B. A Randomized, Controlled Crossover Trial to Assess the Effects of a Lean Pork-Containing, High-Protein Breakfast on Indices of Satiety and Metabolic Health in Men and Women with Prediabetes. National Pork Board, 2017.

24. Navsariwala VD, Dicklin MR, Bell M, **Maki KC**. A Randomized, Double-Blind, Controlled Study to Assess the Fecal Persistence of XXX Consumed in a Snack Bar in Healthy Men and Women. General Mills, 2017.
25. Dicklin MR, Nieman KM, Bell M, **Maki KC**. A Randomized, Crossover Study to Assess the Effect of XXX on Indices of Appetite, Mental Energy, and Glycemic Response in Healthy Men. General Mills, 2017.
26. Dicklin MR, Nieman KM, Huebner M, **Maki KC**. A Randomized, Controlled Crossover Trial to Assess the Effects of XXX Intake on Glucose and Insulin Responses in Healthy Men and Women. Ingredion Incorporated, 2016.
27. Dicklin MR, Nieman KM, Huebner M, **Maki KC**. A Double-Blind, Randomized, Crossover Trial to Assess the Gastrointestinal Tolerability of XXX in Healthy Men and Women. Ingredion Incorporated, 2016.
28. Nieman KM, Dicklin MR, Huebner M, **Maki KC**. A Randomized, Double-Blind, Placebo-Controlled Pilot Trial to Assess the Effects of XXX on Sleep Quantity and Quality in Men and Women with Occasional Self-Reported Sleep Complaints. Kemin Foods, L.C., 2016.
29. Palacios OM, Nieman KM, Huebner M, **Maki KC**. A Randomized Crossover Study to Evaluate the Appetitive Effects of XXX in Healthy Men and Women. Canadian Clinical Compliance, Inc., 2016.
30. Cook CM, Sanoshy KD, **Maki KC**. A Randomized, Controlled, Crossover Study to Evaluate the Acute and Subchronic Bioavailability of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) from Two Dietary Supplements in Men and Women with Mildly Elevated Triglyceride. Arctic Nutrition, 2014.
31. Cook CM, Schild AL, **Maki, KC**. A 5-Day Randomized, Controlled, Crossover Study to Assess the Gastrointestinal Tolerability of a Novel Food Ingredient in Healthy Adults: Study 1. Tate & Lyle, 2014.
32. Cook CM, Schild AL, **Maki, KC**. A 5-Day Randomized, Controlled, Crossover Study to Assess the Gastrointestinal Tolerability of a Novel Food Ingredient in Healthy Adults: Study 2. Tate & Lyle, 2014.
33. Cook CM, Schild AL, **Maki, KC**. A 5-Day Randomized, Controlled, Crossover Study to Assess the Gastrointestinal Tolerability of a Novel Food Ingredient in Healthy Adults: Study 3. Tate & Lyle, 2014.
34. Nieman KM, Dicklin MR, Schild AL, Rains TM, **Maki KC**. A randomized, controlled trial to assess the appetitive effects of XXX in men and women. Dow Wolff Cellulosics, 2013.
35. Nieman KM, Rains TM, Schild A, **Maki KC**. A randomized, controlled, crossover study to assess the effects of XXX on postprandial glucose and insulin excursions in healthy men. PepsiCo, 2013.
36. Nieman KM, Rains TM, Schild A, **Maki KC**. A randomized, controlled, crossover study to assess the effects of XXX on postprandial glucose and insulin excursions in healthy men. PepsiCo, 2013.
37. **Maki KC**, Schild AL, Derrig LH, Dicklin MR, Rains TM. A randomized, double-blind, placebo-controlled crossover study to assess the effects of XXX on indices of glucose homeostasis in men and women. Cargill, 2012.
38. Cook CM, Dicklin MR, Schild AL, Maki C, Derrig LH, Rains TM, **Maki KC**. A randomized, controlled, crossover study to assess the effects of XXX on postprandial glucose and insulin excursions. Tate & Lyle, 2012.
39. Cook CM, Rains TM, **Maki KC**. Randomized, controlled crossover study to assess and compare bioavailability of selected vitamins from XXX. LeSaffre Yeast Corp, 2012.
40. Rains TM, Sohn EL, **Maki KC**. XXX pilot study. PepsiCo, 2012.

41. Rains TM, Cook CM, Sohn EL, **Maki KC**. A randomized, controlled crossover trial to screen the effects of XXX on appetite in women. Kellogg Company, 2012.
42. **Maki KC**, Rains TM, Dicklin MR, Cofer-Chase L. An assessment of the acute effects of XXX on endothelial function, blood pressure, and low-density lipoprotein oxidation in healthy women. Welch's, 2011.
43. Rains TM, **Maki KC**. A randomized, controlled crossover trial to assess the effects of XXX on exercise performance at two intensities in healthy men. Coca Cola, 2011.
44. Rains TM, Sohn E, **Maki KC**. A randomized, controlled crossover pilot study to assess the effects of XXX on XXX and XXX. Coca Cola, 2011.
45. Rains TM, **Maki KC**. A randomized, placebo-controlled, double-blind, crossover study to evaluate the effects of three doses of a dietary supplement containing XXX on alertness, attention, and concentration in healthy men and women. DSM Nutritional Products, 2010.
46. Rains TM, **Maki KC**. A randomized, controlled, crossover trial to evaluate the acute bioavailability of XXX in healthy men. Trygg Pharma, AS, 2010.
47. Shera N, Cofer-Chase L, Rains TM, **Maki KC**. A double-blind, randomized, controlled crossover trial to assess the digestive and physiological effects of XXX in healthy men and women. Kellogg Company, 2010.
48. Rubin M, **Maki KC**, Orcutt A, Shera N, Kaden V, Hubacher R. A randomized, controlled, crossover trial to assess the effects of XXX on work capacity during exercise in trained male athletes. Coca-Cola, 2010.
49. Dicklin M, **Maki KC**. Lipid-altering effects of a dietary supplement tablet containing XXX in men and women with primary hypercholesterolemia. Pharmavite, 2010.
50. Meinel N, Schmiedeberg L, Rianne S, Wesnes K, Rains TM, Rubin MR, Anderson B, **Maki KC**. A double-blind, randomized, controlled crossover study to assess the effect of XXX on cognitive function in healthy men and women. Coca-Cola, 2009.
51. **Maki KC**, Reeves MS, Witchger M, Poulos S. A double-blind, randomized, controlled, crossover trial to assess the effects of XXX containing XXX on postprandial desire to eat in men and women. Coca-Cola, 2008.
52. **Maki KC**, Reeves MS, Witchger M, Jonnalagadda S. Effects of consuming a XXX containing XXX, as part of a therapeutic lifestyle changes diet, on blood lipids in men and women with primary hypercholesterolemia. General Mills, 2008.
53. **Maki KC**, Reeves MS, Kaden V, Sanders L. A randomized, controlled, double-blind parallel trial to assess the effects of XXX on laxation in healthy adults. Tate & Lyle, 2008.
54. **Maki KC**, Reeves MS, Farmer M, Kaden V, Beiseigel J. A randomized, controlled study to assess the effects of XXX, as part of a reduced energy diet, on blood lipids in overweight and obese adults with elevated low-density lipoprotein cholesterol. General Mills, 2008.
55. **Maki KC**, Reeves MS, Kaden V, Kurilich A. A double blind, randomized, controlled crossover trial to evaluate the effects of XXX on postprandial mood, mental energy and desire to eat in women. PepsiCo Beverages and Foods, 2008.
56. **Maki KC**, Reeves MS, Hubacher R, Kurilich A. A double blind, randomized, controlled crossover trial to assess the effects of different forms of XXX and XXX on postprandial mood, mental energy and desire to eat in women. PepsiCo Beverages and Foods, 2008.

57. **Maki KC**, Reeves MS, Wilder DM, Kurilich A. Effects of different XXX on postprandial satiety in overweight men and women. PepsiCo Beverages and Foods, 2008.
58. **Maki KC**, Reeves MS, Hubacher R, Kurilich A. A double-blind, randomized, controlled crossover trial to assess the effects of different forms of XXX on postprandial mood, mental energy and desire to eat in women. PepsiCo Beverages and Foods, 2008.
59. **Maki KC**, Reeves MS, Kaden V, Sanders L. A randomized, controlled, crossover study to assess blood glucose responses to consumption of XXX in healthy men and women. Tate and Lyle Americas, 2008.
60. **Maki KC**, Reeves MS, Farmer M. Effects of XXX on colonic transit time in healthy men and women. Kraft Foods, Inc., 2007.
61. **Maki KC**, Reeves MS, Wesnes K, Edgar C. A double-blind, placebo-controlled, randomized study to assess the effects of XXX on cognitive function in healthy women. Ocean Spray Cranberries, Inc., 2007.
62. **Maki KC**, Rains TM, Hanbury R, Hubacher R, Reeves MS. A randomized, controlled, crossover trial to assess the glycemic indices of two XXX. Pharmavite LLC, 2007.
63. **Maki KC**, MS Reeves, Farmer M, Wesnes K, Edgar C, Dicklin M. Effects of XXX on cognitive processes in children 8-12 years of age. Kellogg Company, 2007.
64. **Maki KC**, Bell M, Farmer, M. A double-blind, controlled trial to assess the safety, tolerability and bioavailability of XXX in healthy adults. Pharmavite LLC, 2005.
65. Adler G, Young D, Galant R, Quinn L, Witchger MS, **Maki KC**. A multi-center, open label study to evaluate patient satisfaction and menopausal quality-of-life in women using Transdermal Estradiol/Norethindrone Acetate therapy for the management of menopausal signs and systems. Novogyne Pharmaceuticals, 2005.
66. Galant R, **Maki KC**, Wheeler A, Hess, S, Bell M. A randomized double-blind, double-dummy, placebo-controlled, phase III study to assess the efficacy and safety of 130 mg of XXX, with and without food, versus a matching placebo, combined with a low saturated-fat diet in subjects with hypertriglyceridemia and metabolic syndrome. Reliant Pharmaceuticals, 2004.
67. **Maki KC**; Kanter M; Quinn LC, Kalkowski JA, Brewczynski C; Hess S. A randomized, double-blind, crossover, dose-ranging trial to assess the gastrointestinal tolerability of XXX in healthy adults. Cargill, 2004.
68. **Maki KC**, Umporowicz DM, Dicklin MR. A randomized, open-label, multicenter study comparing the bleeding profile of ORTHO EVRA® (norgestromin/ethinyl estradiol) continuous regimen vs. ORTHO EVRA® cyclic regimen. Ortho-McNeil Pharmaceutical, Inc., 2004.
69. **Maki KC**, Umporowicz DM, Bell M, Quinn L. A placebo-controlled, randomized, double-blind, parallel-group, dose-finding, at-home study to evaluate the efficacy and safety of intranasally administered XXX in subjects with male erectile dysfunction. Palatin Technologies, Inc., 2004
70. **Maki KC**, Umporowicz DM, Bell M, Hess S. A randomized, open label, multicenter, crossover trial of XXX vs. atorvastatin 10 mg utilization on NCEP ATP III goal achievement in persons with moderate risk for coronary heart disease: The LAUNCH Study. Reliant Pharmaceuticals, 2003
71. **Maki KC**, Umporowicz DM, Bell M, Dicklin MR. A randomized, double-blind, placebo-controlled trial to assess the effects of XXX on erectile dysfunction in men with chronic erectile dysfunction. Welch's, 2003.

72. **Maki KC**, Umporowicz DM, Bell M, Cyrowski M. A double-blind, randomized, placebo- controlled clinical study to evaluate the effect of XXX on body fat mass in overweight or obese men and women. Glanbia, 2002.
73. **Maki KC**, Bookstein M, Hess SH, Umporowicz DM, Bell M. Double-blind, randomized, placebo-controlled, multicenter trial to demonstrate the efficacy of 12 weeks of treatment with XXX synthetic conjugated estrogens, XXX on vasomotor symptoms in postmenopausal women. Barr Research, Inc. 2002.
74. **Maki KC**, Umporowicz DM, Phelps KV, Stevens RE. A double-blind, randomized, placebo-controlled, multicenter trial to demonstrate the efficacy of 12 weeks of treatment with XXX on vasomotor symptoms in postmenopausal woman. Barr Research, Inc. 2002.
75. **Maki KC**, Davidson MH, Dicklin MR, Cyrowski M, Umporowicz DM, Bell M. A comparison of the bioavailability of omega-3 fatty acids from XXX. Roche Vitamins, Inc. 2001.
76. **Maki KC**, Bell M, Umporowicz DM. A 24-week, randomized, multicenter, multinational trial to evaluate the efficacy and safety of XXX, alone and in various combinations, in the treatment of type IIb and IV hyperlipidemia associated with type II diabetes mellitus (DM). AstraZeneca, 2001.
77. **Maki KC**, Bell M, Umporowicz DM. A 30-week, dose-titration and randomized, crossover, multicenter, multinational trial to evaluate the efficacy and safety of XXX in subjects with homozygous familial hypercholesterolemia. AstraZeneca, 2001.
78. **Maki KC**, Bell M, Umporowicz DM. A 18-week randomized double-blind multicenter placebo-controlled trial to evaluate the efficacy and safety of XXX in the treatment of hypercholesterolemic postmenopausal women receiving hormone replacement therapy (HRT). AstraZeneca, 2001.
79. **Maki KC**, Bell M, Umporowicz DM. A 24-week, randomized, multicenter trial to evaluate the efficacy and safety of XXX, as well as selected combinations of XXX, in the treatment of subjects with type IIb or IV hyperlipidemia. AstraZeneca, 2001.
80. **Maki KC**, Bell M, Umporowicz DM. A 24-week, randomized, double-blind, multicenter trial to evaluate the efficacy and safety of starting and maximum doses of XXX in the treatment of high risk hypercholesterolemic subjects. AstraZeneca, 2001.
81. **Maki KC**, Bell M, Umporowicz DM. A randomized, double-blind, multinational, multicenter trial to compare the short-term and long-term efficacy and safety of XXX in the treatment of subjects with hypercholesterolemia. AstraZeneca, 2001.
82. **Maki KC**, Bell M, Umporowicz DM. A 12-week, randomized, double-blind, multicenter trial to evaluate the efficacy and safety of XXX in the treatment of subjects with hypercholesterolemia. AstraZeneca, 2000.
83. **Maki KC**, Bell M, Umporowicz DM. A randomized, double-blind, parallel-group dose-response study with the HMG CoA reductase inhibitor XXX and placebo in subjects with primary hypercholesterolemia. AstraZeneca, 2000.
84. **Maki KC**, Bell M, Umporowicz DM. A randomized, double-blind, multicenter trial to compare the short-term and long-term efficacy and safety of XXX in the treatment of subjects with hypercholesterolemia. AstraZeneca, 2000.
85. **Maki KC**, Bell M, Umporowicz DM. A 24-week, randomized, double-blind, multicenter, multinational trial to evaluate the efficacy and safety of XXX in the treatment of subjects with heterozygous familial hypercholesterolemia. AstraZeneca, 2000.

86. **Maki KC**, Bell M, Umporowicz DM. Study of blood cholesterol levels in subjects consuming a cholesterol lowering diet including XXX. Proctor and Gamble, 2000.
87. **Maki KC**, Davidson MH, Cyrowski MS, Umporowicz DM, Dicklin MR, Samuel P, Subbaiah PV, Paul G. Oat β -glucan cereal reduces postprandial triglyceridemia: Results of a randomized, crossover, controlled clinical trial. Quaker Oats Company, 2000.
88. **Maki KC**, Bell M, Umporowicz DM. A 12-week, randomized, open-label, multicenter trial to evaluate the efficacy, safety, and tolerability of XXX and the combination of XXX and XXX in the treatment of subjects with severe hypercholesterolemia. AstraZeneca, 2000.
89. **Maki KC**, Bell M, Umporowicz DM. A 6-week, randomized, double-blind multicenter trial to evaluate the safety and efficacy of XXX and XXX across their respective dose ranges in the treatment of subjects with hypercholesterolemia. AstraZeneca, 2000.
90. **Maki KC**, Bell M, Umporowicz DM. A 12-week, randomized, double-blind, multicenter, placebo-controlled trial to evaluate the efficacy and safety of XXX in the treatment of subjects with hypertriglyceridemia. AstraZeneca, 2000.
91. **Maki KC**, Bell M, Umporowicz DM. A double-blind, randomized, parallel, placebo-controlled clinical study to compare the effects of XXX vs. placebo tablets on vulvovaginal atrophy in healthy postmenopausal women. Duramed Pharmaceuticals, Inc., 2000.
92. **Maki KC**, Bell M, Umporowicz DM. A randomized, double-blind, controlled clinical trial to compare the lipid responses, in men and women with elevated triglyceride levels, to consumption of eggs laid by chickens who have eaten docosahexaenoic acid feed vs. control eggs. OmegaTech, 2000.
93. **Maki KC**, Bell M, Umporowicz DM. A randomized, double-blind, controlled two-way crossover clinical trial to evaluate the effectiveness of a test food product for inducing satiety in healthy men and women. General Mills, 2000.
94. Davidson MH, **Maki KC**, Ingram K. A randomized, placebo-controlled trial to evaluate a single ingestion of a new protein-based food component. Unilever, 2000.
95. **Maki KC**, Rosenblatt S, Kurlandsky S, Cyrowski M. A single- blind, placebo-controlled trial to evaluate the efficacy of safety of revised XXX in healthy adult men and women consuming a typical "western" diet. Nutrilite Division of Access Business Group ILLC, 2000.
96. **Maki KC**, Bell M, Umporowicz DM. A randomized, double-blind, controlled trial to evaluate the efficacy and safety of a phytosterol-enriched reduced fat spread for reducing serum low density lipoprotein cholesterol in subjects with mild-to-moderate primary hypercholesterolemia. Lipton, 2000.
97. **Maki KC**, Bell M, Umporowicz DM. A randomized, double-blind, controlled trial to evaluate the safety and tolerability of three doses of phytosterols in healthy adult men and women. Lipton, 2000.
98. **Maki KC**, Bell M, Umporowicz DM, Davidson MH, Dicklin MR. Effects of consuming econa oil vs. triglycerides on body composition and regional body fat distribution: a randomized, double-blind, controlled trial. Kao Corporation, 2000.
99. **Maki KC**, Davidson MH, Dicklin MR. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Merck-Wyeth-Ayerst Laboratories, 2000.
100. **Maki KC**, Bell M, Umporowicz DM. A randomized, double-blind clinical trial to evaluate the influence of XXX on serum lipids in men and women with hypercholesterolemia. Archer Daniels Midland, 1999.

101. **Maki KC**, Bell M, Umporowicz DM. A randomized, double-blind, crossover clinical trial to evaluate the effects of a XXX product on serum lipids in men and women with hypercholesterolemia. Archer Daniels Midland, 1999.
102. **Maki KC**, Bell M, Umporowicz DM. Effects of an immune-booster beverage on immune response in humans. Novartis, 1999.
103. **Maki KC**, Bell M, Umporowicz DM. The effects of a calcium-containing test beverage, compared to control, on mineral metabolism. Pharmavite, 1999.
104. **Maki KC**, Bell M, Umporowicz DM. The influence of oat products on the postprandial metabolic profile: a randomized, cross- over, controlled trial. Quaker Oats, 1999.
105. Davidson MH, **Maki KC**, Kurlandsky SB, Dicklin MR, Malik KC. A randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of hydroxy-propylmethylcellulose for reducing serum low density lipoprotein cholesterol in patients with mild-to-moderate hypercholesterolemia. SmithKline Beecham Consumer Healthcare, 1998.
106. Davidson MH, Lardy H, Weeks CE, **Maki KC**, Umporowicz DM, Dicklin MR. A randomized, double-blind, placebo controlled, escalating dose and pharmacokinetic study to evaluate the safety of the investigational oral product HL-9001. Humanetics Corporation, 1998.
107. Davidson MH, **Maki KC**, Marx P, Copp C, Niece J. A double-blind, randomized, placebo-controlled, parallel group study comparing the efficacy and safety of oral tablets of estradiol/norethindrone acetate, estradiol alone, and placebo in the determination of CVD risk markers in postmenopausal women. Novo Nordisk Pharmaceuticals, Inc., 1998.
108. Davidson MH, **Maki KC**, Synecki C. Assessment of the dose response effect of dietary XXX on status of fat-soluble vitamins and selected water-soluble nutrients. Arco Chemical Co., 1997.
109. **Maki KC**. Effects of oatmeal consumption on blood pressure and carbohydrate metabolism: A randomized, controlled, dose-ranging study. Quaker Oats, 1996.
110. Davidson MH, **Maki KC**, Goldblatt D. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy of XXX for improving maximal oxygen uptake and exercise endurance among apparently healthy sedentary men and women. Pharmaton, 1996.
111. Davidson MH, **Maki KC**, Torri SA, Stocki J, Drennan KB. The hypocholesterolemic effects of high molecular weight hydroxypropylmethylcellulose with and between meals: A pilot study. SmithKline Beecham Consumer Healthcare, 1996.
112. Davidson MH, Malik KC, **Maki KC**, Synecki C. A randomized double-blind placebo controlled trial to evaluate the efficacy and safety of XXX as a smoking cessation aid. Metabolic Technologies Incorporated, 1996.
113. Davidson MH, **Maki KC**, Kong J, Weber J, Drennan K. A comparison study evaluating the long-term lipoprotein responses of lean red vs. white meat. National Cattleman's Beef Association, 1995.

RESEARCH PARTICIPATION (confidential information represented with XXX):

1. A randomized, double-blind crossover trial to assess gastrointestinal responses to dietary fibers in adults using weight loss medications. (2025, Study Director). General Mills.
2. A randomized, parallel trial to assess the effects of XXX on lutein and zeaxanthin levels in healthy adults: The VERMEER study. (2024, Study Director). NewAmsterdam Pharma.

3. A randomized, crossover trial to assess the effects of short-term diets with and without XXX on energy expenditure in adults. (2024, Study Director). General Mills.
4. A randomized, crossover trial to assess the effects of acute intake of meals containing higher vs. lower energy from protein on diet induced thermogenesis in adults with overweight or obesity. (2024, Study Director). General Mills.
5. A phase 2 study to evaluate the effect of XXX alone and in combination with XXX on lipoprotein(a) in patients with mild dyslipidemia: The VINCENT study. (2024, Study Director). NewAmsterdam Pharma.
6. A consumer pilot study to understand how continuous glucose monitors impact eating behavior in individuals attempting to lose weight. (2023, Study Director). General Mills.
7. An observational study to assess variability of anti-lactoferrin antibodies in healthy adults. (2023, Study Director). Helaina.
8. A randomized, double-blind, controlled, parallel-arm trial to assess the effects of lactoferrin at two doses vs. active control on markers of immune function in healthy adults. (2023, Study Director). Helaina.
9. A randomized, double-blind, controlled, parallel-arm trial to assess the effects of XXX at two doses vs. control on indicators of cardiometabolic health in metabolically at-risk adults. (2022, Study Director). Greenyn Biotechnology.
10. A randomized, double-blind, crossover, kinetic study to assess the relative bioavailability of XXX in two supplement products in healthy adult men and women. (2022, Study Director). C.I. Naturmega S.A.
11. The effects of XXX on acute appetite hormone release in men and women with normal weight, overweight and type 2 diabetes. (2022, Study Director). Cargill, Inc.
12. A randomized, crossover trial to assess the effects of XXX on pancreatic beta-cell function in men and women with prediabetes (2022, Study Director). National Cattlemen's Beef Association.
13. A randomized, crossover study to assess bioavailability of folic acid, zinc, magnesium, and vitamin B12 from liquid and tablet supplements in healthy adult women of childbearing age. (2022, Study Director). Pharmavite, LLC.
14. Incidence and re-infection of healthy adults with or without prior SARS-CoV-2 Infection: the AEGIS study. (2020, Co-Principal Investigator). Indiana University Foundation.
15. A randomized, parallel trial to assess the effects of replacing XXX with XXX on insulin sensitivity, erythrocyte fatty acid profile and related markers of cardiometabolic health in metabolically at-risk adults. (2020, Study Director). National Dairy Council.
16. A randomized, controlled feeding, double-blind, crossover study to examine the metabolic effects of replacing energy from solid fats and added sugars (SoFAS) with XXX in men and women with elevated triglycerides. (2020, Study Director). Hass Avocado Board.
17. A randomized, crossover study to assess bioavailability of XXX and XXX from five products in healthy adult women of childbearing age. (2020, Study Director). Pharmavite LLC.
18. Daily egg consumption and XXX in older adults. (2020, Co-Investigator). Egg Nutrition Center.
19. A randomized, crossover study to assess the effects of XXX on appetite ratings in children and adolescents 8-14 years of age. (2019, Study Director). Kellogg Company.

20. A randomized, crossover study to assess the effects of XXX added to XXX in crisp and ready-to-mix drink formulations, compared to a XXX ready-to-mix drink, on postprandial plasma amino acid, glucose and insulin concentrations in healthy men and women. (2019, Study Director). Kellogg Company.
21. A randomized, crossover study to assess bioavailability of XXX from two products in healthy adult women of childbearing age. (2019, Study Director). Pharmavite LLC.
22. Pharmacodynamic effects of XXX to ENHANCE efficacy in adults with hypertriglyceridemia: The ENHANCE-IT trial. (2019, Study Director). Matinas BioPharma.
23. A survey to assess the feasibility of conducting a pharmacokinetic and pharmacodynamics evaluation of XXX in subjects with elevated triglycerides. (2019, Study Director). Matinas BioPharma.
24. A randomized, crossover study to assess the effects of XXX on appetite ratings in men and women. (2018, Study Director). The Kellogg Company.
25. A randomized, crossover study to assess the effects of XXX on postprandial glucose and insulin responses. (2018, Study Director). Ingredion Incorporated.
26. XXX and glycemic control in diabetes: a proof of concept study. (2018, Principal Investigator). Abbott Nutrition.
27. A phase 3, multicenter, placebo-controlled, randomized, double-blind 26-week study to assess the safety and efficacy of XXX in patients with severe hypertriglyceridemia. (2018, Principal Investigator). Acasti Pharma, Inc.
28. A study to characterize circulating XXX in response to XXX. (2018, Study Director). ChromaDex, Inc.
29. Effects of XXX on insulin sensitivity, related metabolic markers and satiety in men and women at risk for type 2 diabetes. (2018, Study Director). Sponsor: Alliance for Potato Research & Education.
30. A randomized, double-blind, crossover study to assess the effects of XXX on cognitive function, mood and sleep in healthy older adult men and women. (2018, Study Director). Sponsor: ChromaDex, Inc.
31. A single-center, randomized, double-blind, comparator-controlled, crossover study to evaluate safety and efficacy of the investigational product (XXX) versus comparator (XXX) on cognitive function in healthy adults. (2018, Principal Investigator). Sponsor: Oakland Law Group, PLLC.
32. A randomized, crossover study to assess the relative bioavailability of XXX compared with a standard omega-3-acid ethyl ester product in healthy men and women. (2017, Study Director) Sponsor: Pharmavite.
33. A single-center, randomized, double-blind, placebo controlled parallel study to investigate the safety and efficacy of XXX in a moderately stressed female population. (2017, Principal Investigator) Sponsor: Moon Juice Ventures, LLC.
34. A randomized, crossover trial to assess the effects of replacing commonly consumed breakfast foods with eggs on insulin sensitivity and other markers of cardiometabolic health in men and women at increased risk for type 2 diabetes mellitus. (2017, Study Director) Sponsor: Egg Nutrition Center.
35. A randomized, double-blind, placebo-controlled study to evaluate the effect of XXX on neurocognitive function in patients with heterozygous familial hypercholesterolemia or with non-familial hypercholesterolemia at high and very high cardiovascular risk. (2017, Sub-Investigator) Sponsor: Regeneron Pharmaceuticals, Inc.

36. A randomized, double-blind, controlled, crossover trial to assess the effects of XXX on postprandial responses. (2017, Study Director) Sponsor: Ingredion Incorporated.
37. A randomized, crossover trial to assess the effect of XXX on insulin sensitivity in men and women with pre-diabetes. (2017, Principal Investigator) Sponsor: Almond Board of California.
38. A pilot study to evaluate glucose control in patients with type 2 diabetes. (2016, Principal Investigator) Sponsor: Abbott Nutrition.
39. A double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of XXX in elderly participants with age-associated memory impairment (AAMI). (2016, Consulting Scientist) Sponsor: Tasly Pharmaceuticals.
40. A randomized, double-blind, controlled study to assess the fecal persistence of XXX consumed in a snack bar in healthy men and women. (2016, Study Director) Sponsor: General Mills.
41. An open-label, pilot trial to assess the effects of XXX on fasting lipoprotein lipids and a marker of inflammation in men and women with above-desirable levels of low-density lipoprotein cholesterol. (2016, Study Director) Sponsor: FMC Corporation.
42. A randomized, controlled-feeding, crossover trial to assess the effects of XXX within a healthy dietary pattern on insulin sensitivity in men and women with risk factors for diabetes mellitus. (2016, Study Director) Sponsor: The Beef Checkoff, National Cattlemen's Beef Association.
43. A randomized, double-blind, controlled, crossover, pilot trial comparing the effects of XXX and XXX on fasting lipoprotein lipids and markers of insulin sensitivity and inflammation in men and women. (2016, Study Director) Sponsor: ACH Food Companies, Inc.
44. Effect of XXX on metabolic parameters in subjects with type 2 diabetes. (2016, Principal Investigator) Sponsor: Abbott Nutrition.
45. A randomized, double-blind, controlled crossover study to assess postprandial lipid and glycemic responses to consumption of XXX. (2016, Chief Science Officer) Sponsor: Habit LLC.
46. A randomized, double-blind, controlled, crossover trial to assess the effects of a dietary supplement containing XXX on fasting lipoprotein lipids in men and women with above-desirable levels of cholesterol. (2016, Study Director) Sponsor: Pharmavite.
47. A randomized, crossover study to assess the effect of XXX on indices of appetite, mental energy, and glycemic response in healthy men. (2016, Study Director) Sponsor: General Mills.
48. A randomized, double-blind, placebo-controlled pilot trial to assess the effects of XXX on sleep quantity and quality in men and women with occasional self-reported sleep complaints. (2016, Study Director) Sponsor: Kemin Foods, L.C.
49. A double-blind, randomized, crossover trial to assess the gastrointestinal tolerability of XXX in healthy men and women. (2016, Study Director) Sponsor: Ingredion Incorporated.
50. A randomized, controlled, crossover clinical trial to assess the effects of XXX intake on glucose and insulin responses in healthy men and women. (2016, Chief Science Officer) Sponsor: Ingredion Incorporated.
51. A randomized, controlled, crossover trial to assess the effects of XXX on indices of satiety and metabolic health in men and women with pre-diabetes. (2016, Study Director) Sponsor: National Pork Board.

52. Landmark 2 Study: Survey of demographic characteristics and the health and nutritional status of long and shorter-term multiple dietary supplement users. (2015, Study Director) Sponsor: Shaklee Corporation.
53. Multivitamin/multi-mineral (MVM) supplementation improves nutritional status in older adults at risk of micronutrient inadequacy induced by drug therapies. (2015, Study Director) Sponsor: Tufts University.
54. Effects of XXX and XXX (XXX and XXX) XXX extracts on anxiety, cognitive performance, and mood tested after induced stress. (2015, Study Director) Sponsor: InterHealth Nutraceuticals, Incorporated.
55. A randomized crossover study to evaluate the appetitive effects of ready-to-drink shakes in healthy men and women. (2015, Study Director) Sponsor: Canadian Clinical Compliance, Inc.
56. Metabolic effects of replacing dietary refined carbohydrate with a combination of egg protein and unsaturated fats in men and women with elevated triglycerides. (2014, Study Director) Sponsor: Egg Nutrition Center.
57. A randomized, controlled, crossover trial of acute cognitive, appetite, glucose and insulin responses to five milk, juice, and water beverages in men and premenopausal women. (2014, Study Director) Sponsor: Dairy Research Institute.
58. A randomized, controlled, two-cohort, crossover study to assess the gastrointestinal tolerability of XXX in healthy adults. (2014, Study Director) Sponsor: Tate & Lyle.
59. A randomized, controlled, crossover study to assess the effects of XXX on postprandial glucose and insulin excursions. (2014, Study Director) Sponsor: Tate & Lyle.
60. A 5-day randomized, controlled, crossover study to assess the gastrointestinal tolerability of XXX in healthy adults. (2014, Study Director) Sponsor: Tate & Lyle.
61. A 5-day randomized, controlled, crossover study to assess the gastrointestinal tolerability of XXX in healthy adults. (2013, Study Director) Sponsor: Tate & Lyle.
62. A randomized, controlled, crossover study to evaluate the acute and subchronic bioavailability of XXX in healthy men and women. (2013, Study Director) Sponsor: Arctic Nutrition.
63. A randomized, controlled, crossover study to assess the effects of XXX on postprandial glucose and insulin excursions in healthy men. (2013, Study Director) Sponsor: PepsiCo.
64. A randomized, controlled, crossover study to assess the effects of XXX on postprandial glucose and insulin excursions in healthy men. (2013, Study Director) Sponsor: PepsiCo.
65. A single-center, double-blind, randomized, four-treatment crossover bioavailability study of XXX in healthy subjects. (2013, Study Director) Sponsor: McCormick.
66. A randomized, double-blind, controlled crossover trial to assess the effects of dietary oils on fasting lipoprotein lipids. (2013, Study Director) Sponsor: ACH Food Companies, Inc., PepsiCo.
67. A multicenter, double-blind, randomized, placebo-controlled trial to assess the effects of XXX in women with recent history of urinary tract infections. (2013, Study Director) Sponsor: Ocean Spray Cranberries, Inc.
68. A randomized, controlled crossover trial to assess the appetitive effects of XXX in men and women. (2012, Study Director) Sponsor: Dow Wolff Cellulosics.

69. An efficacy and safety study of XXX in adults with hypertriglyceridemia. (2012, Study Director) Sponsor: DSM Nutritional Products.
70. A randomized, controlled, crossover trial to assess the effects of XXX on insulin sensitivity and β -cell function in men and women at risk for diabetes who are habitual consumers of high sugar beverages. (2012, Study Director) Sponsor: Dairy Research Institute.
71. A randomized, controlled crossover trial to assess the effects of XXX on satiety and cognitive function in women. (2012, Study Director) Sponsor: Hillshire Brands.
72. A randomized, controlled crossover trial to correlate the appetitive effects of XXX with appetite-regulating hormones in women. (2012, Study Director) Sponsor: Kellogg Company.
73. A randomized, double-blind, placebo-controlled crossover study to assess the effects of XXX on indices of glucose homeostasis in men and women. (2012, Study Director) Sponsor: Cargill.
74. A randomized, controlled, crossover study to assess the effects of XXX on postprandial glucose and insulin excursions. (2012, Study Director) Sponsor: Tate & Lyle.
75. A randomized, controlled crossover study to assess and compare bioavailability of selected vitamins from XXX. (2012, Study Director) Sponsor: LeSaffre Yeast Corp.
76. A randomized, controlled crossover trial to screen the effects of XXX on appetite in women. (2011, Study Director) Sponsor: Kellogg Company.
77. XXX pilot study. (2011, Study Director) Sponsor: PepsiCo Global Long Term Research.
78. Sensory profile test of XXX. (2011, Study Director) Sponsor: Kao Corporation.
79. A randomized, controlled, trial to assess the effects of XXX on endothelial function and blood pressure in subjects with pre-hypertension or stage 1 hypertension. (2011, Study Director) Sponsor: Dairy Research Institute.
80. A double-blind, randomized, crossover trial to assess the gastrointestinal tolerability of XXX in healthy men and women. (2011, Study Director) Sponsor: National Starch LLC.
81. An evaluation of the tolerability of the oral soft tissue to increasing concentrations of XXX in healthy study participants. (2011, Study Director) Sponsor: Firmenich S.A.
82. A double-blind, randomized, controlled, crossover trial to assess the effects of XXX on urinary anti-adhesion activity in healthy men and women-Part III. (2011, Study Director) Sponsor: Ocean Spray Cranberries, Inc.
83. A study to determine eligibility for a randomized, double-blind placebo-controlled, crossover study to evaluate the effect of XXX on rehydration after exercise-induced dehydration. (2011, Study Director) Sponsor: PepsiCo Global Long Term Research.
84. A study to determine eligibility for a randomized, double-blind placebo-controlled, repeated measures study to evaluate the effect of XXX on performance and metabolic responses during prolonged cycling. (2011, Study Director) Sponsor: PepsiCo Global Long Term Research.
85. A randomized, controlled, crossover study to evaluate the acute safety and bioavailability of XXX in healthy men and women. (2011, Study Director) Sponsor: Kao Corporation.
86. A randomized, controlled crossover trial to assess the effects of XXX on appetite and subsequent energy intake in women. (2011, Study Director) Sponsor: Kellogg Company.

87. A randomized, controlled crossover trial to assess the effects of XXX on exercise performance at two intensities in healthy men. (2010, Study Director) Sponsor: Coca Cola.
88. A randomized, controlled crossover pilot study to assess the effects of XXX on XXX and XXX. (2010, Study Director) Sponsor: Coca Cola.
89. A randomized, double-blind, controlled crossover trial to assess the acute effects of two doses of XXX on endothelial function in women. (2010, Study Director) Sponsor: Welch Foods, Inc.
90. A randomized, double-blind, parallel group bioequivalence trial with XXX products in healthy adult volunteers. (2010, Overall Principal Investigator) Sponsor: XXX.
91. A single-blind pilot study to assess XXX bioavailability from a softgel capsule compared to a standard tablet. (2010, Study Director) Sponsor: Pharmavite.
92. A randomized, controlled, crossover trial to evaluate the acute bioavailability of omega-3 acid ethyl ester products in healthy men. (2010, Study Director) Sponsor: Trygg Pharma, AS.
93. A study to determine eligibility for a randomized, double-blind placebo-controlled, parallel group trial designed to assess the effects of XXX on XXX in trained cyclists. (2010, Study Director) Sponsor: Gatorade Sports Science Institute.
94. Evaluation of an oral nutritional supplement containing XXX in malnourished and frail subjects. (2010, Principal Investigator) Sponsor: Abbott Nutrition.
95. A randomized, controlled, trial to assess the effects of XXX on eicosapentaenoic acid levels of red blood cells and the omega-3 index. (2010, Study Director) Sponsor: Solae/Monsanto.
96. A double-blind, randomized, controlled, crossover trial to assess the effects of XXX on urinary anti-adhesion activity in healthy men and women. (2010 Study Director) Sponsor: Ocean Spray Cranberries, Inc.
97. Effect of XXX on metabolic parameters in subjects with type 2 diabetes. (2010, Principal Investigator) Sponsor: Abbott Nutrition.
98. Evaluation of a snack food containing XXX on energy intake and satiety. (2010, Principal Investigator) Sponsor: GlaxoSmithKline Consumer Healthcare.
99. A double-blind, randomized, placebo-controlled crossover trial to assess the effects of XXX on indices of glucose homeostasis and plasma lipoproteins in subjects with hypertriglyceridemia. (2010, Principal Investigator) Sponsor: Provident Clinical Research & Consulting, Inc. (Investigator Initiated Trial with support provided by GlaxoSmithKline).
100. A randomized, placebo-controlled, double-blind, crossover study to evaluate the effects of three doses of a dietary supplement containing XXX on alertness, attention, and concentration in healthy men and women. (2010, Study Director) Sponsor: DSM Nutritional Products.
101. A comparison of two methods for assessing insulin sensitivity and secretion: A substudy of a randomized, controlled, double-blind crossover study to assess the effects of XXX, at two doses, on insulin sensitivity. (2010, Principal Investigator) Sponsor: Provident Clinical Research & Consulting, Inc.
102. A randomized, controlled parallel trial to evaluate the effects of XXX on cognitive processes in children 8-12 years of age. (2010, Study Director) Sponsor: Kellogg Company.

103. A randomized, controlled crossover trial to assess the acute bioavailability of XXX in healthy men. (2010, Study Director) Sponsor: XXX.
104. A randomized, double-blind, placebo-controlled, crossover study evaluating the effects of a XXX on physical performance in healthy male volunteers. (2009, Study Director) Sponsor: Gatorade Sports Science Institute.
105. A randomized, controlled, double-blind, crossover study to assess the effects of XXX, at two doses, on insulin sensitivity. (2009, Study Director) Sponsor: National Starch.
106. A randomized, controlled crossover trial to assess the effects of XXX on work capacity during exercise in trained male athletes. (2009, Study Director) Sponsor: Coca Cola.
107. A randomized, controlled crossover study to assess the effects of XXX on the plasma lipid profile in men and women with primary hypercholesterolemia. (2009, Study Director) Sponsor: California Almond Board.
108. A randomized, placebo-controlled, crossover trial to assess the effects of a novel XXX preparation on fasting lipoprotein lipids in men and women with primary hypercholesterolemia. (2009, Study Director) Sponsor: Pharmavite.
109. A randomized, placebo-controlled, crossover trial to assess the effects of XXX on fasting lipoprotein lipids in men and women with primary hypercholesterolemia. (2009, Study Director) Sponsor: Pharmavite.
110. Evaluation of the relationships of time and dose of XXX and XXX to the changes in eicosapentaenoic acid levels of red blood cells. (2009, Study Director) Sponsor: Solae/Monsanto.
111. A randomized, double-blind, controlled, parallel arm trial to assess the effects of XXX on high-density lipoprotein cholesterol and other cardiovascular disease risk markers. (2009, Study Director) Sponsor: Shaklee.
112. A randomized, controlled crossover trial to assess the effects of XXX on fecal fat excretion in men and women. (2009, Study Director) Sponsor: Coca-Cola.
113. A pilot study to evaluate the effects of XXX on dietary intake and blood glucose management in men and women with type 2 diabetes. (2009, Study Director) Sponsor: Kraft.
114. A double-blind, randomized, controlled crossover trial to assess the digestive and physiological effects of XXX in healthy men and women. (2009, Study Director) Sponsor: Kellogg Company.
115. Effects of consuming XXX, as part of a Therapeutic Lifestyle Changes diet, on blood lipids in men and women with primary hypercholesterolemia. (2008, Study Director) Sponsor: General Mills.
116. A double-blind, randomized, controlled crossover trial to assess the effects of XXX on postprandial hunger and satiety in men and women. (2008, Study Director) Sponsor: Dairy Management, Inc.
117. Effect of XXX on metabolic parameters in subjects with type 2 diabetes. (2008, Principal Investigator) Sponsor: Abbott.
118. A randomized, double-blind, parallel study to evaluate the effects of XXX on fecal bile acids and blood lipids in men and women. (2008, Study Director) Sponsor: Solae.
119. A double-blind, randomized, controlled crossover study to assess the effects of consuming a XXX containing XXX on cognitive function in healthy men and women. (2008, Study Director) Sponsor: Coca-Cola.

120. A double-blind, randomized, placebo-controlled, two-period crossover trial to assess the effects of XXX on low-density lipoprotein cholesterol and other aspects of the fasting lipid profile in subjects with primary hypercholesterolemia. (2008, Principal Investigator) Sponsor: Provident Clinical Research & Consulting, Inc. (Investigator Initiated Trial with support provided by GlaxoSmithKline).
121. A phase III, randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of XXX for the treatment of hypoactive sexual desire disorder in surgically menopausal women. (2008 Sub-investigator) Sponsor: BioSante Pharmaceuticals.
122. A phase II, randomized, double-blind, placebo-controlled, multi-center study of the long term safety and efficacy of XXX for the treatment of hypoactive sexual desire disorder in postmenopausal women. (Sub-investigator 2008) Sponsor: BioSante Pharmaceuticals.
123. A double-blind, randomized, 12-month, placebo-controlled, parallel group, fixed-dose to evaluate the efficacy and safety of XXX in patients with primary hypercholesterolemia (2008 Sub-Investigator) Sponsor: Sanofi Aventis.
124. A double-blind, randomized, controlled, crossover trial to assess the effects of XXX on urinary anti-adhesion activity and serum immune factors (2008 Study Director) Sponsor: Ocean Spray Cranberries, Inc.
125. A double-blind, randomized, controlled crossover trial to assess the effects of XXX on postprandial desire to eat in men and women (2008 Study Director) Sponsor: The Coca-Cola Company.
126. XXX status and risk for cardiovascular disease (2008 Study Director) Sponsor: Shaklee Corporation.
127. Effects of consuming XXX containing XXX as part of a Therapeutic Lifestyle Changes diet, on blood lipids in men and women with primary hypercholesterolemia (2008 Study Director) Sponsor: General Mills.
128. A double-blind, randomized, controlled crossover trial to evaluate the effects of XXX on postprandial mood, mental energy and desire to eat in women (2007 Study Director) Sponsor: PepsiCo Beverages and Foods.
129. A double-blind, randomized, controlled crossover trial to assess the effects of XXX on urinary anti-adhesion activity in healthy men and women (2007 Study Director) Sponsor: Ocean Spray.
130. A double-blind, randomized, controlled crossover trial to assess the effects of XXX on postprandial satiety, perceived energy and subsequent food intake responses in men and women. (2007, Study Director) Sponsor: PepsiCo Beverages and Foods.
131. A double-blind, randomized, controlled crossover trial to assess the effects of XXX and XXX on postprandial mood, mental energy and desire to eat in women. (2007, Study Director) Sponsor: PepsiCo Beverages and Foods.
132. A randomized, controlled, double-blind, crossover trial to assess the effects of XXX on laxation in healthy adults. (2007, Study Director) Sponsor: Tate and Lyle Americas.
133. Postprandial glycemic response of XXX in subjects with type 2 diabetes. (2007, Principal Investigator) Sponsor: Abbott Nutrition.
134. A randomized, controlled, double-blind study to evaluate the safety and tolerability of XXX in men and women. (2007, Study Director) Sponsor: Aker BioMarine.

135. A study to evaluate a XXX device for assessing XXX in healthy men and women. (2007, Study Director) Sponsor: Shaklee Corporation.
136. Comparison of XXX for people with type 2 diabetes. (2007, Principal Investigator) Sponsor: Abbott Nutrition.
137. A randomized, controlled, crossover trial to assess the glycemic indices of two XXXs. (2007, Study Director) Sponsor: Pharmavite LLC.
138. A double-blind, randomized, controlled trial to assess the effects of XXX vs XXX on postprandial satiety and subsequent food intake in overweight men and women. (2007, Study Director) Sponsor: Quaker Oats.
139. A randomized, controlled, crossover trial to assess the blood glucose responses to consumption of XXX in healthy men and women. (2007, Study Director) Sponsor: Tate and Lyle Americas.
140. A randomized, controlled study to assess the effects of XXX on enhancing weight loss and reducing blood lipids in overweight and obese adults with elevated low-density lipoprotein (LDL) cholesterol. (2007, Study Director) Sponsor: General Mills.
141. A double-blind, placebo-controlled, randomized study to assess the effects of XXX on cognitive function in healthy women. (2007, Study Director) Sponsor: Ocean Spray Cranberries, Inc.
142. A double-blind, randomized, controlled trial to assess the effects of XXX on colonic transit time in healthy men and women. (2007, Study Director) Sponsor: Kraft Foods.
143. Effects of XXX on cognitive processes in children 8-12 years of age. (2007, Study Director) Sponsor: Kellogg Company.
144. An open-label extension of a randomized, double-blind, placebo-controlled, crossover study to evaluate XXX compared to XXX plus placebo in subjects with mixed dyslipidemia. (2007, Study Director) Sponsor: Reliant Pharmaceuticals (Investigator Initiated Trial).
145. A randomized, double-blind, placebo-controlled trial to assess the hypo-cholesterolemic effects of XXX in men and women with primary hypercholesterolemia. (2006, Study Director) Sponsor: Ito En, Ltd.
146. A randomized, double-blind, placebo-controlled pilot study to assess the hypo-cholesterolemic effects of XXX in men and women with primary hypercholesterolemia. (2006, Study Director) Sponsor: Ito En, Ltd.
147. A double-blind, randomized, controlled trial to assess the influence of consuming XXX on fasting lipids in men and women with primary hypercholesterolemia. (2006, Study Director) Sponsor: Dow Chemical Company.
148. A double-blind, randomized, crossover trial to assess the influence of consuming XXX on fasting lipids in men and women with primary hypercholesterolemia receiving statin therapy. (2006, Study Director) Sponsor: Dow Chemical Company.
149. A phase II, double-blind randomized, placebo-controlled, parallel group, multicenter study to evaluate treatment with XXX in subjects with type 2 diabetes. (2006, Sub- Investigator) Sponsor: Takeda Global Research & Development Center, Inc.
150. Efficacy, safety and tolerability of XXX in subjects with type 2 diabetes and hypertension. (2006, Sub-Investigator) Sponsor: Takeda Global Research & Development Center, Inc.

151. A phase III double-blind, randomized, placebo-controlled study to determine the efficacy, safety and tolerability of XXX in the treatment of subjects with type 2 diabetes and hypertension. (2006, Sub-Investigator) Sponsor: Takeda Global Research & Development Center, Inc.
152. A Double-blind, randomized, controlled trial to assess the influence of several doses and formulations of XXX on fasting lipids in men and women with primary hypercholesterolemia. (2006, Study Director) Sponsor: Dow Chemical Company.
153. A double-blind, randomized, controlled, crossover trial to assess the influence of consuming high-viscosity XXX and XXX on postprandial glucose and insulin responses in men and women at risk for the development of type 2 diabetes. (2006, Study Director) Sponsor: Dow Chemical Company.
154. An evaluation of XXX plus XXX compared to XXX plus placebo in subjects with mixed dyslipidemia. (2006, Principal Investigator and Study Director) Sponsor: Reliant Pharmaceuticals, Inc.
155. Acute and chronic effects of XXX on blood pressure in apparently healthy men and women with normal blood pressure. (2006, Study Director) Sponsor: Cargill.
156. Fatty acid absorption study (FAST). (2006, Sub Investigator) Sponsor: Kellogg Company.
157. A phase III double-blind, randomized, placebo-controlled study to determine the efficacy, safety and tolerability of XXX in the treatment of subjects with type 2 diabetes and hypertension.(2006, Sub Investigator) Sponsor: Takeda Global Research & Development Center, Inc.
158. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of long-term administration of rimonabant in the prevention of type 2 diabetes in patients with prediabetic status (i.e., impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both). (2006, Sub-Investigator) Sponsor: Sanofi-Aventis.
159. A comparison of two dietary approaches for the management of Type 2 diabetes mellitus. (2006, Principal Investigator) Sponsor: Novartis Consumer Health.
160. A double-blind, randomized, controlled, crossover trial to assess the influence of consuming XXX on postprandial glucose and insulin responses in men and women. (2006, Principal Investigator) Sponsor: Dow Chemical Company.
161. Effects of XXX on glucose homeostasis during a meal challenge in men and women with normal glucose tolerance or type 2 diabetes mellitus. (2006, Study Director) Sponsor: Cargill, Inc.
162. Effects of chronic consumption of XXX on glucose homeostasis in men and women with type 2 diabetes mellitus. (2006, Principal Investigator and Study Director) Sponsor: Cargill, Inc.
163. A randomized, double-blind, controlled study to assess the efficacy of XXX for enhancing exercise-induced fat loss. (2006, Principal Investigator) Sponsor: Kao Corporation.
164. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of combined XXX and XXX therapy in hypertriglyceridemic subjects. (2006, Principal Investigator) Sponsor: Reliant Pharmaceuticals, Inc.
165. An open-label extension of a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of combined XXX and XXX therapy in hypertriglyceridemic subjects. (2006, Principal Investigator) Sponsor: Reliant Pharmaceuticals, Inc.
166. A second open-label extension of a double-blind, parallel, phase IV study to assess the efficacy and safety of adjunctive XXX therapy in hypertriglyceridemic subjects treated with XXX. (2006, Principal Investigator) Sponsor: Reliant Pharmaceuticals, Inc.

167. Pharmacogenomic sample collection from subjects with type 2 diabetes treated with pioglitazone or rosiglitazone. (2005, Lead Statistician) Sponsor: Perlegen Science, Inc.
168. A randomized, double-blind, placebo-controlled, parallel-group phase IV study to assess the efficacy and safety of adjunctive XXX therapy in hypertriglyceridemic subjects treated with XXX. (2005, Principal Investigator) Sponsor: Reliant Pharmaceuticals, Inc.
169. An open-label extension of a double-blind, parallel, phase IV study to assess the efficacy and safety of XXX in hypertriglyceridemic subjects treated with XXX. (2005, Principal Investigator) Sponsor: Reliant Pharmaceuticals, Inc.
170. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of combined XXX and XXX therapy in hypertriglyceridemic subjects. (2005, Principal Investigator) Sponsor: Reliant Pharmaceuticals, Inc.
171. A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of XXX (50 mg or 100 mg) when co-administered with XXX in subjects with primary hypercholesterolemia. (2005, Principal Investigator) Sponsor: Takeda Global Research & Development Center, Inc.
172. An open-label extension study to evaluate the safety and tolerability of XXX in subjects with primary hypercholesterolemia or combined hyperlipidemia. (2005, Principal Investigator) Sponsor: Takeda Global Research & Development Center, Inc.
173. A double-blind controlled trial to assess the safety, tolerability and bioavailability of XXX in healthy adults. (2005, Study Director) Sponsor: Pharmavite LLC.
174. Relationship between supplemental vitamin E use and incident heart failure. (2005, Study Director) Sponsor: Pharmavite LLC.
175. A randomized double-blind, double-dummy, placebo-controlled, phase III study to assess the efficacy and safety of 130 mg of XXX, with and without food, versus a matching placebo, combined with a low saturated-fat diet in subjects with hypertriglyceridemia and metabolic syndrome. (2004, Lead Statistician) Sponsor: Reliant Pharmaceuticals.
176. A clinical study to evaluate the effect of a XXX on body weight in overweight or obese men and women extension. (2004, Principal Investigator) Sponsor: Kraft Foods.
177. A clinical study to evaluate the effect of a XXX on body weight in overweight or obese men and women. (2004, Principal Investigator) Sponsor: Kraft Foods.
178. Multiple dose human tolerance of XXX versus XXX. (2004, Principal Investigator) Sponsor: Ross Products Division of Abbott Laboratories.
179. Effect of XXX on satiety in patients with type II diabetes. (2004, Principal Investigator) Sponsor: Ross Products Division of Abbott Laboratories.
180. A double-blind, randomized trial to assess the efficacy of XXX for reducing morbidity and mortality among women undergoing cardiac surgery. (2004, Lead Statistician) Sponsor: AVANT Immunotherapeutics.
181. A randomized, double-blind, crossover, dose-ranging trial to assess the gastrointestinal tolerability of XXX in healthy adults. (2004, Principal Investigator) Sponsor: Cargill.

182. A placebo-controlled, randomized, double-blind, parallel-group, dose-finding, at-home study to evaluate the efficacy and safety of intranasally administered XXX in subjects with male erectile dysfunction. (2004, Lead Statistician) Sponsor: Palatin Technologies.
183. A clinical study to evaluate the effect of XXX on body weight in overweight or obese men and women. (2004, Principal Investigator) Sponsor: Kraft Foods.
184. A randomized double-blind, double-dummy, placebo-controlled, phase III study to assess the efficacy and safety of 130 mg of XXX, with and without food, versus a matching placebo, combined with a low saturated-fat diet in subjects with hypertriglyceridemia and metabolic syndrome. (2004, Lead Statistician) Sponsor: Reliant Pharmaceuticals.
185. The effects of consumption of XXX on carotid intima-media thickness. (2003, Lead Statistician) Sponsor: Roll International.
186. A randomized, open label, multicenter, crossover trial of XXX vs. atorvastatin 10 mg utilization on NCEP ATP III goal achievement in persons with moderate risk for coronary heart disease: The LAUNCH study. (2003, Lead Statistician) Sponsor: Reliant Pharmaceuticals.
187. An open-label, long-term, phase III trial of the safety and efficacy of XXX in male subjects with erectile dysfunction. (2003, Lead Statistician) Sponsor: NexMed (USA), Inc.
188. A randomized, placebo-controlled, double-blind, parallel design phase III bridging trial of the efficacy and safety of XXX in male subjects with erectile dysfunction, 2003-011. (2003, Lead Statistician) Sponsor: NexMed (USA), Inc.
189. A randomized, placebo-controlled, double-blind, parallel design phase III bridging trial of the efficacy and safety of XXX in male subjects with erectile dysfunction, 2003-010. (2003, Lead Statistician) Sponsor: NexMed (USA), Inc.
190. A placebo-controlled, randomized, double-blind, parallel-group, dose-finding, at-home study to evaluate the efficacy and safety of intranasally administered PT-141 in subjects with male erectile dysfunction. (2003, Lead Statistician) Sponsor: Palatin Technologies.
191. A randomized, double-blind, placebo-controlled trial to assess the effects of XXX on erectile dysfunction in men with chronic erectile dysfunction. (2003, Principal Investigator) Sponsor: Welch Foods.
192. A multi-center, open-label study to evaluate patient satisfaction and menopausal quality-of-life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. (2003, Lead Statistician) Sponsor: Novogyne Pharmaceuticals.
193. A randomized, double-blind, crossover trial to evaluate the efficacy of a XXX for lowering low-density lipoprotein cholesterol in African American men and women with mild-to-moderate primary hypercholesterolemia. (2003, Principal Investigator) Sponsor: General Mills.
194. Effect of an energy deficit DASH diet with XXX or an energy deficit diet alone on weight loss in overweight or obese subjects with and without stage 1 hypertension. (2003, Co-Principal Investigator) Sponsor: Ross Products Division, Abbott Laboratories.
195. Glycemic response of foodstuffs using a XXX. (III) (2002, Principal Investigator) Sponsor: Ross Products Division, Abbott Laboratories.
196. Glycemic response of foodstuffs using a XXX. (II) (2002, Principal Investigator) Sponsor: Ross Products Division, Abbott Laboratories.

197. Glycemic response of foodstuffs using a XXX. (I) (2002, Principal Investigator) Sponsor: Ross Products Division, Abbott Laboratories.
198. Human uptake and retention of XXX versus XXX. (2002, Principal Investigator) Sponsor: Ross Products Division, Abbott Laboratories.
199. A randomized, open-label, multicenter study comparing the bleeding profile of ORTHO EVRA (Norelgestromin/Ethinyl Estradiol) continuous regimen vs. ORTHO EVRA Cyclic Regimen. (2002, Lead Statistician) Sponsor: Ortho-McNeil Pharmaceutical, Inc.
200. National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). (2003, Lead Statistician and Co-Chair Steering Committee) Sponsor: AstraZeneca Pharmaceuticals.
201. National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE). (2002, Lead Statistician and Co-Chair Steering Committee) Sponsor: AstraZeneca Pharmaceuticals.
202. A double-blind, randomized, placebo- controlled clinical study to evaluate the effect of XXX on body fat mass in overweight or obese men and women. (2002, Principal Investigator) Sponsor: Glanbia Foods.
203. A double-blind, placebo controlled, multi-center study to evaluate the effects of XXX tablets on blood pressure in subjects with untreated or suboptimally treated blood pressure elevation. (2002, Co-Principal Investigator) Sponsor: Calpis.
204. Investigation of the acute effects of XXX on postprandial lipid response. (2002, Principal Investigator) Sponsor: Ross Products Division, Abbott Laboratories.
205. Effects of XXX on safety in healthy adult male subjects. (2002, Principal Investigator) Sponsor: Ross Products Division, Abbott Laboratories.
206. The effects of test sweeteners vs. glucose on postprandial serum insulin and glucose levels in healthy obese men: A randomized, double-blind, controlled crossover trial. (2002, Principal Investigator) Sponsor: Cargill.
207. A randomized, double blind, three way crossover comparison of XXX and XXX responses during a meal glucose tolerance test in subjects with type II diabetes consuming disease-specific versus standard nutritional formulas. (2002, Principal Investigator) Sponsor: Ross Products Division, Abbott Laboratories.
208. A randomized, double-blind, crossover trial comparing glucose and insulin responses in individuals with type II diabetes consuming disease-specific meal replacement bars and a commercial meal replacement bar. (2001, Principal Investigator) Sponsor: Ross Products Division, Abbott Laboratories.
209. A Randomized, placebo controlled, parallel feasibility trial in hypertensive adults designed to test the anti-hypertensive properties of a food ingredient. (2001, Principal Investigator) Sponsor: Ross Products Division, Abbott Laboratories.
210. A randomized, double-blind, controlled, two-way crossover trial to evaluate the efficacy of a soluble fiber-containing ready-to-eat cereal for reducing serum low-density lipoprotein cholesterol in children and adolescents with mild-to-moderate primary hypercholesterolemia. (2001, Principal Investigator) Sponsor: General Mills.
211. Glycemic response of foodstuffs using a meal tolerance test. (2001, Principal Investigator) Sponsor: Ross Products Division, Abbott Laboratories.
212. Measurement of the glycemic index of a liquid meal replacement. (2001, Principal Investigator) Sponsor: Unilever.

213. A randomized, double-blind, placebo-controlled clinical trial to evaluate the laxative and cholesterol lowering effects of XXX, in chronically constipated men and women. (2001, Principal Investigator) Sponsor: Pharmavite Corporation.
214. A phase II study of the safety and efficacy of XXX in patients with low HDL-cholesterol. (2001, Lead Statistician) Sponsor: AVANT Immunotherapeutics.
215. A randomized, double-blind, controlled trial examining the lipid-lowering effects of free Tall Oil-based Phytosterols (TOP) and oat beta-glucan in food products. (2001, Principal Investigator) Sponsor: Altus Food Company.
216. A double-blind, randomized, placebo-controlled, multicenter trial to demonstrate the efficacy of 12 weeks of treatment with XXX on vasomotor symptoms in postmenopausal women. (2001, Lead Statistician) Sponsor: Duramed Pharmaceuticals, Inc.
217. A randomized, double-blind, placebo-controlled trial to assess the effects of XXX on erectile function in men with chronic erectile dysfunction. (2001, Principal Investigator) Sponsor: Welch's Foods Incorporated.
218. A double-blind, randomized, parallel, controlled clinical trial to evaluate the effects of a docosahexaenoic acid (DHA)-containing capsule on serum lipids in men and women with below-average high density lipoprotein (HDL) cholesterol levels. (2001, Principal Investigator) Sponsor: OmegaTech, Inc.
219. A phase I study of the safety and efficacy of XXX. (2001, Lead Statistician) Sponsor: AVANT Immunotherapeutics.
220. A double-blind, randomized, parallel, placebo-controlled clinical study to compare the effects of XXX vs. placebo tablets on vulvovaginal atrophy in healthy postmenopausal women. (2000, Lead Statistician) Sponsor: Duramed Pharmaceuticals, Inc.
221. A randomized, double-blind, controlled two-way crossover clinical trial to evaluate the effectiveness of a test food product for inducing satiety in healthy men and women. (2000, Principal Investigator) Sponsor: General Mills.
222. A randomized, placebo-controlled, double-blind, crossover design phase 2 study of the efficacy and safety of XXX in patients with erectile dysfunction using rigidity and tumescence monitoring. (2000, Lead Statistician) Sponsor: NexMed (USA), Inc.
223. A randomized, placebo-controlled trial to evaluate a single ingestion of a new protein-based food component. (2000, Principal Investigator) Sponsor: Unilever.
224. A randomized, double-blind, controlled, two-way crossover trial to evaluate the efficacy of a soluble fiber-containing ready-to-eat cereal for reducing serum low-density lipoprotein cholesterol in children and adolescents with mild-to-moderate primary hypercholesterolemia. (2000, Principal Investigator) Sponsor: General Mills.
225. Oat β -glucan cereal reduces postprandial triglyceridemia: results of a randomized, crossover, controlled clinical trial. (2000, Principal Investigator) Sponsor: Quaker Oats Company.
226. A randomized, double-blind, controlled clinical trial to compare the lipid responses, in men and women with elevated triglyceride levels, to consumption of eggs laid by chickens who have eaten docosahexaenoic acid feed vs. control eggs. (2000, Principal Investigator) Sponsor: OmegaTech, Inc.
227. A single-blinded, randomized, three-way crossover study evaluating blood glucose levels after consumption of a XXX compared to a dietary supplement bar and a candy bar in subjects with type II diabetes mellitus. (1999, Principal Investigator) Sponsor: AMBI, Inc.

228. A double-blind, randomized, placebo-controlled, parallel group study evaluating glycemic parameters in subjects with type II diabetes receiving stable doses of an oral hypoglycemic agent and are supplemented with a glucose control drink containing chromium picolinate and biotin twice per day. (1999, Principal Investigator) Sponsor: AMBI, Inc.
229. An open label, randomized study evaluating body weight, body composition, bone density, and cardiovascular risk factors in overweight and obese subjects following the XXX compared to baseline and to subjects following the USDA Food Guide Pyramid weight management program. (1999, Principal Investigator) Sponsor: AMBI, Inc.
230. A randomized, double-blind, crossover clinical trial to evaluate the effects of a XXX product on serum lipids in men and women with hypercholesterolemia. (1999, Principal Investigator) Sponsor: Archer Daniels Midland.
231. A randomized, double-blind clinical trial to evaluate the influence of XXX on serum lipids in men and women with hypercholesterolemia. (1999, Co-Principal Investigator) Sponsor: Archer Daniels Midland.
232. A randomized, double-blind, controlled trial to evaluate the safety and tolerability of three doses of phytosterols in healthy adult men and women. (1999, Co-Principal Investigator) Sponsor: Lipton.
233. Effects of XXX on immune response in humans. (1999, Principal Investigator) Sponsor: Novartis.
234. A single-blind, placebo-controlled trial to evaluate the antioxidant efficacy and safety of XXX in healthy adult men and women consuming a typical "Western" diet. (1999, Principal Investigator) Sponsor: Nutrilite.
235. The effects of a calcium-containing test beverage, compared to control, on mineral metabolism. (1999, Principal Investigator) Sponsor: Pharmavite.
236. Study of blood cholesterol levels in subjects consuming a cholesterol lowering diet including XXX. (1999, Co-Principal Investigator) Sponsor: Proctor and Gamble.
237. The influence of oat products on the postprandial metabolic profile: A randomized, cross-over, controlled trial. (1999, Principal Investigator) Sponsor: Quaker Oats Co.
238. A comparison of the bioavailability of omega-3 fatty acids from XXX. (1999, Co-Principal Investigator) Sponsor: Roche Vitamins.
239. Effects of consuming econa oil vs. triglycerides on body composition and regional body fat distribution: A randomized, double-blind, controlled trial. (1998, Co-Principal Investigator) Sponsor: Kao Corporation.
240. A randomized, double-blind, placebo-controlled, escalating dose and pharmacokinetic study to evaluate the safety of the investigational oral product HL-9001 (3-acetoxy-androst-5-en-7, 17 dione). (1998, Principal Investigator) Sponsor: Humanetics Corporation.
241. A randomized, double-blind, controlled trial to evaluate the efficacy and safety of a phytosterol-enriched reduced fat spread for reducing serum low density lipoprotein cholesterol in subjects with mild-to-moderate primary hypercholesterolemia. (1998, Principal Investigator) Sponsor: Lipton.
242. Effects of XXX consumption on blood pressure and carbohydrate metabolism: A randomized, controlled, dose-ranging study. (1996, Principal Investigator). Sponsor: Quaker Oats Company.
243. Simultaneous monitoring of heart rate and motion to assess energy expenditure. (1995, Co-Principal Investigator) Sponsor: Loyola University Medical Center, Department of Preventive Medicine and Epidemiology.

244. Associations between serum lipids and indicators of adiposity in men with chronic spinal cord injury. (1994, Co-Principal Investigator) Sponsor: Department of Veterans Affairs, Rehabilitation, Research and Development Service.
245. Energy cost and locomotive economy of Handbike and Rowcycle propulsion by persons with spinal cord injury. (1994, Co-Principal Investigator) Sponsor: Department of Veterans Affairs, Rehabilitation, Research and Development Service.
246. Effects of oral albuterol on serum lipids and carbohydrate metabolism in healthy men. (1994, Co-Principal Investigator) Sponsor: Edward Hines, Jr. Veterans Affairs Medical Center, Department of Pulmonary Medicine.
247. Estimating exercise oxygen uptake in the lower limb disabled. (1994, Co-Principal Investigator) Sponsor: Department of Veterans Affairs, Rehabilitation, Research and Development Service.
248. Anthropometric and hormonal covariates of the Metabolic Cardiovascular Syndrome in men ≥ 55 years of age. (1992, Principal Investigator) Sponsor: Department of Veterans Affairs, Rehabilitation, Research and Development Service.
249. Geriatric assessment in Golden Age Games participants: Prevalence of osteoporosis and hypogonadism. (1992, Co-Principal Investigator) Sponsor: Department of Veterans Affairs, Rehabilitation, Research and Development Service.